| 1 |
Ramalingam PS, Balakrishnan P, Rajendran S, Jothi A, Ramalingam R, Arumugam S. Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery. CIMB 2023;45:2136-2156. [DOI: 10.3390/cimb45030137] [Reference Citation Analysis]
|
| 2 |
Sun Z, Li Y, Tan X, Liu W, He X, Pan D, Li E, Xu L, Long L. Friend or Foe: Regulation, Downstream Effectors of RRAD in Cancer. Biomolecules 2023;13:477. [DOI: 10.3390/biom13030477] [Reference Citation Analysis]
|
| 3 |
Alam M, Hasan GM, Eldin SM, Adnan M, Riaz MB, Islam A, Khan I, Hassan MI. Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. Biomed Pharmacother 2023;161:114452. [PMID: 36878052 DOI: 10.1016/j.biopha.2023.114452] [Reference Citation Analysis]
|
| 4 |
Meng GX, Yang CC, Yan LJ, Yang YF, Yan YC, Hong JG, Chen ZQ, Dong ZR, Li T. The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma. Heliyon 2023;9:e14307. [PMID: 36950649 DOI: 10.1016/j.heliyon.2023.e14307] [Reference Citation Analysis]
|
| 5 |
Wang X, Xiao Y, Dong Y, Wang Z, Yi J, Wang J, Wang X, Zhou H, Zhang L, Shi Y. A20 interacts with mTORC2 to inhibit the mTORC2/Akt/Rac1 signaling axis in hepatocellular carcinoma cells. Cancer Gene Ther 2023;30:424-36. [PMID: 36411371 DOI: 10.1038/s41417-022-00562-2] [Reference Citation Analysis]
|
| 6 |
Yang J, Hou C, Wang H, Perez EA, Do-Umehara HC, Dong H, Arunagiri V, Tong F, Van Scoyk M, Cho M, Liu X, Ge X, Winn RA, Ridge KM, Wang X, Chandel NS, Liu J. Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10. Cancer Lett 2023;555:216025. [PMID: 36538983 DOI: 10.1016/j.canlet.2022.216025] [Reference Citation Analysis]
|
| 7 |
Zhao Z, Bohidar N, Bourne PE. Analysis of KRAS-Ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics. J Chem Inf Model 2023;63:1362-70. [PMID: 36780612 DOI: 10.1021/acs.jcim.3c00097] [Reference Citation Analysis]
|
| 8 |
Karimi N, Moghaddam SJ. KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions. Cells 2023;12. [PMID: 36899885 DOI: 10.3390/cells12050749] [Reference Citation Analysis]
|
| 9 |
Meng J, Gao J, Li X, Gao R, Lu X, Zhou J, Yan F, Wang H, Liu Y, Hao Z, Zhang X, Liang C. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies. Cell Oncol (Dordr) 2023. [PMID: 36823338 DOI: 10.1007/s13402-023-00781-1] [Reference Citation Analysis]
|
| 10 |
Jardim SR, de Souza LMP, de Souza HSP. The Rise of Gastrointestinal Cancers as a Global Phenomenon: Unhealthy Behavior or Progress? Int J Environ Res Public Health 2023;20. [PMID: 36834334 DOI: 10.3390/ijerph20043640] [Reference Citation Analysis]
|
| 11 |
Candido MF, Medeiros M, Veronez LC, Bastos D, Oliveira KL, Pezuk JA, Valera ET, Brassesco MS. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. Pharmaceutics 2023;15. [PMID: 36839989 DOI: 10.3390/pharmaceutics15020664] [Reference Citation Analysis]
|
| 12 |
Hudson TJ, Pusztaszeri MP, Hier MP, Forest VI, Yang JW, Payne RJ. Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage? J Otolaryngol Head Neck Surg 2023;52:12. [PMID: 36774522 DOI: 10.1186/s40463-022-00611-8] [Reference Citation Analysis]
|
| 13 |
Wang J, Jiang H, Huang F, Li D, Wen X, Ding Q, Ding Y, Zhang X, Li J. Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients. J Cancer Res Clin Oncol 2023;149:701-8. [PMID: 36454283 DOI: 10.1007/s00432-022-04377-4] [Reference Citation Analysis]
|
| 14 |
Wang X, Xie Q, Ji Y, Yang J, Shen J, Peng F, Zhang Y, Jiang F, Kong X, Ma W, Liu D, Zheng L, Qing C, Lang JY. Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. Cell Rep 2023;42:111972. [PMID: 36641751 DOI: 10.1016/j.celrep.2022.111972] [Reference Citation Analysis]
|
| 15 |
Akhlaghipour I, Taghehchian N, Zangouei AS, Maharati A, Mahmoudian RA, Saburi E, Moghbeli M. MicroRNA-377: A therapeutic and diagnostic tumor marker. Int J Biol Macromol 2023;226:1226-35. [PMID: 36442575 DOI: 10.1016/j.ijbiomac.2022.11.236] [Reference Citation Analysis]
|
| 16 |
Kusakabe M, Taguchi A, Tanikawa M, Hoshi D, Tsuchimochi S, Qian X, Toyohara Y, Kawata A, Wagatsuma R, Yamaguchi K, Yamamoto Y, Ikemura M, Sone K, Mori-Uchino M, Matsunaga H, Tsuruga T, Nagamatsu T, Kukimoto I, Wada-Hiraike O, Kawazu M, Ushiku T, Takeyama H, Oda K, Kawana K, Hippo Y, Osuga Y. Application of organoid culture from HPV18-positive small cell carcinoma of the uterine cervix for precision medicine. Cancer Med 2023. [PMID: 36691316 DOI: 10.1002/cam4.5588] [Reference Citation Analysis]
|
| 17 |
Park YJ, Yoon G, Suh J, Jo BS, Lee DW, Kim D, Choi M, Jeong EK, Lee HC, Lee J, Chung CP, Park YS. Synthetic cell-penetrating RAS-binding peptide for the treatment of KRAS-mutated cancer.. [DOI: 10.21203/rs.3.rs-2394020/v1] [Reference Citation Analysis]
|
| 18 |
Abuasaker B, Garrido E, Vilaplana M, Gómez-Zepeda JD, Brun S, Garcia-Cajide M, Mauvezin C, Jaumot M, Pujol MD, Rubio-Martínez J, Agell N. α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death. Int J Mol Sci 2023;24. [PMID: 36614192 DOI: 10.3390/ijms24010748] [Reference Citation Analysis]
|
| 19 |
Cheng R, Li F, Zhang M, Xia X, Wu J, Gao X, Zhou H, Zhang Z, Huang N, Yang X, Zhang Y, Shen S, Kang T, Liu Z, Xiao F, Yao H, Xu J, Yan C, Zhang N. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers. Cell Res 2023;33:30-45. [PMID: 36241718 DOI: 10.1038/s41422-022-00726-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Mainardi S, Bernards R. RASON, a new player in cancer's Premier League. Cell Res 2023;33:1-2. [PMID: 36588118 DOI: 10.1038/s41422-022-00750-7] [Reference Citation Analysis]
|
| 21 |
Tsamis I, Gomatou G, Chachali SP, Trontzas IP, Patriarcheas V, Panagiotou E, Kotteas E. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it. Clin Transl Oncol 2023;25:10-20. [PMID: 35729451 DOI: 10.1007/s12094-022-02849-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Maiti S. Arsenic-induced mutagenesis and carcinogenesis: A possible mechanism. Handbook of Arsenic Toxicology 2023. [DOI: 10.1016/b978-0-323-89847-8.00016-x] [Reference Citation Analysis]
|
| 23 |
Feng K, Shi Q, Jiao D, Chen Y, Yang W, Su K, Wang Y, Huang Y, Zhang P, Li Y, Wang C. SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF. Cell Biosci 2022;12:211. [PMID: 36585710 DOI: 10.1186/s13578-022-00950-z] [Reference Citation Analysis]
|
| 24 |
Do MH, Thanh HD, To PK, Kim MS, Moon C, Jung C. CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity. Sci Rep 2022;12:22420. [PMID: 36575233 DOI: 10.1038/s41598-022-27107-9] [Reference Citation Analysis]
|
| 25 |
Maietta I, Del Peschio F, Buonocore P, Viscusi E, Laudati S, Iannaci G, Minopoli M, Motti ML, De Falco V. p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors. Cancers (Basel) 2022;15. [PMID: 36612117 DOI: 10.3390/cancers15010121] [Reference Citation Analysis]
|
| 26 |
Xu J, Xiong Y, Xu Z, Xing H, Zhou L, Zhang X. From targeted therapy to a novel way: Immunogenic cell death in lung cancer. Front Med (Lausanne) 2022;9:1102550. [PMID: 36619616 DOI: 10.3389/fmed.2022.1102550] [Reference Citation Analysis]
|
| 27 |
Hoxha M, Zappacosta B. A review on the role of fatty acids in colorectal cancer progression. Front Pharmacol 2022;13:1032806. [PMID: 36578540 DOI: 10.3389/fphar.2022.1032806] [Reference Citation Analysis]
|
| 28 |
Cristofani R, Piccolella M, Montagnani Marelli M, Tedesco B, Poletti A, Moretti RM. HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy. Cell Death Dis 2022;13:973. [PMID: 36400750 DOI: 10.1038/s41419-022-05365-9] [Reference Citation Analysis]
|
| 29 |
Reyes-castro RA, Chen S, Seemann J, Arur S. ERK-dependent DICER1 phosphorylation promotes open chromatin state and lineage plasticity to mediate tumor progression.. [DOI: 10.1101/2022.11.01.514714] [Reference Citation Analysis]
|
| 30 |
Pierotti MA, Frattini M, Epistolio S, Sozzi G, Croce CM. Oncogenes. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm004.pub2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
He Q, Liu Z, Wang J. Targeting KRAS in PDAC: A New Way to Cure It? Cancers 2022;14:4982. [DOI: 10.3390/cancers14204982] [Reference Citation Analysis]
|
| 32 |
Puccini A, Seeber A, Berger MD. Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers 2022;14:4828. [DOI: 10.3390/cancers14194828] [Reference Citation Analysis]
|
| 33 |
Gu G, Yu B, Wan H, Lu S, Zhu X, Zhao Y, Fuxi Y, Liu C. Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China. Onco Targets Ther 2022;15:1021-32. [PMID: 36172169 DOI: 10.2147/OTT.S381825] [Reference Citation Analysis]
|
| 34 |
Pallara C, Cabot D, Rivas J, Brun S, Seco J, Abuasaker B, Tarragó T, Jaumot M, Prades R, Agell N. Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds. Sci Rep 2022;12:15810. [PMID: 36138080 DOI: 10.1038/s41598-022-19703-6] [Reference Citation Analysis]
|
| 35 |
Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, Binder ZA, O'Rourke DM, Nathanson DA, Furnari FB, Miller CR. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol 2022;24:2035-62. [PMID: 36125064 DOI: 10.1093/neuonc/noac204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
Liu S, Ren L, Gao X, Hao M, Wang G. Pathogenesis of central nervous system germ cell tumors. Front Oncol 2022;12:991484. [DOI: 10.3389/fonc.2022.991484] [Reference Citation Analysis]
|
| 37 |
Comito F, Aprile M, Pagani R, Siepe G, Sperandi F, Gruppioni E, Altimari A, De Biase D, Melotti B. Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience. Melanoma Res 2022. [PMID: 36039514 DOI: 10.1097/CMR.0000000000000854] [Reference Citation Analysis]
|
| 38 |
Cekani E, Epistolio S, Dazio G, Cefalì M, Wannesson L, Frattini M, Froesch P. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. Cancers (Basel) 2022;14. [PMID: 36077640 DOI: 10.3390/cancers14174103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 39 |
Chen Q, Zhou X, Jin J, Feng J, Xu Z, Chen Y, Zhao H, Li Z, Pan J. A Novel Defined RAS-Related Gene Signature for Predicting the Prognosis and Characterization of Biological Function in Osteosarcoma. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/5939158] [Reference Citation Analysis]
|
| 40 |
Gligorijević N, Dobrijević Z, Šunderić M, Robajac D, Četić D, Penezić A, Miljuš G, Nedić O. The Insulin-like Growth Factor System and Colorectal Cancer. Life (Basel) 2022;12:1274. [PMID: 36013453 DOI: 10.3390/life12081274] [Reference Citation Analysis]
|
| 41 |
Sun P, Wang H, Liu L, Guo K, Li X, Cao Y, Ko C, Lan Z, Lei Z. Aberrant activation of KRAS in mouse theca-interstitial cells results in female infertility. Front Physiol 2022;13:991719. [DOI: 10.3389/fphys.2022.991719] [Reference Citation Analysis]
|
| 42 |
Jiang Y, Chen W, Wang X, Zhou B, Xie H, Hou Y, Guo Z, Yu B, Zhong S, Su X. Novel natural inhibitors targeting KRAS G12C by computational study. Anticancer Drugs 2022. [PMID: 35980001 DOI: 10.1097/CAD.0000000000001317] [Reference Citation Analysis]
|
| 43 |
Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, Zhang W, Qin JJ. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer 2022;21:159. [PMID: 35922812 DOI: 10.1186/s12943-022-01629-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 44 |
Kato S, Fujiwara Y, Hong DS. Targeting KRAS: Crossroads of Signaling and Immune Inhibition. Journal of Immunotherapy and Precision Oncology 2022;5:68-78. [DOI: 10.36401/jipo-22-5] [Reference Citation Analysis]
|
| 45 |
Li X, Wang N, Wu Y, Liu Y, Wang R. ALDH6A1 weakens the progression of colon cancer via modulating the RAS/RAF/MEK/ERK pathway in cancer cell lines. Gene 2022;:146757. [PMID: 35907565 DOI: 10.1016/j.gene.2022.146757] [Reference Citation Analysis]
|
| 46 |
Wu H, Wei M, Li Y, Ma Q, Zhang H. Research Progress on the Regulation Mechanism of Key Signal Pathways Affecting the Prognosis of Glioma. Front Mol Neurosci 2022;15:910543. [DOI: 10.3389/fnmol.2022.910543] [Reference Citation Analysis]
|
| 47 |
Ferreira A, Pereira F, Reis C, Oliveira MJ, Sousa MJ, Preto A. Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications. Cells 2022;11:2183. [DOI: 10.3390/cells11142183] [Reference Citation Analysis]
|
| 48 |
Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol 2022;6:e2100547. [PMID: 35862868 DOI: 10.1200/PO.21.00547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Nagasaka M, Azmi AS. Clinical progress of KRAS-targeted therapies: what next? Future Med Chem 2022. [PMID: 35758004 DOI: 10.4155/fmc-2022-0128] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 50 |
Khalifeh D, Neveu E, Fasshauer D. Megaviruses contain various genes encoding for eukaryotic vesicle trafficking factors. Traffic 2022. [PMID: 35701729 DOI: 10.1111/tra.12860] [Reference Citation Analysis]
|
| 51 |
Kobayashi E, Kondo S, Dochi H, Moriyama-Kita M, Hirai N, Komori T, Ueno T, Nakanishi Y, Hatano M, Endo K, Sugimoto H, Wakisaka N, Yoshizaki T. Protein Farnesylation on Nasopharyngeal Carcinoma, Molecular Background and Its Potential as a Therapeutic Target. Cancers (Basel) 2022;14:2826. [PMID: 35740492 DOI: 10.3390/cancers14122826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 52 |
Spagnuolo A, Maione P, Gridelli C. The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review. Transl Lung Cancer Res 2022;11:1199-216. [PMID: 35832439 DOI: 10.21037/tlcr-21-948] [Reference Citation Analysis]
|
| 53 |
Lietman CD, Johnson ML, McCormick F, Lindsay CR. More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C. Am Soc Clin Oncol Educ Book 2022;42:1-13. [PMID: 35561303 DOI: 10.1200/EDBK_351333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 54 |
Waitman K, Parise-Filho R. New kinase and HDAC hybrid inhibitors: recent advances and perspectives. Future Med Chem 2022. [PMID: 35543381 DOI: 10.4155/fmc-2021-0276] [Reference Citation Analysis]
|
| 55 |
Zhao J, Luo Z. Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway. Int J Mol Sci 2022;23:5158. [PMID: 35563547 DOI: 10.3390/ijms23095158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 56 |
Ilter M, Kaşmer R, Jalalypour F, Atilgan C, Topcu O, Karakaş N, Sensoy O. Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS.. [DOI: 10.1101/2022.04.24.489309] [Reference Citation Analysis]
|
| 57 |
Negri F, Bottarelli L, de'Angelis GL, Gnetti L. KRAS: A Druggable Target in Colon Cancer Patients. Int J Mol Sci 2022;23:4120. [PMID: 35456940 DOI: 10.3390/ijms23084120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 58 |
Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, Rose AAN, Siegel PM, Watson IR. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell Rep 2022;39:110634. [PMID: 35385748 DOI: 10.1016/j.celrep.2022.110634] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 59 |
Zeng J, Chen J, Xia F, Cui Q, Deng X, Xu X. Identification of functional substates of KRas during GTP hydrolysis with enhanced sampling simulations. Phys Chem Chem Phys 2022;24:7653-65. [PMID: 35297922 DOI: 10.1039/d2cp00274d] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 60 |
Hedberg ML, Berry CT, Moshiri AS, Xiang Y, Yeh CJ, Attilasoy C, Capell BC, Seykora JT. Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma. Int J Mol Sci 2022;23. [PMID: 35408839 DOI: 10.3390/ijms23073478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 61 |
Caratti B, Fidan M, Caratti G, Breitenecker K, Engler M, Kazemitash N, Traut R, Wittig R, Casanova E, Ahmadian MR, Tuckermann JP, Moll HP, Cirstea IC. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Sci Signal 2022;15:eabm4452. [PMID: 35316097 DOI: 10.1126/scisignal.abm4452] [Reference Citation Analysis]
|
| 62 |
Youssef ASE, Abdel-fattah MA, Lotfy MM, Nassar A, Abouelhoda M, Touny AO, Hassan ZK, Mohey Eldin M, Bahnassy AA, Khaled H, Zekri ARN. Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. CIMB 2022;44:1332-52. [DOI: 10.3390/cimb44030090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 63 |
La Marca JE, Ely RW, Diepstraten ST, Burke P, Kelly GL, Humbert PO, Richardson HE. A Drosophila in vivo chemical screen reveals that combination drug treatment targeting MEK and DGKα mitigates Ras-driven polarity-impaired tumourigenesis.. [DOI: 10.1101/2022.03.14.484232] [Reference Citation Analysis]
|
| 64 |
Désage AL, Léonce C, Swalduz A, Ortiz-Cuaran S. Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. Front Oncol 2022;12:796832. [PMID: 35251972 DOI: 10.3389/fonc.2022.796832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 65 |
Humbert PO, Pryjda TZ, Pranjic B, Farrell A, Fujikura K, de Matos Simoes R, Karim R, Kozieradzki I, Cronin SJF, Neely GG, Meyer TF, Hagelkruys A, Richardson HE, Penninger JM. TSPAN6 is a suppressor of Ras-driven cancer. Oncogene. [DOI: 10.1038/s41388-022-02223-y] [Reference Citation Analysis]
|
| 66 |
Garcia-Robledo JE, Rosell R, Ruíz-Patiño A, Sotelo C, Arrieta O, Zatarain-Barrón L, Ordoñez C, Jaller E, Rojas L, Russo A, de Miguel-Pérez D, Rolfo C, Cardona AF. KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. Ther Adv Respir Dis 2022;16:17534666211066064. [PMID: 35098800 DOI: 10.1177/17534666211066064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 67 |
Al Mahi A, Ablain J. RAS pathway regulation in melanoma. Dis Model Mech 2022;15:dmm049229. [PMID: 35234863 DOI: 10.1242/dmm.049229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 68 |
Leibetseder A, Preusser M, Berghoff AS. New Approaches with Precision Medicine in Adult Brain Tumors. Cancers 2022;14:712. [DOI: 10.3390/cancers14030712] [Reference Citation Analysis]
|
| 69 |
Neveu E, Khalifeh D, Fasshauer D. Megaviruses contain various genes encoding for eukaryotic vesicle trafficking factors.. [DOI: 10.1101/2022.01.28.478187] [Reference Citation Analysis]
|
| 70 |
Kolawole OR, Kashfi K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. Int J Mol Sci 2022;23:1432. [PMID: 35163356 DOI: 10.3390/ijms23031432] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 71 |
Shen M, Qi R, Ren J, Lv D, Yang H. Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer. Front Oncol 2021;11:780655. [PMID: 35070984 DOI: 10.3389/fonc.2021.780655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 72 |
Ozdemir ES, Koester AM, Nan X. Ras Multimers on the Membrane: Many Ways for a Heart-to-Heart Conversation. Genes (Basel) 2022;13:219. [PMID: 35205266 DOI: 10.3390/genes13020219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 73 |
Xu Q, Zhang G, Liu Q, Li S, Zhang Y. Inhibitors of the GTPase KRAS G12C in cancer: a patent review (2019-2021). Expert Opinion on Therapeutic Patents. [DOI: 10.1080/13543776.2022.2032648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 74 |
Kwan AK, Piazza GA, Keeton AB, Leite CA. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-021-02225-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 75 |
Han Z, Zhou D, Wang J, Jiang B, Liu X. Reflections on drug resistance to KRASG12C inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment. Biochim Biophys Acta Rev Cancer 2022;:188677. [PMID: 35033622 DOI: 10.1016/j.bbcan.2022.188677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 76 |
Guo M, He S, Cheng J, Li Y, Dong G, Sheng C. Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells. ACS Med Chem Lett 2022;13:298-303. [PMID: 35178186 DOI: 10.1021/acsmedchemlett.1c00670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 77 |
Tripathi S, Dsouza NR, Mathison AJ, Leverence E, Urrutia R, Zimmermann MT. Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics. Comput Struct Biotechnol J 2022;20:117-27. [PMID: 34976316 DOI: 10.1016/j.csbj.2021.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 78 |
Westfall AK, Perry BW, Kamal AHM, Hales NR, Kay JC, Sapkota M, Schield DR, Pellegrino MW, Secor SM, Chowdhury SM, Castoe TA. Identification of an integrated stress and growth response signaling switch that directs vertebrate intestinal regeneration. BMC Genomics 2022;23:6. [PMID: 34983392 DOI: 10.1186/s12864-021-08226-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 79 |
Sadhukhan S, Dey S. Biology, Chemistry, and Physics of Cancer Cell Motility and Metastasis. Cancer Diagnostics and Therapeutics 2022. [DOI: 10.1007/978-981-16-4752-9_5] [Reference Citation Analysis]
|
| 80 |
Orhan A. The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_65] [Reference Citation Analysis]
|
| 81 |
Bunz F. Oncogenes. Principles of Cancer Genetics 2022. [DOI: 10.1007/978-3-030-99387-0_2] [Reference Citation Analysis]
|
| 82 |
Dilmac S, Ozpolat B. Pathophysiology roles and translational opportunities of miRNAs in pancreatic cancer. MicroRNA in Human Malignancies 2022. [DOI: 10.1016/b978-0-12-822287-4.00003-7] [Reference Citation Analysis]
|
| 83 |
Orhan A. Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_147-1] [Reference Citation Analysis]
|
| 84 |
Newton AD, Chun YS. History of Treatment of Colorectal Liver Metastases. Colorectal Liver Metastasis 2022. [DOI: 10.1007/978-3-031-09323-4_1] [Reference Citation Analysis]
|
| 85 |
Rhodes SD, Angus SP. Prospects for Targeted Kinase Inhibition in Cancer: Neurofibromatosis Type 1-Related Neoplasia. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00174-2] [Reference Citation Analysis]
|
| 86 |
Ilter M, Kasmer R, Jalalypour F, Atilgan C, Topcu O, Karakas N, Sensoy O. Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS. Elife 2022;11. [PMID: 36458814 DOI: 10.7554/eLife.79747] [Reference Citation Analysis]
|
| 87 |
Sriramulu S, Malayaperumal S, Deka D, Banerjee A, Pathak S. A General Overview on Causes, Risk Factors, Diagnosis, Treatment, and Role of Oxidative Stress Biomarkers in Colorectal Cancer. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-1247-3_223-1] [Reference Citation Analysis]
|
| 88 |
Sriramulu S, Malayaperumal S, Deka D, Banerjee A, Pathak S. A General Overview on Causes, Risk Factors, Diagnosis, Treatment, and Role of Oxidative Stress Biomarkers in Colorectal Cancer. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-5422-0_223] [Reference Citation Analysis]
|
| 89 |
Yu K, Wang Y. The Advance and Correlation of KRAS Mutation With the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application. Pathol Oncol Res 2021;27. [DOI: 10.3389/pore.2021.1609906] [Reference Citation Analysis]
|
| 90 |
Azman MS, Dodel M, Capraro F, Faraway R, Dermit M, Fan W, Ule J, Mardakheh FK. An RNA-binding switch drives ribosome biogenesis and tumorigenesis downstream of RAS oncogene.. [DOI: 10.1101/2021.12.16.472890] [Reference Citation Analysis]
|
| 91 |
Hayashi R, Inomata M. Small cell lung cancer; recent advances of its biology and therapeutic perspective. Respir Investig 2021:S2212-5345(21)00193-3. [PMID: 34896039 DOI: 10.1016/j.resinv.2021.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 92 |
Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021;10:3348. [PMID: 34943856 DOI: 10.3390/cells10123348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 93 |
Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, Ravelli C, Maccarinelli F, Bianchi G, Belotti A, Ribolla R, Favasuli V, Revenko AS, Macleod AR, Willis B, Cai H, Hauser J, Rooney C, Willis SE, Martin PL, Staniszewska A, Ambrose H, Hanson L, Cattaneo C, Tucci A, Rossi G, Ronca R, Neri A, Mitola S, Bolli N, Presta M, Moschetta M, Ross S, Roccaro AM. Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Blood 2021;138:1705-20. [PMID: 34077955 DOI: 10.1182/blood.2020010572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 94 |
Qiu Y, Wang Y, Chai Z, Ni D, Li X, Pu J, Chen J, Zhang J, Lu S, Lv C, Ji M. Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators. Acta Pharm Sin B 2021;11:3433-46. [PMID: 34900528 DOI: 10.1016/j.apsb.2021.02.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 95 |
Andrews LJ, Thornton ZA, Saincher SS, Yao IY, Dawson S, McGuinness LA, Jones HE, Jefferies S, Short SC, Cheng HY, McAleenan A, Higgins JPT, Kurian KM. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro Oncol 2021:noab247. [PMID: 34718782 DOI: 10.1093/neuonc/noab247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 96 |
Yang WW, Yang L, Lu HZ, Sun YK. Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature. World J Clin Cases 2021; 9(30): 9134-9143 [PMID: 34786397 DOI: 10.12998/wjcc.v9.i30.9134] [Reference Citation Analysis]
|
| 97 |
Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer 2021;125:1185-96. [PMID: 34262149 DOI: 10.1038/s41416-021-01435-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 98 |
Wang X. Conformational Fluctuations in GTP-Bound K-Ras: A Metadynamics Perspective with Harmonic Linear Discriminant Analysis. J Chem Inf Model 2021;61:5212-22. [PMID: 34570515 DOI: 10.1021/acs.jcim.1c00844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 99 |
Li C, Vides A, Kim D, Xue JY, Zhao Y, Lito P. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Science 2021;374:197-201. [PMID: 34618566 DOI: 10.1126/science.abf1730] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 100 |
Nagai K, Niihori T, Okamoto N, Kondo A, Suga K, Ohhira T, Hayabuchi Y, Homma Y, Nakagawa R, Ifuku T, Abe T, Mizuguchi T, Matsumoto N, Aoki Y. Duplications in the G3 domain or switch II region in HRAS identified in patients with Costello syndrome. Hum Mutat 2021. [PMID: 34618388 DOI: 10.1002/humu.24287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 101 |
Tang D, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer 2021;20:128. [PMID: 34607583 DOI: 10.1186/s12943-021-01422-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 102 |
Plangger A, Rath B, Hochmair M, Funovics M, Hamilton G. Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells. Transl Oncol 2021;14:101230. [PMID: 34598083 DOI: 10.1016/j.tranon.2021.101230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 103 |
Applications of Constrained Helices. Cyclized Helical Peptides 2021. [DOI: 10.1002/9783527343430.ch4] [Reference Citation Analysis]
|
| 104 |
Li H, Qi W, Wang Y, Meng L. Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead. Genes & Diseases 2021. [DOI: 10.1016/j.gendis.2021.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 105 |
Cabot D, Brun S, Paco N, Ginesta MM, Gendrau-Sanclemente N, Abuasaker B, Ruiz-Fariña T, Barceló C, Cuatrecasas M, Bosch M, Rentero C, Pons G, Estanyol JM, Capellà G, Jaumot M, Agell N. KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer. Oncogene 2021;40:5730-40. [PMID: 34333552 DOI: 10.1038/s41388-021-01967-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 106 |
Roskoski R Jr. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Pharmacol Res 2021;172:105806. [PMID: 34450320 DOI: 10.1016/j.phrs.2021.105806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 107 |
Toropovsky AN, Pavlova ON, Viktorov DA, Nikitin AG. Molecular-genetic mechanisms of the signal cascade RAS-RAF-MEK-ERK associated with the development of the tumor process and the purpose of targeted drugs for colorectal cancer. jour 2021;11:25-35. [DOI: 10.20340/vmi-rvz.2021.4.morph.3] [Reference Citation Analysis]
|
| 108 |
Xiao W, Zhou H, Chen B, Shen B, Zhou J. miR-582-5p inhibits migration and chemo-resistant capabilities of colorectal cancer cells by targeting TNKS2. Genes Genomics 2021. [PMID: 34357507 DOI: 10.1007/s13258-021-01141-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 109 |
Hinoi T. Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. J Anus Rectum Colon 2021;5:213-28. [PMID: 34395933 DOI: 10.23922/jarc.2021-009] [Reference Citation Analysis]
|
| 110 |
Salmón M, Paniagua G, Lechuga CG, Fernández-García F, Zarzuela E, Álvarez-Díaz R, Musteanu M, Guerra C, Caleiras E, Muñoz J, Ortega S, Drosten M, Barbacid M. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Proc Natl Acad Sci U S A 2021;118:e2023112118. [PMID: 34301865 DOI: 10.1073/pnas.2023112118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 111 |
Li H, Zheng C, Han J, Zhu J, Liu S, Jin T. PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. Front Cell Neurosci 2021;15:716747. [PMID: 34381337 DOI: 10.3389/fncel.2021.716747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 112 |
Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J Hematol Oncol 2021;14:116. [PMID: 34301278 DOI: 10.1186/s13045-021-01127-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 113 |
Lakatos G, Köhne CH, Bodoky G. Current therapy of advanced colorectal cancer according to RAS/RAF mutational status.Cancer Metastasis Rev. 2020;39:1143-1157. [PMID: 32648137 DOI: 10.1007/s10555-020-09913-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 114 |
Ghosh S, Javia A, Shetty S, Bardoliwala D, Maiti K, Banerjee S, Khopade A, Misra A, Sawant K, Bhowmick S. Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches. J Control Release 2021;337:27-58. [PMID: 34273417 DOI: 10.1016/j.jconrel.2021.07.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 115 |
Osaka N, Hirota Y, Ito D, Ikeda Y, Kamata R, Fujii Y, Chirasani VR, Campbell SL, Takeuchi K, Senda T, Sasaki AT. Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification. Front Mol Biosci 2021;8:707439. [PMID: 34307463 DOI: 10.3389/fmolb.2021.707439] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 116 |
Gora RJ, de Jong B, van Hage P, Rhiemus MA, van Steenis F, van Noort J, Schmidt T, Schaaf MJ. Analysis of the H-Ras mobility pattern in vivo shows cellular heterogeneity inside epidermal tissue.. [DOI: 10.1101/2021.06.21.449125] [Reference Citation Analysis]
|
| 117 |
Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, Fillinger J, Klepetko W, Lang C, Dome B, Megyesfalvi Z. Current therapy of KRAS-mutant lung cancer.Cancer Metastasis Rev. 2020;39:1159-1177. [PMID: 32548736 DOI: 10.1007/s10555-020-09903-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 118 |
Garcia-Alvarez A, Ortiz C, Muñoz-Couselo E. Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma. Onco Targets Ther 2021;14:3709-19. [PMID: 34135599 DOI: 10.2147/OTT.S278095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 119 |
Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol 2021;32:1101-10. [PMID: 34089836 DOI: 10.1016/j.annonc.2021.06.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 120 |
Lauri A, Fasano G, Venditti M, Dallapiccola B, Tartaglia M. In vivo Functional Genomics for Undiagnosed Patients: The Impact of Small GTPases Signaling Dysregulation at Pan-Embryo Developmental Scale. Front Cell Dev Biol 2021;9:642235. [PMID: 34124035 DOI: 10.3389/fcell.2021.642235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 121 |
Muñoz-Félix JM, Martínez-Salgado C. Dissecting the Involvement of Ras GTPases in Kidney Fibrosis. Genes (Basel) 2021;12:800. [PMID: 34073961 DOI: 10.3390/genes12060800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 122 |
Meng M, Zhong K, Jiang T, Liu Z, Kwan HY, Su T. The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother 2021;140:111717. [PMID: 34044280 DOI: 10.1016/j.biopha.2021.111717] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 123 |
Zhang Y, Han P, Guo Q, Hao Y, Qi Y, Xin M, Zhang Y, Cui B, Wang P. Oncogenic Landscape of Somatic Mutations Perturbing Pan-Cancer lncRNA-ceRNA Regulation. Front Cell Dev Biol 2021;9:658346. [PMID: 34079798 DOI: 10.3389/fcell.2021.658346] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 124 |
Ohnami S, Maruyama K, Chen K, Takahashi Y, Hatakeyama K, Ohshima K, Shimoda Y, Sakai A, Kamada F, Nakatani S, Naruoka A, Ohnami S, Kusuhara M, Akiyama Y, Kagawa H, Shiomi A, Nagashima T, Urakami K, Yamaguchi K. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer. Mol Cell Biochem 2021;476:3469-82. [PMID: 33982211 DOI: 10.1007/s11010-021-04172-8] [Reference Citation Analysis]
|
| 125 |
Feng Z, Shi H, Lv M, Ma Y, Li J. Protein farnesylation negatively regulates brassinosteroid signaling via reducing BES1 stability in Arabidopsis thaliana. J Integr Plant Biol 2021;63:1353-66. [PMID: 33764637 DOI: 10.1111/jipb.13093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 126 |
Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, Rathi B, Kumar D. Oxidative Stress in Cancer Cell Metabolism. Antioxidants (Basel) 2021;10:642. [PMID: 33922139 DOI: 10.3390/antiox10050642] [Cited by in Crossref: 68] [Cited by in F6Publishing: 78] [Article Influence: 34.0] [Reference Citation Analysis]
|
| 127 |
Wen Z, Rajagopalan A, Flietner ED, Yun G, Chesi M, Furumo Q, Burns RT, Papadas A, Ranheim EA, Pagenkopf AC, Morrow ZT, Finn R, Zhou Y, Li S, You X, Jensen J, Yu M, Cicala A, Menting J, Mitsiades CS, Callander NS, Bergsagel PL, Wang D, Asimakopoulos F, Zhang J. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood 2021;137:61-74. [PMID: 32640012 DOI: 10.1182/blood.2020007156] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 128 |
Vargas-ibarra D, Velez-vasquez M, Bermudez-munoz M. Regulation of MAPK ERK1/2 Signaling by Phosphorylation: Implications in Physiological and Pathological Contexts. Post-Translational Modifications in Cellular Functions and Diseases [Working Title] 2021. [DOI: 10.5772/intechopen.97061] [Reference Citation Analysis]
|
| 129 |
Han CW, Jeong MS, Jang SB. Understand KRAS and the Quest for Anti-Cancer Drugs. Cells 2021;10:842. [PMID: 33917906 DOI: 10.3390/cells10040842] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 130 |
Li S, Fu J, Yang J, Ma H, Bhutani D, Mapara MY, Marcireau C, Lentzsch S. Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma. Blood 2021;137:1754-64. [PMID: 33036022 DOI: 10.1182/blood.2020006334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 131 |
Kim JH, Hong JH, Choi Y, Lee JA, Seo M, Lee M, An SB, Sung MJ, Cho N, Kim S, Shin YK, Kim S, Kang GH. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.. [DOI: 10.1101/2021.03.29.21253871] [Reference Citation Analysis]
|
| 132 |
Roskoski R Jr. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacol Res 2021;168:105579. [PMID: 33774181 DOI: 10.1016/j.phrs.2021.105579] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 133 |
Pareja F, Toss MS, Geyer FC, da Silva EM, Vahdatinia M, Sebastiao APM, Selenica P, Szatrowski A, Edelweiss M, Wen HY, Mihai R, Varga Z, Foschini MP, Rubin BP, Ellis IO, Chandarlapaty S, Jungbluth AA, Brogi E, Weigelt B, Reis-Filho JS, Rakha EA. Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas. Histopathology 2020;76:865-74. [PMID: 31887226 DOI: 10.1111/his.14057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 134 |
Yip HYK, Papa A. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells 2021;10:659. [PMID: 33809714 DOI: 10.3390/cells10030659] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 135 |
Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 136 |
Ehrlich M, Bacharach E. Oncolytic Virotherapy: The Cancer Cell Side. Cancers (Basel) 2021;13:939. [PMID: 33668131 DOI: 10.3390/cancers13050939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 137 |
Yan L, Tsujita K, Fujita Y, Itoh T. PTEN is required for the migration and invasion of Ras-transformed MDCK cells. FEBS Lett 2021;595:1303-12. [PMID: 33540467 DOI: 10.1002/1873-3468.14053] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 138 |
Cararo-Lopes E, Dias MH, da Silva MS, Zeidler JD, Vessoni AT, Reis MS, Boccardo E, Armelin HA. Autophagy buffers Ras-induced genotoxic stress enabling malignant transformation in keratinocytes primed by human papillomavirus. Cell Death Dis 2021;12:194. [PMID: 33602932 DOI: 10.1038/s41419-021-03476-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 139 |
Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. Eur J Cancer 2021;146:74-83. [PMID: 33588147 DOI: 10.1016/j.ejca.2021.01.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 140 |
Hu W, Liu Z, Salato V, North PE, Bischoff J, Kumar SN, Fang Z, Rajan S, Hussain MM, Miao QR. NOGOB receptor-mediated RAS signaling pathway is a target for suppressing proliferating hemangioma. JCI Insight 2021;6:142299. [PMID: 33400686 DOI: 10.1172/jci.insight.142299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 141 |
Kiel C, Matallanas D, Kolch W. The Ins and Outs of RAS Effector Complexes. Biomolecules 2021;11:236. [PMID: 33562401 DOI: 10.3390/biom11020236] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 142 |
Chippalkatti R, Abankwa D. Promotion of cancer cell stemness by Ras. Biochem Soc Trans 2021;49:467-76. [PMID: 33544116 DOI: 10.1042/BST20200964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 143 |
Ferino A, Xodo LE. Effect of DNA Glycosylases OGG1 and Neil1 on Oxidized G-Rich Motif in the KRAS Promoter. Int J Mol Sci 2021;22:1137. [PMID: 33498912 DOI: 10.3390/ijms22031137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 144 |
Choi BH, Kou Z, Colon TM, Chen CH, Chen Y, Dai W. Identification of Radil as a Ras binding partner and putative activator. J Biol Chem 2021;296:100314. [PMID: 33482197 DOI: 10.1016/j.jbc.2021.100314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 145 |
Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med 2021;2:100186. [PMID: 33521700 DOI: 10.1016/j.xcrm.2020.100186] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 146 |
Wen Z, Yun G, Hebert A, Kong G, Ranheim EA, Finn R, Rajagoplan A, Li S, Zhou Y, Yu M, Damnernsawad A, Roose JP, Coon JJ, Wen R, Wang D, Zhang J. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors. Blood 2021;137:3259-71. [PMID: 33512434 DOI: 10.1182/blood.2020009082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 147 |
Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat Res Rev Mutat Res 2021;787:108365. [PMID: 34083039 DOI: 10.1016/j.mrrev.2021.108365] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 19.5] [Reference Citation Analysis]
|
| 148 |
Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:E612. [PMID: 33435440 DOI: 10.3390/ijms22020612] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 149 |
Ruffinelli JC, Santos Vivas C, Sanz-Pamplona R, Moreno V. New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. Expert Rev Gastroenterol Hepatol 2021;15:65-79. [PMID: 32946312 DOI: 10.1080/17474124.2021.1826305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 150 |
Zhao J, Galvez C, Beckermann KE, Johnson DB, Sosman JA. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. Expert Rev Precis Med Drug Dev 2021;6:281-94. [PMID: 34485698 DOI: 10.1080/23808993.2021.1938545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 151 |
Yao Y, Shaligram SS, Su H. Brain vascular biology. Handb Clin Neurol 2021;176:49-69. [PMID: 33272410 DOI: 10.1016/B978-0-444-64034-5.00005-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 152 |
Joon S, Bhatnagar S, Bhatnagar R. Transcriptional Regulators in Bacillus anthracis: A Potent Biothreat Agent. Recent Developments in Microbial Technologies 2021. [DOI: 10.1007/978-981-15-4439-2_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 153 |
El-guendy N. Prostate Apoptosis Response-4 in Inflammation. Tumor Suppressor Par-4 2021. [DOI: 10.1007/978-3-030-80558-6_2] [Reference Citation Analysis]
|
| 154 |
Mohanta TK, Sharma N, Arina P, Defilippi P. Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues. Biomed Res Int 2020;2020:8827752. [PMID: 33426074 DOI: 10.1155/2020/8827752] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 155 |
Harrell Stewart DR, Schmidt ML, Donninger H, Clark GJ. The RASSF1A Tumor Suppressor Binds the RasGAP DAB2IP and Modulates RAS Activation in Lung Cancer. Cancers (Basel) 2020;12:E3807. [PMID: 33348649 DOI: 10.3390/cancers12123807] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 156 |
Mund JA, Park S, Smith AE, He Y, Jiang L, Hawley E, Roberson MJ, Mitchell DK, Abu-Sultanah M, Yuan J, Bessler WK, Sandusky G, Chen S, Zhang C, Rhodes SD, Clapp DW. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 17. J Biol Chem 2020;295:9948-58. [PMID: 33685622 DOI: 10.1074/jbc.RA119.010981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 157 |
Jhawat V, Gulia M, Gupta S, Maddiboyina B, Dutt R. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. J Control Release 2020;327:500-11. [PMID: 32858073 DOI: 10.1016/j.jconrel.2020.08.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 158 |
Patergnani S, Danese A, Bouhamida E, Aguiari G, Previati M, Pinton P, Giorgi C. Various Aspects of Calcium Signaling in the Regulation of Apoptosis, Autophagy, Cell Proliferation, and Cancer. Int J Mol Sci 2020;21:E8323. [PMID: 33171939 DOI: 10.3390/ijms21218323] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 21.7] [Reference Citation Analysis]
|
| 159 |
Huang Z, Liu M, Li D, Tan Y, Zhang R, Xia Z, Wang P, Jiao B, Liu P, Ren R. PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells. J Biol Chem 2020;295:18343-54. [PMID: 33122197 DOI: 10.1074/jbc.RA119.011060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 160 |
Rodríguez Stewart RM, Raghuram V, Berry JTL, Joshi GN, Mainou BA. Noncanonical Cell Death Induction by Reassortant Reovirus. J Virol 2020;94:e01613-20. [PMID: 32847857 DOI: 10.1128/JVI.01613-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 161 |
Zhang X, Mariano CF, Ando Y, Shen K. Bioengineering tools for probing intracellular events in T lymphocytes. Wiley Interdiscip Rev Syst Biol Med 2020;:e1510. [PMID: 33073545 DOI: 10.1002/wsbm.1510] [Reference Citation Analysis]
|
| 162 |
Kim D, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell 2020;183:850-9. [PMID: 33065029 DOI: 10.1016/j.cell.2020.09.044] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 22.7] [Reference Citation Analysis]
|
| 163 |
Smith SF, Collins SE, Charest PG. Ras, PI3K and mTORC2 - three's a crowd? J Cell Sci 2020;133. [PMID: 33033115 DOI: 10.1242/jcs.234930] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 164 |
Neven Q, Boulanger C, Bruwier A, de Ville de Goyet M, Meyts I, Moens L, Van Damme A, Brichard B. Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD). J Clin Immunol 2021;41:51-8. [PMID: 33011939 DOI: 10.1007/s10875-020-00883-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 165 |
Xu J, Pan Q, Ju W. Ras inhibition by zoledronic acid effectively sensitizes cervical cancer to chemotherapy. Anticancer Drugs 2019;30:821-7. [PMID: 30882399 DOI: 10.1097/CAD.0000000000000779] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 166 |
Assi M, Pirlot B, Stroobant V, Thissen JP, Jacquemin P. A Novel KRAS Antibody Highlights a Regulation Mechanism of Post-Translational Modifications of KRAS during Tumorigenesis. Int J Mol Sci 2020;21:E6361. [PMID: 32887255 DOI: 10.3390/ijms21176361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 167 |
Polivka J, Windrichova J, Pesta M, Houfkova K, Rezackova H, Macanova T, Vycital O, Kucera R, Slouka D, Topolcan O. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases. Cancers (Basel) 2020;12:E2434. [PMID: 32867151 DOI: 10.3390/cancers12092434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 168 |
Tian X, Zhu X, Meng W, Bai S, Shi M, Xiang S, Zhao C, Wang Y. A 12-immune cell signature to predict relapse and guide chemotherapy for stage II colorectal cancer. Aging (Albany NY) 2020;12:18363-83. [PMID: 32855365 DOI: 10.18632/aging.103707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 169 |
Gasper R, Wittinghofer F. The Ras switch in structural and historical perspective. Biol Chem 2019;401:143-63. [PMID: 31600136 DOI: 10.1515/hsz-2019-0330] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 170 |
Katata Y, Inoue SI, Asao A, Kobayashi S, Terui H, Inoue-Shibui A, Abe T, Niihori T, Aiba S, Ishii N, Kure S, Aoki Y. Costello syndrome model mice with a HrasG12S/+ mutation are susceptible to develop house dust mite-induced atopic dermatitis. Cell Death Dis 2020;11:617. [PMID: 32792500 DOI: 10.1038/s41419-020-02845-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 171 |
Wang X, Xie Q, Ji Y, Shen J, Zhang Y, Jiang F, Kong X, Liu D, Zheng L, Qing C, Lang J. Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex.. [DOI: 10.1101/2020.08.12.247460] [Reference Citation Analysis]
|
| 172 |
Ji X, Liu Y, Kao X, Chen X, Zhao Y, Zhang S, Chen L, Yu M, Wei J, Yang Z, Wang F. miR-144 suppresses cell proliferation and migration in colorectal cancer by targeting NRAS. J Cell Biochem 2020;121:3871-81. [PMID: 31693229 DOI: 10.1002/jcb.29543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 173 |
Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL, Spreafico A, LoConte N, Anders NM, Miles T, Rudek MA, Doyle LA, Nelkin B, Maitra A, Azad NS; ETCTN-9231 Study Team. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Clin Transl Sci 2020;13:1178-88. [PMID: 32738099 DOI: 10.1111/cts.12802] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 174 |
Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau RB. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn 2020;22:1238-45. [PMID: 32745614 DOI: 10.1016/j.jmoldx.2020.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 175 |
Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther 2020;5:137. [PMID: 32728057 DOI: 10.1038/s41392-020-0199-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 176 |
Weiss RA. A perspective on the early days of RAS research. Cancer Metastasis Rev 2020;39:1023-8. [PMID: 32728828 DOI: 10.1007/s10555-020-09919-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 177 |
Klein-Scory S, Wahner I, Maslova M, Al-Sewaidi Y, Pohl M, Mika T, Ladigan S, Schroers R, Baraniskin A. Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer. Front Oncol 2020;10:1115. [PMID: 32766143 DOI: 10.3389/fonc.2020.01115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 178 |
Dong G, Chen L, Zhang J, Liu T, Du L, Sheng C, Li M. Discovery of Turn-On Fluorescent Probes for Detecting PDEδ Protein in Living Cells and Tumor Slices. Anal Chem 2020;92:9516-22. [PMID: 32571022 DOI: 10.1021/acs.analchem.0c00335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 179 |
Cavo M, Delle Cave D, D'Amone E, Gigli G, Lonardo E, Del Mercato LL. A synergic approach to enhance long-term culture and manipulation of MiaPaCa-2 pancreatic cancer spheroids. Sci Rep 2020;10:10192. [PMID: 32576846 DOI: 10.1038/s41598-020-66908-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 180 |
Rossat S, Perrier H, Lefevre M, Louvet C, Le Berre N, Chamois J, Dorel M, Vacque D, Guillaudeau A, Genet D, Maillet E, Triby S, Sabourin JC. Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions. Pathol Oncol Res 2020;26:2469-73. [PMID: 32572821 DOI: 10.1007/s12253-020-00818-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 181 |
Lu KH, Lu EW, Lin CW, Yang JS, Yang SF. New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacol Ther 2020;214:107611. [PMID: 32565177 DOI: 10.1016/j.pharmthera.2020.107611] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 182 |
Tebar F, Chavero A, Agell N, Lu A, Rentero C, Enrich C, Grewal T. Pleiotropic Roles of Calmodulin in the Regulation of KRas and Rac1 GTPases: Functional Diversity in Health and Disease. Int J Mol Sci 2020;21:E3680. [PMID: 32456244 DOI: 10.3390/ijms21103680] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 183 |
Stewart RMR, Raghuram V, Berry JT, Mainou BA. Non-canonical cell death by reassortant reovirus.. [DOI: 10.1101/2020.05.20.107706] [Reference Citation Analysis]
|
| 184 |
Remsberg JR, Suciu RM, Zambetti NA, Hanigan TW, Firestone AJ, Inguva A, Long A, Ngo N, Lum KM, Henry CL, Richardson SK, Predovic M, Huang B, Howell AR, Niphakis MJ, Shannon K, Cravatt BF. ABHD17 enzymes regulate dynamic plasma membrane palmitoylation and N-Ras-dependent cancer growth.. [DOI: 10.1101/2020.05.21.108316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 185 |
Lee HS, Hwang DY, Han HS. Histology and its prognostic effect on KRAS-mutated colorectal carcinomas in Korea. Oncol Lett 2020;20:655-66. [PMID: 32565990 DOI: 10.3892/ol.2020.11606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 186 |
Jun S, Kim SW, Kim B, Chang IY, Park SJ. Oncogenic Ras downregulates mdr1b expression through generation of reactive oxygen species. Korean J Physiol Pharmacol 2020;24:267-76. [PMID: 32395078 DOI: 10.4196/kjpp.2020.24.3.267] [Reference Citation Analysis]
|
| 187 |
Van Sciver RE, Cao Y, Tang AH. The phylogenetic functional conservation ofDrosophilaSeven-In-Absentia (SINA) E3 ligase and its two human paralogs, SIAH1 and SIAH2, inDrosophilaeye development.. [DOI: 10.1101/2020.04.28.067074] [Reference Citation Analysis]
|
| 188 |
Anwar A, Siddiqui R, Khan NA. Whole Organism Model to Study Molecular Mechanisms of Differentiation and Dedifferentiation. Biology (Basel) 2020;9:E79. [PMID: 32316619 DOI: 10.3390/biology9040079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 189 |
Drosten M, Barbacid M. Targeting the MAPK Pathway in KRAS-Driven Tumors. Cancer Cell 2020;37:543-50. [PMID: 32289276 DOI: 10.1016/j.ccell.2020.03.013] [Cited by in Crossref: 155] [Cited by in F6Publishing: 128] [Article Influence: 51.7] [Reference Citation Analysis]
|
| 190 |
Yue J, Vendramin R, Liu F, Lopez O, Valencia MG, Gomes Dos Santos H, Gaidosh G, Beckedorff F, Blumenthal E, Speroni L, Nimer SD, Marine JC, Shiekhattar R. Targeted chemotherapy overcomes drug resistance in melanoma. Genes Dev 2020;34:637-49. [PMID: 32241802 DOI: 10.1101/gad.333864.119] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 191 |
Sheng SG, Wang YN, Wang SR, Zhao K, Wang YY, Xu XN, Wang QM, Tong L, Chen ZG. [Effects of farnesyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma]. Hua Xi Kou Qiang Yi Xue Za Zhi 2020;38:177-84. [PMID: 32314892 DOI: 10.7518/hxkq.2020.02.012] [Reference Citation Analysis]
|
| 192 |
Hung PS, Huang MH, Kuo YY, Yang JC. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer. Cancers (Basel) 2020;12:E837. [PMID: 32244355 DOI: 10.3390/cancers12040837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 193 |
Shang A, Gu C, Zhou C, Yang Y, Chen C, Zeng B, Wu J, Lu W, Wang W, Sun Z, Li D. Exosomal KRAS mutation promotes the formation of tumour-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression.Cell Commun Signal. 2020;18:52. [PMID: 32228650 DOI: 10.1186/s12964-020-0517-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 194 |
LoRusso PM, Schalper K, Sosman J. Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. Pigment Cell Melanoma Res 2020;33:390-402. [PMID: 31705737 DOI: 10.1111/pcmr.12847] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 195 |
Sarkar S, García AE. Presence or Absence of Ras Dimerization Shows Distinct Kinetic Signature in Ras-Raf Interaction. Biophys J 2020;118:1799-810. [PMID: 32199071 DOI: 10.1016/j.bpj.2020.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 196 |
Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S, Garrett JT. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers (Basel) 2020;12:E482. [PMID: 32092958 DOI: 10.3390/cancers12020482] [Cited by in Crossref: 66] [Cited by in F6Publishing: 77] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 197 |
Li S, Zhuo Z, Chang X, Ma Y, Zhou H, Zhang J, Cheng J, He J, Li Y. NRAS rs2273267 A>T polymorphism reduces neuroblastoma risk in Chinese children. Gene 2020;727:144262. [PMID: 31759987 DOI: 10.1016/j.gene.2019.144262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 198 |
Biernacki MA, Bleakley M. Neoantigens in Hematologic Malignancies. Front Immunol 2020;11:121. [PMID: 32117272 DOI: 10.3389/fimmu.2020.00121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 199 |
Zhang Y, Meng X, Tang H, Cheng M, Yang F, Xu W. Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions. J Enzyme Inhib Med Chem 2020;35:344-53. [PMID: 31851852 DOI: 10.1080/14756366.2019.1702653] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 200 |
Lee JS, Kim E, Lee J, Kim D, Kim H, Kim CJ, Kim S, Jeong D, Lee Y. Capicua suppresses colorectal cancer progression via repression of ETV4 expression. Cancer Cell Int 2020;20:42. [PMID: 32042269 DOI: 10.1186/s12935-020-1111-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 201 |
Li X, Meng X, Luan S, Luo K, Cao B, Chen B, Kong J. Effect of white spot syndrome virus infection on a Ras gene in the Chinese shrimp Fenneropenaeus chinensis. Aquaculture 2020;516:734604. [DOI: 10.1016/j.aquaculture.2019.734604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 202 |
Post JB, Roodhart JML, Snippert HJG. Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. Trends Cancer 2020;6:111-29. [PMID: 32061302 DOI: 10.1016/j.trecan.2019.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 203 |
Muratcioglu S, Aydin C, Odabasi E, Ozdemir ES, Firat-Karalar EN, Jang H, Tsai CJ, Nussinov R, Kavakli IH, Gursoy A, Keskin O. Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling. J Mol Biol 2020;432:1199-215. [PMID: 31931009 DOI: 10.1016/j.jmb.2020.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 204 |
Hanrahan AJ, Iyer G, Solit DB. Intracellular Signaling. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00002-5] [Reference Citation Analysis]
|
| 205 |
Denayer E, Legius E, Brems H. Genetics and Pathway in Neurofibromatosis Type 1. Multidisciplinary Approach to Neurofibromatosis Type 1 2020. [DOI: 10.1007/978-3-319-92450-2_2] [Reference Citation Analysis]
|
| 206 |
Blanden MJ, Ashok S, Hougland JL. Mechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I. Comprehensive Natural Products III 2020. [DOI: 10.1016/b978-0-12-409547-2.14837-1] [Reference Citation Analysis]
|
| 207 |
You B, Mercier F, Assenat E, Langlois-Jacques C, Glehen O, Soulé J, Payen L, Kepenekian V, Dupuy M, Belouin F, Morency E, Saywell V, Flacelière M, Elies P, Liaud P, Mazard T, Maucort-Boulch D, Tan W, Vire B, Villeneuve L, Ychou M, Kohli M, Joubert D, Prieur A. The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 2020;51:102574. [PMID: 31877416 DOI: 10.1016/j.ebiom.2019.11.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 208 |
Fraser NJ, Howie J, Wypijewski KJ, Fuller W. Therapeutic targeting of protein S-acylation for the treatment of disease. Biochemical Society Transactions 2020;48:281-90. [DOI: 10.1042/bst20190707] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 209 |
Endo T. Dominant-negative antagonists of the Ras-ERK pathway: DA-Raf and its related proteins generated by alternative splicing of Raf. Exp Cell Res 2020;387:111775. [PMID: 31843497 DOI: 10.1016/j.yexcr.2019.111775] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 210 |
Sun G, Su G, Liu F, Han W. NRAS Contributes to Retinoblastoma Progression Through SNHG16/miR-183-5p/NRAS Regulatory Network. Onco Targets Ther 2019;12:10703-15. [PMID: 31827328 DOI: 10.2147/OTT.S232470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 211 |
Hwang KT, Kim BH, Oh S, Park SY, Jung J, Kim J, Choi IS, Jeon SY, Kim WY. Prognostic Role of KRAS mRNA Expression in Breast Cancer. J Breast Cancer 2019;22:548-61. [PMID: 31897329 DOI: 10.4048/jbc.2019.22.e55] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 212 |
Spannl S, Tereshchenko M, Mastromarco GJ, Ihn SJ, Lee HO. Biomolecular condensates in neurodegeneration and cancer. Traffic 2019;20:890-911. [PMID: 31606941 DOI: 10.1111/tra.12704] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 213 |
Post JB, Hami N, Lohuis J, van de Ven M, de Korte-grimmerink R, Stangl C, Stelloo E, Verlaan I, van Rheenen J, Snippert HJ. Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic RAS and BRAF variants.. [DOI: 10.1101/860122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 214 |
Hong S, Yan Z, Wang H, Ding L, Song Y, Bi M. miR-663b promotes colorectal cancer progression by activating Ras/Raf signaling through downregulation of TNK1. Hum Cell 2020;33:104-15. [PMID: 31758392 DOI: 10.1007/s13577-019-00294-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 215 |
Chen F, Alphonse MP, Liu Y, Liu Q. Targeting Mutant KRAS for Anticancer Therapy. CTMC 2019;19:2098-113. [DOI: 10.2174/1568026619666190902151307] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 216 |
Che Y, Siprashvili Z, Kovalski JR, Jiang T, Wozniak G, Elcavage L, Khavari PA. KRAS regulation by small non-coding RNAs and SNARE proteins. Nat Commun 2019;10:5118. [PMID: 31712554 DOI: 10.1038/s41467-019-13106-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 217 |
Jha MK, Sarode AY, Saha B. Ras isoforms selectively regulate antigen-specific immune response. Cytokine 2020;126:154914. [PMID: 31707328 DOI: 10.1016/j.cyto.2019.154914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 218 |
Georgakopoulou E, Stebbing J, Scully C. Targeted cancer therapies: Oral health care implications. J Am Dent Assoc 2018;149:100-11. [PMID: 29389333 DOI: 10.1016/j.adaj.2017.08.046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 219 |
Barbosa Do Prado L, Han C, Oh SP, Su H. Recent Advances in Basic Research for Brain Arteriovenous Malformation. Int J Mol Sci 2019;20:E5324. [PMID: 31731545 DOI: 10.3390/ijms20215324] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 220 |
Sarkar S, Garcia AE. Presence or absence of Ras-dimerization shows distinct kinetic signature in Ras-Raf interaction.. [DOI: 10.1101/810150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 221 |
Newbury LJ, Wang JH, Hung G, Hendry BM, Sharpe CC. Inhibition of Kirsten-Ras reduces fibrosis and protects against renal dysfunction in a mouse model of chronic folic acid nephropathy. Sci Rep 2019;9:14010. [PMID: 31570767 DOI: 10.1038/s41598-019-50422-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 222 |
Wu Z, Zhang Y, Zhang JZ, Xia K, Xia F. Determining Optimal Coarse-Grained Representation for Biomolecules Using Internal Cluster Validation Indexes. J Comput Chem 2020;41:14-20. [PMID: 31568566 DOI: 10.1002/jcc.26070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 223 |
Roncarati R, Lupini L, Shankaraiah RC, Negrini M. The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer. Front Oncol 2019;9:988. [PMID: 31612113 DOI: 10.3389/fonc.2019.00988] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 224 |
Yan J, Xu L, Yu J, Wu X, Dai J, Xu T, Yu H, Guo J, Kong Y. Prognostic role of NRAS isoforms in Chinese melanoma patients. Melanoma Res 2019;29:263-9. [PMID: 30489482 DOI: 10.1097/CMR.0000000000000557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 225 |
Khan K, Valeri N, Dearman C, Rao S, Watkins D, Starling N, Chau I, Cunningham D. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Crit Rev Oncol Hematol. 2019;143:153-163. [PMID: 31678702 DOI: 10.1016/j.critrevonc.2019.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 226 |
Chen P, Wang S, Janardhan KS, Zemans RL, Deng W, Karmaus P, Shen S, Sunday M, Que LG, Fessler MB, Zhong XP. Efficient CD4Cre-Mediated Conditional KRas Expression in Alveolar Macrophages and Alveolar Epithelial Cells Causes Fatal Hyperproliferative Pneumonitis. J Immunol 2019;203:1208-17. [PMID: 31315887 DOI: 10.4049/jimmunol.1900566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 227 |
Bertoli E, Giavarra M, Vitale MG, Minisini AM. Neuroblastoma rat sarcoma mutated melanoma: That's what we got so far. Pigment Cell Melanoma Res 2019;32:744-52. [PMID: 31403745 DOI: 10.1111/pcmr.12819] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 228 |
Goloshvili G, Barbakadze T, Mikeladze D. Sodium nitroprusside induces H‐Ras depalmitoylation and alters the cellular response to hypoxia in differentiated and undifferentiated PC12 cells. Cell Biochem Funct 2019;37:545-52. [DOI: 10.1002/cbf.3431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 229 |
Jelski W, Mroczko B. Biochemical diagnostics of pancreatic cancer - Present and future. Clin Chim Acta. 2019;498:47-51. [PMID: 31430440 DOI: 10.1016/j.cca.2019.08.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 230 |
Wang W, Zhou Y, Zhong L, Wang L, Tang X, Ma M, Li J, Song H. RAS-associated Autoimmune Leukoproliferative disease (RALD) manifested with early-onset SLE-like syndrome: a case series of RALD in Chinese children. Pediatr Rheumatol Online J 2019;17:55. [PMID: 31412876 DOI: 10.1186/s12969-019-0346-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 231 |
Vatansever S, Erman B, Gümüş ZH. Oncogenic G12D mutation alters local conformations and dynamics of K-Ras. Sci Rep 2019;9:11730. [PMID: 31409810 DOI: 10.1038/s41598-019-48029-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 232 |
Yoshino H, Yin G, Kawaguchi R, Popov KI, Temple B, Sasaki M, Kofuji S, Wolfe K, Kofuji K, Okumura K, Randhawa J, Malhotra A, Majd N, Ikeda Y, Shimada H, Kahoud ER, Haviv S, Iwase S, Asara JM, Campbell SL, Sasaki AT. Identification of lysine methylation in the core GTPase domain by GoMADScan. PLoS One 2019;14:e0219436. [PMID: 31390367 DOI: 10.1371/journal.pone.0219436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 233 |
Moghadamchargari Z, Huddleston J, Shirzadeh M, Zheng X, Clemmer DE, M Raushel F, Russell DH, Laganowsky A. Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry. Biochemistry 2019;58:3396-405. [PMID: 31306575 DOI: 10.1021/acs.biochem.9b00532] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 234 |
Talens F, Van Vugt MATM. Inflammatory signaling in genomically instable cancers. Cell Cycle 2019;18:1830-48. [PMID: 31260383 DOI: 10.1080/15384101.2019.1638192] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 235 |
Quattrini L, Coviello V, Sartini S, Di Desidero T, Orlandi P, Ke YY, Liu KL, Hsieh HP, Bocci G, La Motta C. Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation. Sci Rep 2019;9:9943. [PMID: 31289333 DOI: 10.1038/s41598-019-46287-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 236 |
Mehta A, Dalle Vedove E, Isert L, Merkel OM. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles. Pharm Res 2019;36:133. [PMID: 31289919 DOI: 10.1007/s11095-019-2665-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 237 |
Zhou X, Shang YN, Lu R, Fan CW, Mo XM. High ANKZF1 expression is associated with poor overall survival and recurrence-free survival in colon cancer. Future Oncol 2019;15:2093-106. [PMID: 31257922 DOI: 10.2217/fon-2018-0920] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 238 |
Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: Roles in precision medicine. Semin Cancer Biol. 2019;59:23-35. [PMID: 31255772 DOI: 10.1016/j.semcancer.2019.06.007] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 239 |
Bechtel W. From parts to mechanisms: research heuristics for addressing heterogeneity in cancer genetics. Hist Philos Life Sci 2019;41:27. [PMID: 31240400 DOI: 10.1007/s40656-019-0266-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 240 |
Ni D, Li X, He X, Zhang H, Zhang J, Lu S. Drugging K-RasG12C through covalent inhibitors: Mission possible? Pharmacol Ther 2019;202:1-17. [PMID: 31233765 DOI: 10.1016/j.pharmthera.2019.06.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 241 |
Olea-Flores M, Zuñiga-Eulogio MD, Mendoza-Catalán MA, Rodríguez-Ruiz HA, Castañeda-Saucedo E, Ortuño-Pineda C, Padilla-Benavides T, Navarro-Tito N. Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial-Mesenchymal Transition in Cancer. Int J Mol Sci 2019;20:E2885. [PMID: 31200510 DOI: 10.3390/ijms20122885] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 242 |
Sharma Y, Miladi M, Dukare S, Boulay K, Caudron-Herger M, Groß M, Backofen R, Diederichs S. A pan-cancer analysis of synonymous mutations. Nat Commun 2019;10:2569. [PMID: 31189880 DOI: 10.1038/s41467-019-10489-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 243 |
Londhe P, Gutwillig M, London C. Targeted Therapies in Veterinary Oncology. Vet Clin North Am Small Anim Pract 2019;49:917-31. [PMID: 31186124 DOI: 10.1016/j.cvsm.2019.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 244 |
Diamantopoulos PT, Lakiotaki E, Kyriakakis G, Gogas H. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma. Melanoma Res 2020;30:206-8. [PMID: 31157737 DOI: 10.1097/CMR.0000000000000627] [Reference Citation Analysis]
|
| 245 |
Cagir A, Azmi AS. KRASG12C inhibitors on the horizon. Future Med Chem 2019;11:923-5. [PMID: 31140867 DOI: 10.4155/fmc-2018-0304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 246 |
Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Sci Signal 2019;12:eaaw9450. [PMID: 31138768 DOI: 10.1126/scisignal.aaw9450] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 22.3] [Reference Citation Analysis]
|
| 247 |
Roslan NH, Makpol S, Mohd Yusof YA. A Review on Dietary Intervention in Obesity Associated Colon Cancer. Asian Pac J Cancer Prev 2019;20:1309-19. [PMID: 31127882 DOI: 10.31557/APJCP.2019.20.5.1309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 248 |
Marampon F, Ciccarelli C, Zani BM. Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation. Int J Mol Sci 2019;20:E2530. [PMID: 31126017 DOI: 10.3390/ijms20102530] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 249 |
Lara-Lemus R. On The Role of Myelin and Lymphocyte Protein (MAL) In Cancer: A Puzzle With Two Faces. J Cancer 2019;10:2312-8. [PMID: 31258734 DOI: 10.7150/jca.30376] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 250 |
Ferreirós A, Pedrosa P, Da Silva-Álvarez S, Triana-Martínez F, Vilas JM, Picallos-Rabina P, González P, Gómez M, Li H, García-Caballero T, González-Barcia M, Vidal A, Collado M. Context-Dependent Impact of RAS Oncogene Expression on Cellular Reprogramming to Pluripotency. Stem Cell Reports 2019;12:1099-112. [PMID: 31056476 DOI: 10.1016/j.stemcr.2019.04.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 251 |
Daw S, Law A, Law S. Myelodysplastic Syndrome related alterations of MAPK signaling in the bone marrow of experimental mice including stem/progenitor compartment. Acta Histochem 2019;121:330-43. [PMID: 30808519 DOI: 10.1016/j.acthis.2019.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 252 |
Takahara S, Inoue SI, Miyagawa-Tomita S, Matsuura K, Nakashima Y, Niihori T, Matsubara Y, Saiki Y, Aoki Y. New Noonan syndrome model mice with RIT1 mutation exhibit cardiac hypertrophy and susceptibility to β-adrenergic stimulation-induced cardiac fibrosis. EBioMedicine 2019;42:43-53. [PMID: 30898653 DOI: 10.1016/j.ebiom.2019.03.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 253 |
Fu W, Zhuo Z, Hua RX, Fu K, Jia W, Zhu J, Zhang J, Cheng J, Zhou H, Xia H, He J, Liu G. Association of KRAS and NRAS gene polymorphisms with Wilms tumor risk: a four-center case-control study. Aging (Albany NY) 2019;11:1551-63. [PMID: 30860980 DOI: 10.18632/aging.101855] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 254 |
Shimomura I, Yokoi A, Kohama I, Kumazaki M, Tada Y, Tatsumi K, Ochiya T, Yamamoto Y. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. Cancer Lett 2019;451:11-22. [PMID: 30862488 DOI: 10.1016/j.canlet.2019.03.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 255 |
Suzuki-Muromoto S, Miyabayashi T, Nagai K, Yamamura-Suzuki S, Anzai M, Takezawa Y, Sato R, Okubo Y, Endo W, Inui T, Togashi N, Kikuchi A, Niihori T, Aoki Y, Kure S, Haginoya K. Leucine-485 deletion variant of BRAF may exhibit the severe end of the clinical spectrum of CFC syndrome. J Hum Genet 2019;64:499-504. [PMID: 30842599 DOI: 10.1038/s10038-019-0579-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 256 |
Jin X, Qin T, Zhao M, Bailey N, Liu L, Yang K, Ng V, Higashimoto T, Coolon R, Ney G, Figueroa ME, Li Q. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells. Blood Adv 2018;2:1259-71. [PMID: 29866713 DOI: 10.1182/bloodadvances.2018017400] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 257 |
Soong YV, Liu N, Yoon S, Lawton C, Xie D. Cellular and metabolic engineering of oleaginous yeast Yarrowia lipolytica for bioconversion of hydrophobic substrates into high-value products. Eng Life Sci 2019;19:423-43. [PMID: 32625020 DOI: 10.1002/elsc.201800147] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 258 |
Cao S, Chung S, Kim S, Li Z, Manor D, Buck M. K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function. J Biol Chem 2019;294:7068-84. [PMID: 30792310 DOI: 10.1074/jbc.RA118.004021] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 259 |
Roskoski R Jr. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacol Res 2019;142:151-68. [PMID: 30794926 DOI: 10.1016/j.phrs.2019.01.039] [Cited by in Crossref: 115] [Cited by in F6Publishing: 127] [Article Influence: 28.8] [Reference Citation Analysis]
|
| 260 |
Gergely PA, Murnyák B, Bencze J, Kurucz A, Varjas T, Gombos K, Hortobágyi T. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. Biomed Res Int 2019;2019:8670398. [PMID: 30882001 DOI: 10.1155/2019/8670398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 261 |
Sakthianandeswaren A, Sabljak P, J. Elliott M, Palmieri M, M. Sieber O. Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer. Advances in the Molecular Understanding of Colorectal Cancer 2019. [DOI: 10.5772/intechopen.80690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 262 |
Yin C, Zhu B, Zhang T, Liu T, Chen S, Liu Y, Li X, Miao X, Li S, Mi X, Zhang J, Li L, Wei G, Xu Z, Gao X, Huang C, Wei Z, Goding CR, Wang P, Deng X, Cui R. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell 2019;176:1113-1127.e16. [DOI: 10.1016/j.cell.2019.01.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 263 |
Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. J Exp Clin Cancer Res 2019;38:41. [PMID: 30691487 DOI: 10.1186/s13046-019-1035-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 264 |
Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019;25:185-197. [PMID: 30686761 DOI: 10.1016/j.molmed.2018.12.009] [Cited by in Crossref: 68] [Cited by in F6Publishing: 78] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 265 |
Vail DM, Thamm DH, Liptak JM. Molecular/Targeted Therapy of Cancer. Withrow and MacEwen's Small Animal Clinical Oncology 2019. [DOI: 10.1016/b978-0-323-59496-7.00015-3] [Reference Citation Analysis]
|
| 266 |
Eng S, Loh THT, Goh B, Lee W. KRAS as Potential Target in Colorectal Cancer Therapy. Natural Bio-active Compounds 2019. [DOI: 10.1007/978-981-13-7154-7_12] [Reference Citation Analysis]
|
| 267 |
Lin A, Hua RX, Tang J, Zhu J, Zhang R, Zhou H, Zhang J, Cheng J, Xia H, He J. KRAS rs7973450 A>G increases neuroblastoma risk in Chinese children: a four-center case-control study. Onco Targets Ther 2019;12:7289-95. [PMID: 31564912 DOI: 10.2147/OTT.S223220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 268 |
Yang T, Wen Y, Li J, Tan T, Yang J, Pan J, Hu C, Yao Y, Zhang J, Xin Y, Li S, Xia H, He J, Zou Y. NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children. Exp Hematol Oncol 2019;8:11. [PMID: 31086727 DOI: 10.1186/s40164-019-0135-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 148] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 269 |
Liu M, Liu X, Huang Z, Tang X, Lin X, Xu Y, Chen G, Kwok HF, Lin Y, Feng S. Rapid discrimination of colon cancer cells with single base mutation in KRAS gene segment using laser tweezers Raman spectroscopy. J Biophotonics 2019;12. [DOI: 10.1002/jbio.201800332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 270 |
Prakash P, Litwin D, Liang H, Sarkar-Banerjee S, Dolino D, Zhou Y, Hancock JF, Jayaraman V, Gorfe AA. Dynamics of Membrane-Bound G12V-KRAS from Simulations and Single-Molecule FRET in Native Nanodiscs. Biophys J 2019;116:179-83. [PMID: 30616834 DOI: 10.1016/j.bpj.2018.12.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 271 |
Horio Y. Blocking KRAS Signaling for the Treatment of Lung Cancer: Mission Possible? JJLC 2018;58:953-958. [DOI: 10.2482/haigan.58.953] [Reference Citation Analysis]
|
| 272 |
Anelli V, Ordas A, Kneitz S, Sagredo LM, Gourain V, Schartl M, Meijer AH, Mione M. Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression. Front Genet 2018;9:675. [PMID: 30619488 DOI: 10.3389/fgene.2018.00675] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 273 |
Schöneborn H, Raudzus F, Coppey M, Neumann S, Heumann R. Perspectives of RAS and RHEB GTPase Signaling Pathways in Regenerating Brain Neurons. Int J Mol Sci 2018;19:E4052. [PMID: 30558189 DOI: 10.3390/ijms19124052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 274 |
Felisiak-Goląbek A, Inaguma S, Kowalik A, Wasąg B, Wang ZF, Zięba S, Pięciak L, Ryś J, Kopczynski J, Sarlomo-Rikala M, Góźdź S, Lasota J, Miettinen M. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma. Appl Immunohistochem Mol Morphol 2018;26:40-5. [PMID: 29206715 DOI: 10.1097/PAI.0000000000000500] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 275 |
Rudd AK, Brea RJ, Devaraj NK. Amphiphile-Mediated Depalmitoylation of Proteins in Living Cells. J Am Chem Soc 2018;140:17374-8. [PMID: 30516377 DOI: 10.1021/jacs.8b10806] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 276 |
Seo GH, Yoo HW. Growth hormone therapy in patients with Noonan syndrome. Ann Pediatr Endocrinol Metab 2018;23:176-81. [PMID: 30599478 DOI: 10.6065/apem.2018.23.4.176] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 277 |
Zhang G, Yu Z, Fu S, Lv C, Dong Q, Fu C, Kong C, Zeng Y. ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway. Cancer Gene Ther 2019;26:323-33. [PMID: 30459398 DOI: 10.1038/s41417-018-0064-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 278 |
Saeed O, Lopez-Beltran A, Fisher KW, Scarpelli M, Montironi R, Cimadamore A, Massari F, Santoni M, Cheng L. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J Clin Pathol 2019;72:135-9. [PMID: 30425122 DOI: 10.1136/jclinpath-2018-205471] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 279 |
Lu JW, Raghuram D, Fong PA, Gong Z. Inducible Intestine-Specific Expression of krasV12 Triggers Intestinal Tumorigenesis In Transgenic Zebrafish. Neoplasia 2018;20:1187-97. [PMID: 30390498 DOI: 10.1016/j.neo.2018.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 280 |
Dankner M. Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. JCO Precision Oncology 2018. [DOI: 10.1200/po.18.00195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 281 |
Garrido E, Lázaro J, Jaumot M, Agell N, Rubio-Martinez J. Modeling and subtleties of K-Ras and Calmodulin interaction. PLoS Comput Biol 2018;14:e1006552. [PMID: 30376570 DOI: 10.1371/journal.pcbi.1006552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 282 |
Choi SM, Andea AA, Wang M, Behdad A, Shao L, Zhang Y, Lu X, Dittmann D, Castro J, Chen YH, Gao J. KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma. Diagn Pathol 2018;13:78. [PMID: 30322385 DOI: 10.1186/s13000-018-0758-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 283 |
Szlachta K, Kuscu C, Tufan T, Adair SJ, Shang S, Michaels AD, Mullen MG, Fischer NL, Yang J, Liu L, Trivedi P, Stelow EB, Stukenberg PT, Parsons JT, Bauer TW, Adli M. CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 2018;9:4275. [PMID: 30323222 DOI: 10.1038/s41467-018-06676-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 284 |
Messenger ZJ, Hall JR, Jima DD, House JS, Tam HW, Tokarz DA, Smart RC. C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event. Cell Death Dis 2018;9:1054. [PMID: 30323292 DOI: 10.1038/s41419-018-1103-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 285 |
Biancucci M, Minasov G, Banerjee A, Herrera A, Woida PJ, Kieffer MB, Bindu L, Abreu-Blanco M, Anderson WF, Gaponenko V, Stephen AG, Holderfield M, Satchell KJF. The bacterial Ras/Rap1 site-specific endopeptidase RRSP cleaves Ras through an atypical mechanism to disrupt Ras-ERK signaling. Sci Signal 2018;11:eaat8335. [PMID: 30279169 DOI: 10.1126/scisignal.aat8335] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 286 |
Hong K, Choi Y. Role of estrogen and RAS signaling in repeated implantation failure. BMB Rep 2018;51:225-9. [PMID: 29519295 DOI: 10.5483/bmbrep.2018.51.5.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 287 |
Pattanayak R, Barua A, Das A, Chatterjee T, Pathak A, Choudhury P, Sen S, Saha P, Bhattacharyya M. Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy. Eur J Pharm Sci 2018;125:39-53. [PMID: 30223034 DOI: 10.1016/j.ejps.2018.09.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 288 |
Spit M, Koo BK, Maurice MM. Tales from the crypt: intestinal niche signals in tissue renewal, plasticity and cancer. Open Biol 2018;8:180120. [PMID: 30209039 DOI: 10.1098/rsob.180120] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 289 |
Adhikari H, Counter CM. Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nat Commun 2018;9:3646. [PMID: 30194290 DOI: 10.1038/s41467-018-05692-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 290 |
Calaf GM. CARCINOGENICITY OF MALATHION AND ESTROGEN IN AN EXPERIMENTAL RAT MAMMARY GLAND MODEL. Sib onkol ž 2018;17:5-13. [DOI: 10.21294/1814-4861-2018-17-4-5-13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 291 |
Roskoski R. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research 2018;135:239-58. [DOI: 10.1016/j.phrs.2018.08.013] [Cited by in Crossref: 94] [Cited by in F6Publishing: 101] [Article Influence: 18.8] [Reference Citation Analysis]
|
| 292 |
Azmi AS. Some chinks in RAS armor. Semin Cancer Biol 2019;54:iii-iv. [PMID: 30092255 DOI: 10.1016/j.semcancer.2018.08.005] [Reference Citation Analysis]
|
| 293 |
Rao G, Kim I, Conforti F, Liu J, Zhang Y, Giaccone G. Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. European Journal of Cancer 2018;99:37-48. [DOI: 10.1016/j.ejca.2018.05.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 294 |
Peng W, Sun ZY, Zhang Q, Cheng SQ, Wang SK, Wang XN, Kuang GT, Su XX, Tan JH, Huang ZS, Ou TM. Design, Synthesis, and Evaluation of Novel p-(Methylthio)styryl Substituted Quindoline Derivatives as Neuroblastoma RAS (NRAS) Repressors via Specific Stabilizing the RNA G-Quadruplex. J Med Chem 2018;61:6629-46. [PMID: 29799749 DOI: 10.1021/acs.jmedchem.8b00257] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 295 |
Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-Mutant non-small cell lung cancer: From biology to therapy. Lung Cancer 2018;124:53-64. [PMID: 30268480 DOI: 10.1016/j.lungcan.2018.07.013] [Cited by in Crossref: 156] [Cited by in F6Publishing: 168] [Article Influence: 31.2] [Reference Citation Analysis]
|
| 296 |
Subramaniam D, Kaushik G, Dandawate P, Anant S. Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer. Curr Med Chem. 2018;25:2585-2594. [PMID: 28137215 DOI: 10.2174/0929867324666170127095832] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 297 |
Hussein HAM, Okafor IB, Walker LR, Abdel-Raouf UM, Akula SM. Cellular and viral oncogenes: the key to unlocking unknowns of Kaposi's sarcoma-associated herpesvirus pathogenesis. Arch Virol 2018;163:2633-43. [PMID: 29936609 DOI: 10.1007/s00705-018-3918-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 298 |
Chen F, Zhang Q, Wang Y, Wang S, Feng S, Qi L, Li X, Ding C. KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature. Oncol Lett 2018;15:9786-92. [PMID: 29805686 DOI: 10.3892/ol.2018.8558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 299 |
Villagomez FR, Medina-Contreras O, Cerna-Cortes JF, Patino-Lopez G. The role of the oncogenic Rab35 in cancer invasion, metastasis, and immune evasion, especially in leukemia. Small GTPases 2020;11:334-45. [PMID: 29781368 DOI: 10.1080/21541248.2018.1463895] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 300 |
Poon CLC, Brumby AM, Richardson HE. Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue. Int J Mol Sci 2018;19:E1585. [PMID: 29861494 DOI: 10.3390/ijms19061585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 301 |
López-Morató M, Brook JD, Wojciechowska M. Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1. Front Neurol 2018;9:349. [PMID: 29867749 DOI: 10.3389/fneur.2018.00349] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 302 |
Cao S, Chung S, Kim S, Li Z, Manor D, Buck M. K-Ras G-domain binding with signaling lipid phosphoinositides: PIP2 association, orientation, function.. [DOI: 10.1101/324210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 303 |
Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 304 |
Kinoshita-Kikuta E, Kinoshita E, Ueda S, Ino Y, Kimura Y, Hirano H, Koike T. Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers. Biochim Biophys Acta Proteins Proteom 2019;1867:62-70. [PMID: 29753091 DOI: 10.1016/j.bbapap.2018.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 305 |
Minari JB, Okelola CA, Ugochukwu NC. Analysis of Kras gene from induced pancreatic cancer rats administered with Momordicacharantia and Ocimumbasilicum leaf extracts. J Tradit Complement Med 2018;8:282-8. [PMID: 29736383 DOI: 10.1016/j.jtcme.2017.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 306 |
Schmidt ML, Hobbing KR, Donninger H, Clark GJ. RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis. Cancer Res 2018;78:2614-23. [PMID: 29735543 DOI: 10.1158/0008-5472.CAN-17-2466] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 307 |
Guo F, Gong H, Zhao H, Chen J, Zhang Y, Zhang L, Shi X, Zhang A, Jin H, Zhang J, He Y. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep 2018;8:6076. [PMID: 29666387 DOI: 10.1038/s41598-018-24306-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 308 |
de Koster EJ, de Geus-Oei LF, Dekkers OM, van Engen-van Grunsven I, Hamming J, Corssmit EPM, Morreau H, Schepers A, Smit J, Oyen WJG, Vriens D. Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocr Rev 2018;39:154-91. [PMID: 29300866 DOI: 10.1210/er.2017-00133] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 309 |
Keohavong P, Lan Q, Gao W. p53 and K-ras mutations in lung tissues and sputum samples of individuals exposed to smoky coal emissions in Xuan Wei County, China. Mutat Res Genet Toxicol Environ Mutagen 2018;829-830:70-4. [PMID: 29704996 DOI: 10.1016/j.mrgentox.2018.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 310 |
Schorch B, Heni H, Zahaf NI, Brummer T, Mione M, Schmidt G, Papatheodorou P, Aktories K. Targeting oncogenic Ras by the Clostridium perfringens toxin TpeL. Oncotarget 2018;9:16489-500. [PMID: 29662661 DOI: 10.18632/oncotarget.24740] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 311 |
Zhang T, Li Q, Chen S, Luo Y, Fan Y, Xu B. Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Oncotarget 2017;8:36750-60. [PMID: 27902470 DOI: 10.18632/oncotarget.13581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 312 |
Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 2018;37:3183-99. [DOI: 10.1038/s41388-018-0171-x] [Cited by in Crossref: 183] [Cited by in F6Publishing: 196] [Article Influence: 36.6] [Reference Citation Analysis]
|
| 313 |
Chen L, Zhuang C, Lu J, Jiang Y, Sheng C. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design. J Med Chem 2018;61:2604-10. [PMID: 29510040 DOI: 10.1021/acs.jmedchem.8b00057] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 314 |
Bennani B, Gilles S, Fina F, Nanni I, Ibrahimi SA, Riffi AA, Nejjari C, Benajeh D, Abkari ME, Martin P, Ouafik L. Mutation Analysis of Braf Exon 15 and Kras Codons 12 and 13 in Moroccan Patients with Colorectal Cancer. Int J Biol Markers 2010;25:179-84. [DOI: 10.5301/jbm.2010.6091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 315 |
Gagné-Sansfaçon J, Coulombe G, Langlois MJ, Langlois A, Paquet M, Carrier J, Feng GS, Qu CK, Rivard N. SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development. Oncotarget 2016;7:65676-95. [PMID: 27582544 DOI: 10.18632/oncotarget.11601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 316 |
Rivas S, Gómez-Oro C, Antón IM, Wandosell F. Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal. Biomedicines 2018;6:E29. [PMID: 29518912 DOI: 10.3390/biomedicines6010029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 317 |
Chen L, Yang R, Qiao W, Yuan X, Wang S, Goltzman D, Miao D. 1,25-Dihydroxy vitamin D prevents tumorigenesis by inhibiting oxidative stress and inducing tumor cellular senescence in mice. Int J Cancer 2018;143:368-82. [PMID: 29441580 DOI: 10.1002/ijc.31317] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 318 |
Bueno A, Morilla I, Diez D, Moya-Garcia AA, Lozano J, Ranea JA. Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies. Oncotarget 2016;7:75810-26. [PMID: 27713118 DOI: 10.18632/oncotarget.12416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 319 |
Sadlecki P, Grzanka D, Grabiec M. Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas. Dis Markers 2018;2018:1497879. [PMID: 29682098 DOI: 10.1155/2018/1497879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 320 |
Kim BJ, Jang HJ, Kim JH, Kim HS, Lee J. KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. Oncotarget 2016;7:58001-6. [PMID: 27517148 DOI: 10.18632/oncotarget.11156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 321 |
Nakhaei-Rad S, Haghighi F, Nouri P, Rezaei Adariani S, Lissy J, Kazemein Jasemi NS, Dvorsky R, Ahmadian MR. Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms. Crit Rev Biochem Mol Biol 2018;53:130-56. [PMID: 29457927 DOI: 10.1080/10409238.2018.1431605] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 322 |
Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S, Gil-Bazo I. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer 2018;17:33. [PMID: 29455666 DOI: 10.1186/s12943-018-0789-x] [Cited by in Crossref: 178] [Cited by in F6Publishing: 186] [Article Influence: 35.6] [Reference Citation Analysis]
|
| 323 |
Cazzanelli G, Pereira F, Alves S, Francisco R, Azevedo L, Dias Carvalho P, Almeida A, Côrte-Real M, Oliveira MJ, Lucas C, Sousa MJ, Preto A. The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis. Cells 2018;7:E14. [PMID: 29463063 DOI: 10.3390/cells7020014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 324 |
Upchurch E, Isabelle M, Lloyd GR, Kendall C, Barr H. An update on the use of Raman spectroscopy in molecular cancer diagnostics: current challenges and further prospects. Expert Review of Molecular Diagnostics 2018;18:245-58. [DOI: 10.1080/14737159.2018.1439739] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 325 |
Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 2017;8:3980-4000. [PMID: 28002810 DOI: 10.18632/oncotarget.14012] [Cited by in Crossref: 157] [Cited by in F6Publishing: 174] [Article Influence: 31.4] [Reference Citation Analysis]
|
| 326 |
Shi L, Middleton J, Jeon YJ, Magee P, Veneziano D, Laganà A, Leong HS, Sahoo S, Fassan M, Booton R, Shah R, Crosbie PAJ, Garofalo M. KRAS induces lung tumorigenesis through microRNAs modulation. Cell Death Dis 2018;9:219. [PMID: 29440633 DOI: 10.1038/s41419-017-0243-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 327 |
Lin YK, Fang Z, Jiang TY, Wan ZH, Pan YF, Ma YH, Shi YY, Tan YX, Dong LW, Zhang YJ, Wang HY. Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy. Cancer Lett 2018;421:161-9. [PMID: 29452147 DOI: 10.1016/j.canlet.2018.02.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 328 |
Masemann D, Köther K, Kuhlencord M, Varga G, Roth J, Lichty BD, Rapp UR, Wixler V, Ludwig S. Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. Oncoimmunology 2018;7:e1423171. [PMID: 29721377 DOI: 10.1080/2162402X.2017.1423171] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 329 |
Li S, Jang H, Zhang J, Nussinov R. Raf-1 Cysteine-Rich Domain Increases the Affinity of K-Ras/Raf at the Membrane, Promoting MAPK Signaling. Structure 2018;26:513-525.e2. [PMID: 29429878 DOI: 10.1016/j.str.2018.01.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 330 |
Manevitz-Mendelson E, Leichner GS, Barel O, Davidi-Avrahami I, Ziv-Strasser L, Eyal E, Pessach I, Rimon U, Barzilai A, Hirshberg A, Chechekes K, Amariglio N, Rechavi G, Yaniv K, Greenberger S. Somatic NRAS mutation in patient with generalized lymphatic anomaly. Angiogenesis 2018;21:287-98. [PMID: 29397482 DOI: 10.1007/s10456-018-9595-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 331 |
Tsuchida N, Murugan AK, Grieco M. Kirsten Ras* oncogene: significance of its discovery in human cancer research. Oncotarget 2016;7:46717-33. [PMID: 27102293 DOI: 10.18632/oncotarget.8773] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 332 |
Kunjiappan S, Panneerselvam T, Somasundaram B, Sankaranarayanan M, Chowdhury R, Chowdhury A, Bhattacharjee C. Design, in silico modeling, biodistribution study of rutin and quercetin loaded stable human hair keratin nanoparticles intended for anticancer drug delivery. Biomed Phys Eng Express 2018;4:025019. [DOI: 10.1088/2057-1976/aaa1cf] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 333 |
Fukawa T, Kanayama HO. Current knowledge of risk factors for testicular germ cell tumors. Int J Urol 2018;25:337-44. [PMID: 29345008 DOI: 10.1111/iju.13519] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 334 |
Lee TH, Chennakrishnaiah S, Meehan B, Montermini L, Garnier D, D'Asti E, Hou W, Magnus N, Gayden T, Jabado N, Eppert K, Majewska L, Rak J. Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras. Oncotarget 2016;7:51991-2002. [PMID: 27437771 DOI: 10.18632/oncotarget.10627] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 335 |
Spiliotis ET. Spatial effects - site-specific regulation of actin and microtubule organization by septin GTPases. J Cell Sci 2018;131:jcs207555. [PMID: 29326311 DOI: 10.1242/jcs.207555] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 13.4] [Reference Citation Analysis]
|
| 336 |
Shishina AK, Kovrigina EA, Galiakhmetov AR, Rathore R, Kovrigin EL. Study of Förster Resonance Energy Transfer to Lipid Domain Markers Ascertains Partitioning of Semisynthetic Lipidated N-Ras in Lipid Raft Nanodomains. Biochemistry 2018;57:872-81. [PMID: 29280621 DOI: 10.1021/acs.biochem.7b01181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 337 |
Heard JJ, Phung I, Potes MI, Tamanoi F. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer 2018;18:69. [PMID: 29320991 DOI: 10.1186/s12885-017-3938-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 338 |
Bo X, Chen Y, Sheng W, Gong Y, Wang H, Gao W, Zhang B. The regulation and function of microRNA-377/RASSF8 signaling axis in gastric cancer. Oncol Lett 2018;15:3630-8. [PMID: 29456730 DOI: 10.3892/ol.2018.7740] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 339 |
Momenzadeh H, Mirzai M, Jowkar Z, Geramizadeh B. Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study. Middle East J Dig Dis 2018;10:18-23. [PMID: 29682243 DOI: 10.15171/mejdd.2017.85] [Reference Citation Analysis]
|
| 340 |
Ni D, Liu D, Zhang J, Lu S. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin. Int J Mol Sci 2018;19:E151. [PMID: 29300353 DOI: 10.3390/ijms19010151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 341 |
Tebar F, Enrich C, Rentero C, Grewal T. GTPases Rac1 and Ras Signaling from Endosomes. Prog Mol Subcell Biol 2018;57:65-105. [PMID: 30097772 DOI: 10.1007/978-3-319-96704-2_3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 342 |
Ma X, Wang L, Cao Z, Hu H, Lu Z, Xu-monette Z, Young K, Li Y. Physiological and Pathological Functions of Mammalian MicroRNAs. Comprehensive Toxicology 2018. [DOI: 10.1016/b978-0-12-801238-3.95612-5] [Reference Citation Analysis]
|
| 343 |
Grimes AB. Evans Syndrome: Background, Clinical Presentation, Pathophysiology, and Management. Immune Hematology 2018. [DOI: 10.1007/978-3-319-73269-5_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 344 |
Martinelli C. Signaling Landscape of AML: The Story So Far. Recent Trends in Cancer Biology: Spotlight on Signaling Cascades and microRNAs 2018. [DOI: 10.1007/978-3-319-71553-7_13] [Reference Citation Analysis]
|
| 345 |
Neugent ML, Goodwin J, Sankaranarayanan I, Yetkin CE, Hsieh MH, Kim JW. A New Perspective on the Heterogeneity of Cancer Glycolysis. Biomol Ther (Seoul) 2018;26:10-8. [PMID: 29212302 DOI: 10.4062/biomolther.2017.210] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 346 |
Martins M, Mansinho A, Cruz-Duarte R, Martins SL, Costa L. Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. Adv Exp Med Biol 2018;1110:113-31. [PMID: 30623369 DOI: 10.1007/978-3-030-02771-1_8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 347 |
Haraguchi M, Takahashi K. EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer? Respiratory Disease Series: Diagnostic Tools and Disease Managements 2018. [DOI: 10.1007/978-981-10-8144-6_15] [Reference Citation Analysis]
|
| 348 |
Battaglin F, Puccini A, Naseem M, Schirripa M, Berger MD, Tokunaga R, McSkane M, Khoukaz T, Soni S, Zhang W, Lenz HJ. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. J Cancer Metastasis Treat 2018;4:12. [PMID: 34532592 DOI: 10.20517/2394-4722.2018.04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 349 |
Cao B, Zhou X, Yang W, Ma J, Zhou W, Fan D, Hong L. The role of cell-free DNA in predicting colorectal cancer prognosis. Expert Rev Gastroenterol Hepatol 2018;12:39-48. [PMID: 28838275 DOI: 10.1080/17474124.2017.1372191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 350 |
Kanno E, Kawasaki O, Takahashi K, Takano K, Endo T. DA-Raf, a dominant-negative antagonist of the Ras–ERK pathway, is a putative tumor suppressor. Experimental Cell Research 2018;362:111-20. [DOI: 10.1016/j.yexcr.2017.11.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 351 |
Cantini L, Calzone L, Martignetti L, Rydenfelt M, Blüthgen N, Barillot E, Zinovyev A. Classification of gene signatures for their information value and functional redundancy. NPJ Syst Biol Appl 2018;4:2. [PMID: 29263798 DOI: 10.1038/s41540-017-0038-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 352 |
Basu SK, Lee S, Salotti J, Basu S, Sakchaisri K, Xiao Z, Walia V, Westlake CJ, Morrison DK, Johnson PF. Oncogenic RAS-Induced Perinuclear Signaling Complexes Requiring KSR1 Regulate Signal Transmission to Downstream Targets. Cancer Res 2018;78:891-908. [PMID: 29259016 DOI: 10.1158/0008-5472.CAN-17-2353] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 353 |
Jing H, Zhang X, Wisner SA, Chen X, Spiegelman NA, Linder ME, Lin H. SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a. Elife 2017;6:e32436. [PMID: 29239724 DOI: 10.7554/eLife.32436] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 354 |
Winters IP, Chiou SH, Paulk NK, McFarland CD, Lalgudi PV, Ma RK, Lisowski L, Connolly AJ, Petrov DA, Kay MA, Winslow MM. Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nat Commun 2017;8:2053. [PMID: 29233960 DOI: 10.1038/s41467-017-01519-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 355 |
Yan J, Wu X, Yu J, Yu H, Xu T, Brown KM, Bai X, Dai J, Ma M, Tang H, Si L, Chi Z, Sheng X, Cui C, Kong Y, Guo J. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. Eur J Cancer 2018;89:90-101. [PMID: 29245078 DOI: 10.1016/j.ejca.2017.11.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 356 |
Karmakar S, Kaushik G, Nimmakayala R, Rachagani S, Ponnusamy MP, Batra SK. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention. Semin Cancer Biol 2019;54:63-71. [PMID: 29199014 DOI: 10.1016/j.semcancer.2017.11.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 357 |
Popovska SL, Dineva TB, Damyanova PD. Molecular Diagnosis of Lung Cancer. Journal of Biomedical and Clinical Research 2017;10:98-103. [DOI: 10.1515/jbcr-2017-0016] [Reference Citation Analysis]
|
| 358 |
Cicchini M, Buza EL, Sagal KM, Gudiel AA, Durham AC, Feldser DM. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression. Cell Rep 2017;18:1958-69. [PMID: 28228261 DOI: 10.1016/j.celrep.2017.01.069] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 359 |
Shishina AK, Kovrigina EA, Galiakhmetov AR, Rathore R, Kovrigin EL. Partitioning of semisynthetic lipidated N-Ras in lipid raft nanodomains determined by FRET to lipid domain markers.. [DOI: 10.1101/221382] [Reference Citation Analysis]
|
| 360 |
Martinez-useros J, Li W, Georgiev-hristov T, Fernandez-aceñero MJ, Borrero-palacios A, Perez N, Celdran A, Garcia-foncillas J. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Pathol Oncol Res 2019;25:269-78. [DOI: 10.1007/s12253-017-0341-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 361 |
Xu X, Lu Y, Li Y, Prinz RA. Sonic Hedgehog Signaling in Thyroid Cancer. Front Endocrinol (Lausanne) 2017;8:284. [PMID: 29163356 DOI: 10.3389/fendo.2017.00284] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 362 |
Sun L, Dou F, Chen J, Chi H, Xing S, Liu T, Sun S, Chen C. Salidroside slows the progression of EA.hy926 cell senescence by regulating the cell cycle in an atherosclerosis model. Mol Med Rep 2018;17:257-63. [PMID: 29115447 DOI: 10.3892/mmr.2017.7872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 363 |
Jing H, Zhang X, Wisner SA, Chen X, Spiegelman NA, Linder ME, Lin H. SIRT2 and lysine fatty acylation regulate the oncogenic activity of K-Ras4a.. [DOI: 10.1101/203638] [Reference Citation Analysis]
|
| 364 |
Jiang Y, Zhuang C, Chen L, Lu J, Dong G, Miao Z, Zhang W, Li J, Sheng C. Structural Biology-Inspired Discovery of Novel KRAS–PDEδ Inhibitors. J Med Chem 2017;60:9400-6. [DOI: 10.1021/acs.jmedchem.7b01243] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 365 |
Matsunaga S, Hano Y, Saito Y, Fujimoto KJ, Kumasaka T, Matsumoto S, Kataoka T, Shima F, Tanaka S. Structural transition of solvated H-Ras/GTP revealed by molecular dynamics simulation and local network entropy. Journal of Molecular Graphics and Modelling 2017;77:51-63. [DOI: 10.1016/j.jmgm.2017.07.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 366 |
Fu L, Wang Y, Tan J, Xu J, Gao Q, Chen Y, Fang J. Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms. Oncogene 2018;37:389-402. [DOI: 10.1038/onc.2017.345] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 367 |
Ramón Y Cajal S, Capdevila C, Hernandez-Losa J, De Mattos-Arruda L, Ghosh A, Lorent J, Larsson O, Aasen T, Postovit LM, Topisirovic I. Cancer as an ecomolecular disease and a neoplastic consortium. Biochim Biophys Acta Rev Cancer 2017;1868:484-99. [PMID: 28947238 DOI: 10.1016/j.bbcan.2017.09.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 368 |
Tian X, Zhu X, Yan T, Yu C, Shen C, Hu Y, Hong J, Chen H, Fang JY. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer. Mol Oncol 2017;11:1544-60. [PMID: 28796930 DOI: 10.1002/1878-0261.12117] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 369 |
Jia Y, Jiang T, Li X, Zhao C, Zhang L, Zhao S, Liu X, Qiao M, Luo J, Shi J, Yang H, Wang Y, Xi L, Zhang S, Gao G, Su C, Ren S, Zhou C. Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Oncol Lett 2017;14:6525-32. [PMID: 29163686 DOI: 10.3892/ol.2017.7016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 370 |
Johnston L, Power M, Sloan P, Long A, Silmon A, Chaffey B, Lisgo AJ, Little L, Vercauteren E, Steiniche T, Meyer T, Simpson J. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. J Clin Pathol 2018;71:336-43. [PMID: 28899979 DOI: 10.1136/jclinpath-2017-204629] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 371 |
Liu WN, Yan M, Chan AM. A thirty-year quest for a role of R-Ras in cancer: from an oncogene to a multitasking GTPase. Cancer Letters 2017;403:59-65. [DOI: 10.1016/j.canlet.2017.06.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 372 |
Chi XZ, Lee JW, Lee YS, Park IY, Ito Y, Bae SC. Runx3 plays a critical role in restriction-point and defense against cellular transformation. Oncogene 2017;36:6884-94. [PMID: 28846108 DOI: 10.1038/onc.2017.290] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 373 |
Simón-Carrasco L, Graña O, Salmón M, Jacob HKC, Gutierrez A, Jiménez G, Drosten M, Barbacid M. Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes Dev 2017;31:1456-68. [PMID: 28827401 DOI: 10.1101/gad.300244.117] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 374 |
Barbakadze T, Goloshvili G, Narmania N, Zhuravliova E, Mikeladze D. Subcellular Distribution of S-Nitrosylated H-Ras in Differentiated and Undifferentiated PC12 Cells during Hypoxia. Cell J 2017;19:443-51. [PMID: 28836406 DOI: 10.22074/cellj.2017.4546] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 375 |
Vatansever S, Erman B, Gümüş ZH. Oncogenic G12D mutation alters local conformations and dynamics of K-Ras.. [DOI: 10.1101/178483] [Reference Citation Analysis]
|
| 376 |
Dai J, Kunder CA, Chu EY, Chan EF, Egan CL, Novoa RA. Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy. J Cutan Pathol 2017;44:1053-6. [PMID: 28796396 DOI: 10.1111/cup.13024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 377 |
Schuhmacher AJ, Hernández-porras I, García-medina R, Guerra C. Noonan syndrome: lessons learned from genetically modified mouse models. Expert Review of Endocrinology & Metabolism 2017;12:367-78. [DOI: 10.1080/17446651.2017.1361821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 378 |
Muñoz-Couselo E, Adelantado EZ, Ortiz C, García JS, Perez-Garcia J. NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther 2017;10:3941-7. [PMID: 28860801 DOI: 10.2147/OTT.S117121] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 379 |
Pepper IJ, Van Sciver RE, Tang AH. Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa. BMC Evol Biol 2017;17:182. [PMID: 28784114 DOI: 10.1186/s12862-017-1024-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 380 |
Zhang Y, Cao Z, Xia F. Construction of ultra-coarse-grained model of protein with a Gō-like potential. Chemical Physics Letters 2017;681:1-6. [DOI: 10.1016/j.cplett.2017.05.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 381 |
Lu L, Zeng J. Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas. PLoS One. 2017;12:e0181532. [PMID: 28742845 DOI: 10.1371/journal.pone.0181532] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 382 |
Pawlina-Tyszko K, Gurgul A, Szmatoła T, Ropka-Molik K, Semik-Gurgul E, Klukowska-Rötzler J, Koch C, Mählmann K, Bugno-Poniewierska M. Genomic landscape of copy number variation and copy neutral loss of heterozygosity events in equine sarcoids reveals increased instability of the sarcoid genome. Biochimie 2017;140:122-32. [PMID: 28743673 DOI: 10.1016/j.biochi.2017.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 383 |
Herrero A, Matallanas D, Kolch W. The spatiotemporal regulation of RAS signalling. Biochem Soc Trans 2016;44:1517-22. [PMID: 27911734 DOI: 10.1042/BST20160127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 384 |
Pomeroy EJ, Eckfeldt CE. Targeting Ras signaling in AML: RALB is a small GTPase with big potential. Small GTPases 2020;11:39-44. [PMID: 28682649 DOI: 10.1080/21541248.2017.1339765] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 385 |
Schirripa M, Cohen SA, Battaglin F, Lenz HJ. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin Oncol 2018;45:124-32. [PMID: 30262397 DOI: 10.1053/j.seminoncol.2017.06.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 386 |
Zhang L, Zhang X, Zhang X, Lu Y, Li L, Cui S. MiRNA-143 mediates the proliferative signaling pathway of FSH and regulates estradiol production. Journal of Endocrinology 2017;234:1-14. [DOI: 10.1530/joe-16-0488] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 387 |
Riva A, BØrgesen M, Guldmann-Christensen M, Hauge Kyneb M, Voogd K, Andersen C, Epistolio S, Merlo E, Yding Wolff T, Hamilton-Dutoit S, Lorenzen J, Christensen UB, Frattini M. SensiScreen®KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations. PLoS One 2017;12:e0178027. [PMID: 28636636 DOI: 10.1371/journal.pone.0178027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 388 |
Kenney C, Stites EC. Analysis of RAS as a tumor suppressor.. [DOI: 10.1101/153692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 389 |
Pierotti MA. The molecular understanding of cancer: from the unspeakable illness to a curable disease. Ecancermedicalscience 2017;11:747. [PMID: 28690678 DOI: 10.3332/ecancer.2017.747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 390 |
Kumari A, Folk WP, Sakamuro D. The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance. Genes (Basel) 2017;8:E158. [PMID: 28590415 DOI: 10.3390/genes8060158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 391 |
Kim SJ, Kim JH, Yang B, Jeong JS, Lee SW. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement. Mol Ther 2017;25:356-67. [PMID: 28153088 DOI: 10.1016/j.ymthe.2016.11.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 392 |
Manent J, Banerjee S, de Matos Simoes R, Zoranovic T, Mitsiades C, Penninger JM, Simpson KJ, Humbert PO, Richardson HE. Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species. Oncogene 2017;36:5576-92. [PMID: 28581519 DOI: 10.1038/onc.2017.175] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 393 |
Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH, Zask A, Zhang Y, Sanchez-Martin M, Badgley MA, Huang CS, Tran TH, Akkiraju H, Brown LM, Nandakumar R, Cremers S, Yang WS, Tong L, Olive KP, Ferrando A, Stockwell BR. Multivalent Small-Molecule Pan-RAS Inhibitors. Cell 2017;168:878-889.e29. [PMID: 28235199 DOI: 10.1016/j.cell.2017.02.006] [Cited by in Crossref: 164] [Cited by in F6Publishing: 176] [Article Influence: 27.3] [Reference Citation Analysis]
|
| 394 |
Yu ZH, Zhang ZY. Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases. Chem Rev 2018;118:1069-91. [PMID: 28541680 DOI: 10.1021/acs.chemrev.7b00105] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 395 |
Vignola-gagné E, Keating P, Cambrosio A. Informing materials: drugs as tools for exploring cancer mechanisms and pathways. HPLS 2017;39. [DOI: 10.1007/s40656-017-0135-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 396 |
Biancucci M, Rabideau AE, Lu Z, Loftis AR, Pentelute BL, Satchell KJF. Substrate Recognition of MARTX Ras/Rap1-Specific Endopeptidase. Biochemistry 2017;56:2747-57. [PMID: 28459538 DOI: 10.1021/acs.biochem.7b00246] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 397 |
Cantini L, Calzone L, Martignetti L, Rydenfelt M, Blüthgen N, Barillot E, Zinovyev A. Classification of gene signatures for their information value and functional redundancy.. [DOI: 10.1101/136499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 398 |
Acunzo M, Romano G, Nigita G, Veneziano D, Fattore L, Laganà A, Zanesi N, Fadda P, Fassan M, Rizzotto L, Kladney R, Coppola V, Croce CM. Selective targeting of point-mutated KRAS through artificial microRNAs. Proc Natl Acad Sci U S A 2017;114:E4203-12. [PMID: 28484014 DOI: 10.1073/pnas.1620562114] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 399 |
Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, Mills GB, Gimotty PA, Xu X, Herlyn M, Zhang L. Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 2017;77:3745-57. [PMID: 28473531 DOI: 10.1158/0008-5472.CAN-16-1768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 400 |
Heidenreich B, Kumar R. Altered TERT promoter and other genomic regulatory elements: occurrence and impact. Int J Cancer 2017;141:867-76. [PMID: 28407294 DOI: 10.1002/ijc.30735] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 401 |
Barnoud T, Schmidt ML, Donninger H, Clark GJ. The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence. Cancer Lett 2017;400:30-6. [PMID: 28455242 DOI: 10.1016/j.canlet.2017.04.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 402 |
Ramaswamy A, Ostwal V, Pande N, Sahu A, Jandyal S, Ramadwar M, Shetty N, Patkar S, Goel M, Gupta S. Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option. J Gastrointest Cancer 2016;47:305-12. [PMID: 27211249 DOI: 10.1007/s12029-016-9828-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 403 |
Jansen JM, Wartchow C, Jahnke W, Fong S, Tsang T, Pfister K, Zavorotinskaya T, Bussiere D, Cheng JM, Crawford K, Dai Y, Dove J, Fang E, Feng Y, Florent JM, Fuller J, Gossert AD, Hekmat-Nejad M, Henry C, Klopp J, Lenahan WP, Lingel A, Ma S, Meyer A, Mishina Y, Narberes J, Pardee G, Ramurthy S, Rieffel S, Stuart D, Subramanian S, Tandeske L, Widger S, Widmer A, Winterhalter A, Zaror I, Hardy S. Inhibition of prenylated KRAS in a lipid environment. PLoS One 2017;12:e0174706. [PMID: 28384226 DOI: 10.1371/journal.pone.0174706] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 404 |
Teng Y, Ngoka L, Cowell JK. Promotion of invasion by mutant RAS is dependent on activation of the WASF3 metastasis promoter gene. Genes Chromosomes Cancer 2017;56:493-500. [PMID: 28233357 DOI: 10.1002/gcc.22453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 405 |
Lasota J, Kowalik A, Felisiak-Golabek A, Inaguma S, Wang ZF, Pięciak L, Zięba S, Pęksa R, Kopczynski J, Okoń K, Waloszczyk P, Gozdz S, Biernat W, Miettinen M. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma. Arch Pathol Lab Med 2017;141:564-8. [PMID: 28353383 DOI: 10.5858/arpa.2016-0147-OA] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 406 |
McDermott N, Meunier A, Wong S, Buchete V, Marignol L. Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs. Clin Transl Radiat Oncol 2017;2:63-8. [PMID: 29658003 DOI: 10.1016/j.ctro.2017.01.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 407 |
Lau HY, Tang J, Casey PJ, Wang M. Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms. Oncogene 2017;36:3934-42. [PMID: 28192404 DOI: 10.1038/onc.2016.508] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 408 |
Kubiniok P, Lavoie H, Therrien M, Thibault P. Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. Mol Cell Proteomics 2017;16:663-79. [PMID: 28188228 DOI: 10.1074/mcp.M116.065128] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 409 |
Zhang Y, Cao Z, Zhang JZ, Xia F. Performance Comparison of Systematic Methods for Rigorous Definition of Coarse-Grained Sites of Large Biomolecules. J Chem Inf Model 2017;57:214-22. [PMID: 28128949 DOI: 10.1021/acs.jcim.6b00683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 410 |
Kamath VP, Torres-Roca JF, Eschrich SA. Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. Int J Genomics 2017;2017:6576840. [PMID: 28280724 DOI: 10.1155/2017/6576840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 411 |
Schirripa M, Lenz HJ. Biomarker in Colorectal Cancer. Cancer J 2016;22:156-64. [PMID: 27341592 DOI: 10.1097/PPO.0000000000000190] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 412 |
Scrima M, Zito Marino F, Oliveira DM, Marinaro C, La Mantia E, Rocco G, De Marco C, Malanga D, De Rosa N, Rizzuto A, Botti G, Franco R, Zoppoli P, Viglietto G. Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients. J Cancer 2017;8:227-39. [PMID: 28243327 DOI: 10.7150/jca.17093] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 413 |
Jia Z, Liu W, Gong L, Xiao Z. Downregulation of RASAL2 promotes the proliferation, epithelial-mesenchymal transition and metastasis of colorectal cancer cells. Oncol Lett 2017;13:1379-85. [PMID: 28454265 DOI: 10.3892/ol.2017.5581] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 414 |
Jonckheere N, Vasseur R, Van Seuningen I. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting. Crit Rev Oncol Hematol 2017;111:7-19. [PMID: 28259298 DOI: 10.1016/j.critrevonc.2017.01.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 415 |
Panaccione A, Zhang Y, Mi Y, Mitani Y, Yan G, Prasad ML, McDonald WH, El-Naggar AK, Yarbrough WG, Ivanov SV. Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma. Oral Oncol 2017;66:38-45. [PMID: 28249646 DOI: 10.1016/j.oraloncology.2016.12.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 416 |
Crescenzi A, Fulciniti F, Bongiovanni M, Giovanella L, Trimboli P. Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry. Endocr Pathol 2017;28:71-4. [DOI: 10.1007/s12022-016-9466-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 417 |
Hosoya K, Matsusaka S, Kashiwada T, Suzuki K, Ureshino N, Sato A, Miki Y, Kitera K, Hirai M, Hatake K, Kimura S, Sueoka-aragane N. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. Pathol Oncol Res 2017;23:737-44. [DOI: 10.1007/s12253-016-0175-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 418 |
Biancucci M, Dolores JS, Wong J, Grimshaw S, Anderson WF, Satchell KJ, Kwon K. New ligation independent cloning vectors for expression of recombinant proteins with a self-cleaving CPD/6xHis-tag. BMC Biotechnol 2017;17:1. [PMID: 28056928 DOI: 10.1186/s12896-016-0323-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 419 |
Yamazaki H, Shirao T. Homer, Spikar, and Other Drebrin-Binding Proteins in the Brain. Adv Exp Med Biol 2017;1006:249-68. [PMID: 28865024 DOI: 10.1007/978-4-431-56550-5_14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 420 |
Serrano C, Demetri GD. Cancer as a Paradigm for Translational and Clinical Biomedical Research. Clinical and Translational Science 2017. [DOI: 10.1016/b978-0-12-802101-9.00032-6] [Reference Citation Analysis]
|
| 421 |
Lechuga CG, Simón-Carrasco L, Jacob HK, Drosten M. Genetic Validation of Cell Proliferation via Ras-Independent Activation of the Raf/Mek/Erk Pathway. Methods Mol Biol 2017;1487:269-76. [PMID: 27924574 DOI: 10.1007/978-1-4939-6424-6_20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 422 |
Hernández-Porras I, Guerra C. Modeling RASopathies with Genetically Modified Mouse Models. Methods Mol Biol 2017;1487:379-408. [PMID: 27924582 DOI: 10.1007/978-1-4939-6424-6_28] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 423 |
Asati V, Mahapatra DK, Bharti SK. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. European Journal of Medicinal Chemistry 2017;125:299-314. [DOI: 10.1016/j.ejmech.2016.09.049] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 424 |
Pandiri A, Kovi R, Alden C, Sills R. The Future of Carcinogenicity Testing. Comprehensive Medicinal Chemistry III 2017. [DOI: 10.1016/b978-0-12-409547-2.12386-8] [Reference Citation Analysis]
|
| 425 |
Khatami M. Cancer Biology: Severe Cumulative Delayed Type Hypersensitivity Reactions. Inflammation, Aging and Cancer 2017. [DOI: 10.1007/978-3-319-66475-0_6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 426 |
Ashton-beaucage D, Therrien M. How Genetics Has Helped Piece Together the MAPK Signaling Pathway. Methods in Molecular Biology 2017. [DOI: 10.1007/978-1-4939-6424-6_1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 427 |
Khatami M. Theories of Aging and Chronic Diseases: Chronic Inflammation an Interdependent ‘Roadmap’ to Age-Associated Illnesses. Inflammation, Aging and Cancer 2017. [DOI: 10.1007/978-3-319-66475-0_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 428 |
Lin G, Chen C, Yin F, Yang C, Tian J, Chen T, Xu G, He C, Lin MC, Wang J, Lu F, Wang X, Yong K. Biodegradable nanoparticles as siRNA carriers for in vivo gene silencing and pancreatic cancer therapy. J Mater Chem B 2017;5:3327-37. [DOI: 10.1039/c6tb03116a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 429 |
Trang P, Weidhaas JB, Slack FJ. MicroRNAs and Cancer. The Molecular Basis of Human Cancer 2017. [DOI: 10.1007/978-1-59745-458-2_17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 430 |
Van Sciver R, Njogu M, Isbell A, Odanga J, Bian M, Svyatova E, Siewertsz van Reesema L, Zheleva V, Eisner J, Bruflat J, Schmidt R, Tang-tan A, Tang A. Blocking SIAH Proteolysis, an Important K-RAS Vulnerability, to Control and Eradicate K-RAS-Driven Metastatic Cancer. Conquering RAS 2017. [DOI: 10.1016/b978-0-12-803505-4.00012-6] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 431 |
Martinelli E, Morgillo F, Troiani T, Ciardiello F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treat Rev. 2017;53:61-69. [PMID: 28073102 DOI: 10.1016/j.ctrv.2016.12.001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 10.9] [Reference Citation Analysis]
|
| 432 |
Kassouf E, Tabchi S, Tehfe M. Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis. BioDrugs 2016;30:95-104. [PMID: 26927802 DOI: 10.1007/s40259-016-0166-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 433 |
Marín-Ramos NI, Piñar C, Vázquez-Villa H, Martín-Fontecha M, González Á, Canales Á, Algar S, Mayo PP, Jiménez-Barbero J, Gajate C, Mollinedo F, Pardo L, Ortega-Gutiérrez S, Viso A, López-Rodríguez ML. Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling. Chemistry 2017;23:1676-85. [PMID: 27885731 DOI: 10.1002/chem.201604905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 434 |
Lee SH, Chung AM, Lee A, Oh WJ, Choi YJ, Lee YS, Jung ES. KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay. J Pathol Transl Med 2017;51:24-31. [PMID: 28013534 DOI: 10.4132/jptm.2016.10.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 435 |
Shpak M, Lu J. An Evolutionary Genetic Perspective on Cancer Biology. Annu Rev Ecol Evol Syst 2016;47:25-49. [DOI: 10.1146/annurev-ecolsys-121415-032109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 436 |
De Rosa M, Rega D, Costabile V, Duraturo F, Niglio A, Izzo P, Pace U, Delrio P. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therap Adv Gastroenterol 2016;9:861-86. [PMID: 27803741 DOI: 10.1177/1756283X16659790] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 437 |
Mansha M, Kumari UU, Cournia Z, Ullah N. Pyrazole-based potent inhibitors of GGT1: Synthesis, biological evaluation, and molecular docking studies. European Journal of Medicinal Chemistry 2016;124:666-76. [DOI: 10.1016/j.ejmech.2016.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 438 |
Liu C, Wang C, Wang J, Huang H. miR-1297 promotes cell proliferation by inhibiting RB1 in liver cancer. Oncol Lett 2016;12:5177-82. [PMID: 28105225 DOI: 10.3892/ol.2016.5326] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 439 |
Gomez-Millan J, Pajares B, Perez-Villa L, Carnero A, Alvarez M, De Luque V, Rivas F, Trigo JM, Toledo MD, Alba E, Medina JA. Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. BMC Cancer 2016;16:829. [PMID: 27793200 DOI: 10.1186/s12885-016-2869-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 440 |
Chen M, Peters A, Huang T, Nan X. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. Mini Rev Med Chem 2016;16:391-403. [PMID: 26423697 DOI: 10.2174/1389557515666151001152212] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 441 |
Ji Y, Wang Z, Li Z, Huang N, Chen H, Li B, Hui B. Silencing IGF-II impairs C-myc and N-ras expressions of SMMC-7721 cells via suppressing FAK/PI3K/Akt signaling pathway. Cytokine 2017;90:44-53. [PMID: 27768959 DOI: 10.1016/j.cyto.2016.10.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 442 |
Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ. Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. Int J Cancer 2017;140:431-9. [PMID: 27681944 DOI: 10.1002/ijc.30453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 443 |
Dastan M, Najafzadeh N, Abedelahi A, Sarvi M, Niapour A. Human platelet lysate versus minoxidil stimulates hair growth by activating anagen promoting signaling pathways. Biomed Pharmacother 2016;84:979-86. [PMID: 27764761 DOI: 10.1016/j.biopha.2016.10.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 444 |
Clarke M, Volpe G, Sheriff L, Walton D, Ward C, Wei W, Dumon S, García P, Frampton J. Transcriptional regulation of SPROUTY2 by MYB influences myeloid cell proliferation and stem cell properties by enhancing responsiveness to IL-3. Leukemia 2017;31:957-66. [PMID: 27748374 DOI: 10.1038/leu.2016.289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 445 |
Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, Chen X, Xu C, Xiang AP, Huang Q, Xu X, Zhang L. Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. Mol Cell Biol 2016;36:2742-54. [PMID: 27550813 DOI: 10.1128/MCB.00079-16] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 446 |
Sobani ZA, Sawant A, Jafri M, Correa AK, Sahin IH. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World J Clin Oncol 2016; 7(5): 340-351 [PMID: 27777877 DOI: 10.5306/wjco.v7.i5.340] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 447 |
Solassol J, Vendrell J, Märkl B, Haas C, Bellosillo B, Montagut C, Smith M, O'Sullivan B, D'Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M, Mescoli C, Collin C, Pagès JC, Sillekens P. Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer. PLoS One 2016;11:e0163444. [PMID: 27685259 DOI: 10.1371/journal.pone.0163444] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 448 |
Antontseva EV, Matveeva MY, Bondar NP, Kashina EV, Leberfarb EY, Bryzgalov LO, Gervas PA, Ponomareva AA, Cherdyntseva NV, Orlov YL, Merkulova TI. Regulatory single nucleotide polymorphisms at the beginning of intron 2 of the human KRAS gene. J Biosci 2015;40:873-83. [PMID: 26648033 DOI: 10.1007/s12038-015-9567-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 449 |
Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, Loupakis F, Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, Tonini G, Aprile G. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget 2015;6:31604-12. [PMID: 26384309 DOI: 10.18632/oncotarget.5231] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 450 |
Malka-Mahieu H, Girault I, Rubington M, Leriche M, Welsch C, Kamsu-Kom N, Zhao Q, Desaubry L, Vagner S, Robert C. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. Cell Cycle 2016;15:2405-9. [PMID: 27533468 DOI: 10.1080/15384101.2016.1208862] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 451 |
Chen H, Sun X, Ge W, Qian Y, Bai R, Zheng S. A seven-gene signature predicts overall survival of patients with colorectal cancer. Oncotarget 2017;8:95054-65. [PMID: 29221110 DOI: 10.18632/oncotarget.10982] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 452 |
Miyamoto Y, Zhang W, Lenz HJ. Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. Indian J Surg Oncol 2017;8:580-90. [PMID: 29203992 DOI: 10.1007/s13193-016-0543-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 453 |
Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs 2016;34:604-13. [PMID: 27424159 DOI: 10.1007/s10637-016-0374-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 454 |
Smal MP, Rolevich AI, Nabebina TI, Krasny SA, Goncharova RI. The opposite association of HRAS and KRAS mutations with clinical variables of bladder cancer. Russ J Genet Appl Res 2016;6:613-621. [DOI: 10.1134/s2079059716050129] [Reference Citation Analysis]
|
| 455 |
Palomba G, Cossu A, Paliogiannis P, Pazzola A, Baldino G, Scartozzi M, Ionta MT, Ortu S, Capelli F, Lanzillo A, Sedda T, Sanna G, Barca M, Virdis L, Budroni M, Palmieri G. Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. Oncol Lett 2016;12:1415-21. [PMID: 27446446 DOI: 10.3892/ol.2016.4798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 456 |
Matsunaga Y, Adachi Y, Sasaki Y, Koide H, Motoya M, Nosho K, Takagi H, Yamamoto H, Sasaki S, Arimura Y, Tokino T, Carbone DP, Imai K, Shinomura Y. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy: IGF-1R TARGETING FOR K-RAS MUTATED GI CANCERS. Mol Carcinog 2017;56:515-26. [DOI: 10.1002/mc.22513] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 457 |
Drosten M, Barbacid M. Ras and p53: An unsuspected liaison. Mol Cell Oncol 2016;3:e996001. [PMID: 27308624 DOI: 10.1080/23723556.2014.996001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 458 |
Jiang AG, Lu HY. k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis. Contemp Oncol (Pozn) 2016;20:124-9. [PMID: 27358590 DOI: 10.5114/wo.2016.60068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 459 |
Lui GY, Kovacevic Z, Richardson V, Merlot AM, Kalinowski DS, Richardson DR. Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget 2015;6:18748-79. [PMID: 26125440 DOI: 10.18632/oncotarget.4349] [Cited by in Crossref: 112] [Cited by in F6Publishing: 115] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 460 |
Kamata T, Jin H, Giblett S, Patel B, Patel F, Foster C, Pritchard C. The cholesterol-binding protein NPC2 restrains recruitment of stromal macrophage-lineage cells to early-stage lung tumours. EMBO Mol Med 2015;7:1119-37. [PMID: 26183450 DOI: 10.15252/emmm.201404838] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 461 |
Chang YY, Lin PC, Lin HH, Lin JK, Chen WS, Jiang JK, Yang SH, Liang WY, Chang SC. Mutation spectra of RAS gene family in colorectal cancer. Am J Surg. 2016;212:537-544.e3. [PMID: 27394063 DOI: 10.1016/j.amjsurg.2016.02.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 462 |
Posch C, Vujic I, Monshi B, Sanlorenzo M, Weihsengruber F, Rappersberger K, Ortiz-Urda S. Searching for the Chokehold of NRAS Mutant Melanoma. J Invest Dermatol 2016;136:1330-6. [PMID: 27160069 DOI: 10.1016/j.jid.2016.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 463 |
Guo Z, Cremer D. Methods for a Rapid and Automated Description of Proteins. Reviews in Computational Chemistry 2016. [DOI: 10.1002/9781119148739.ch7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 464 |
Pattanayak R, Basak P, Sen S, Bhattacharyya M. Interaction of KRAS G-quadruplex with natural polyphenols: A spectroscopic analysis with molecular modeling. Int J Biol Macromol 2016;89:228-37. [PMID: 27130653 DOI: 10.1016/j.ijbiomac.2016.04.074] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 465 |
Kong G, Chang YI, You X, Ranheim EA, Zhou Y, Burd CE, Zhang J. The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent. Leukemia 2016;30:1935-8. [PMID: 27109513 DOI: 10.1038/leu.2016.89] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 466 |
Shahbazi R, Ozpolat B, Ulubayram K. Oligonucleotide-based theranostic nanoparticles in cancer therapy. Nanomedicine (Lond) 2016;11:1287-308. [PMID: 27102380 DOI: 10.2217/nnm-2016-0035] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 467 |
Calaf GM, Abarca-Quinones J. Ras protein expression as a marker for breast cancer. Oncol Lett 2016;11:3637-42. [PMID: 27284366 DOI: 10.3892/ol.2016.4461] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 468 |
Khrenova MG, Kots ED, Nemukhin AV. Reaction Mechanism of Guanosine Triphosphate Hydrolysis by the Vision-Related Protein Complex Arl3-RP2. J Phys Chem B 2016;120:3873-9. [PMID: 27043216 DOI: 10.1021/acs.jpcb.6b03363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 469 |
Baldassarre G, Belletti B. Meet me in the cytoplasm: A role for p27(Kip1) in the control of H-Ras. Small GTPases 2016;7:71-5. [PMID: 27057815 DOI: 10.1080/21541248.2016.1171279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 470 |
Tohidpour A. CagA-mediated pathogenesis of Helicobacter pylori. Microbial Pathogenesis 2016;93:44-55. [DOI: 10.1016/j.micpath.2016.01.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 471 |
Alonso S, Dai Y, Yamashita K, Horiuchi S, Dai T, Matsunaga A, Sánchez-Muñoz R, Bilbao-Sieyro C, Díaz-Chico JC, Chernov AV, Strongin AY, Perucho M. Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget 2015;6:3420-31. [PMID: 25638164 DOI: 10.18632/oncotarget.2852] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 472 |
Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell 2015;163:1237-51. [PMID: 26590425 DOI: 10.1016/j.cell.2015.10.041] [Cited by in Crossref: 144] [Cited by in F6Publishing: 126] [Article Influence: 20.6] [Reference Citation Analysis]
|
| 473 |
Zangari A, Zaini J, Gulìa C. Genetics of Bladder Malignant Tumors in Childhood. Curr Genomics 2016;17:14-32. [PMID: 27013922 DOI: 10.2174/1389202916666151014221954] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 474 |
Alonso-Curbelo D, Osterloh L, Cañón E, Calvo TG, Martínez-Herranz R, Karras P, Martínez S, Riveiro-Falkenbach E, Romero PO, Rodríguez-Peralto JL, Pastor J, Soengas MS. RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development. Oncotarget 2015;6:11848-62. [PMID: 26008978 DOI: 10.18632/oncotarget.4055] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 475 |
Barnoud T, Wilkey DW, Merchant ML, Clark JA, Donninger H. Proteomics Analysis Reveals Novel RASSF2 Interaction Partners. Cancers (Basel) 2016;8:E37. [PMID: 26999212 DOI: 10.3390/cancers8030037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 476 |
Vu HL, Aplin AE. Targeting mutant NRAS signaling pathways in melanoma. Pharmacol Res 2016;107:111-6. [PMID: 26987942 DOI: 10.1016/j.phrs.2016.03.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 477 |
Mecucci C, Battista VD, Nofrini V. The myelodysplastic syndromes. The Genetic Basis of Haematological Cancers 2016. [DOI: 10.1002/9781118527948.ch1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 478 |
Moosa BA, Sagar S, Li S, Esau L, Kaur M, Khashab NM. Synthesis and anticancer evaluation of spermatinamine analogues. Bioorganic & Medicinal Chemistry Letters 2016;26:1629-32. [DOI: 10.1016/j.bmcl.2016.01.083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 479 |
Donninger H, Barnoud T, Clark GJ. NORE1A is a double barreled Ras senescence effector that activates p53 and Rb. Cell Cycle 2016;15:2263-4. [PMID: 26919075 DOI: 10.1080/15384101.2016.1152431] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 480 |
Abdel-Rahman O. Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations. Ther Adv Respir Dis 2016;10:265-74. [PMID: 26893312 DOI: 10.1177/1753465816632111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 481 |
Jenkins RW, Sullivan RJ. NRAS mutant melanoma: an overview for the clinician for melanoma management. Melanoma Manag 2016;3:47-59. [PMID: 30190872 DOI: 10.2217/mmt.15.40] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 482 |
Zdanov S, Mandapathil M, Abu Eid R, Adamson-Fadeyi S, Wilson W, Qian J, Carnie A, Tarasova N, Mkrtichyan M, Berzofsky JA, Whiteside TL, Khleif SN. Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. Cancer Immunol Res 2016;4:354-65. [PMID: 26880715 DOI: 10.1158/2326-6066.CIR-15-0241] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 483 |
White Y, Bagchi A, Van Ziffle J, Inguva A, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ. KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nat Commun 2016;7:10647. [PMID: 26854029 DOI: 10.1038/ncomms10647] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 484 |
Cogoi S, Xodo LE. G4 DNA in ras genes and its potential in cancer therapy. Biochim Biophys Acta 2016;1859:663-74. [PMID: 26855080 DOI: 10.1016/j.bbagrm.2016.02.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 485 |
Yong Y, Liao C, Wei D, Chen Z, Bian H. CD147 overexpression promotes tumorigenicity in Chinese hamster ovary cells: CD147 promotes tumorigenicity in CHO cells. Cell Biol Int 2016;40:375-86. [DOI: 10.1002/cbin.10571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 486 |
Chakrabarti M, Jang H, Nussinov R. Comparison of the Conformations of KRAS Isoforms, K-Ras4A and K-Ras4B, Points to Similarities and Significant Differences. J Phys Chem B 2016;120:667-79. [PMID: 26761128 DOI: 10.1021/acs.jpcb.5b11110] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 487 |
Lu S, Jang H, Muratcioglu S, Gursoy A, Keskin O, Nussinov R, Zhang J. Ras Conformational Ensembles, Allostery, and Signaling. Chem Rev 2016;116:6607-65. [PMID: 26815308 DOI: 10.1021/acs.chemrev.5b00542] [Cited by in Crossref: 227] [Cited by in F6Publishing: 234] [Article Influence: 32.4] [Reference Citation Analysis]
|
| 488 |
Downward J. RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? Clin Cancer Res 2015;21:1802-9. [PMID: 25878361 DOI: 10.1158/1078-0432.CCR-14-2180] [Cited by in Crossref: 131] [Cited by in F6Publishing: 134] [Article Influence: 18.7] [Reference Citation Analysis]
|
| 489 |
Jinesh GG, Kamat AM. Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. Cell Death Discov 2016;2:15069. [PMID: 27226900 DOI: 10.1038/cddiscovery.2015.69] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 490 |
Rainone V, Martelli C, Ottobrini L, Biasin M, Texido G, Degrassi A, Borelli M, Lucignani G, Trabattoni D, Clerici M. Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. PLoS One 2016;11:e0146622. [PMID: 26795765 DOI: 10.1371/journal.pone.0146622] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 491 |
Wang M, Casey PJ. Protein prenylation: unique fats make their mark on biology. Nat Rev Mol Cell Biol 2016;17:110-22. [DOI: 10.1038/nrm.2015.11] [Cited by in Crossref: 300] [Cited by in F6Publishing: 306] [Article Influence: 42.9] [Reference Citation Analysis]
|
| 492 |
Lin SJ, Lin CY, Yang DR, Izumi K, Yan E, Niu X, Chang HC, Miyamoto H, Wang N, Li G, Chang C. The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status. Neoplasia 2015;17:339-47. [PMID: 25925376 DOI: 10.1016/j.neo.2015.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 493 |
Mehdizadeh A, Somi MH, Darabi M, Jabbarpour-bonyadi M. Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma. Mol Biol Rep 2016;43:107-16. [DOI: 10.1007/s11033-016-3943-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 494 |
Shang J, Yao Y, Fan X, Shangguan L, Li J, Liu H, Zhou Y. miR-29c-3p promotes senescence of human mesenchymal stem cells by targeting CNOT6 through p53-p21 and p16-pRB pathways. Biochim Biophys Acta. 2016;1863:520-532. [PMID: 26792405 DOI: 10.1016/j.bbamcr.2016.01.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 495 |
Schäfer R. RAS Transformation Targets. Encyclopedia of Cancer 2016. [DOI: 10.1007/978-3-662-46875-3_4956] [Reference Citation Analysis]
|
| 496 |
Kralian S, Carr BI. Targeted Therapies for Hepatocellular Carcinoma. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_34] [Reference Citation Analysis]
|
| 497 |
Aisner DL, Doebele RC, Varella-garcia M, Franklin WA. Lung Cancer. Molecular Pathology in Clinical Practice 2016. [DOI: 10.1007/978-3-319-19674-9_32] [Reference Citation Analysis]
|
| 498 |
Sadeghian-Rizi S, Sakhteman A, Hassanzadeh F. A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors. Res Pharm Sci 2016;11:445-53. [PMID: 28003837 DOI: 10.4103/1735-5362.194869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 499 |
Zhang J, Park D, Shin DM, Deng X. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. Acta Biochim Biophys Sin (Shanghai) 2016;48:11-6. [PMID: 26578706 DOI: 10.1093/abbs/gmv118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 500 |
Wong YH, Pellicer A, Liu W. RAS Genes. Encyclopedia of Cancer 2016. [DOI: 10.1007/978-3-662-46875-3_4951] [Reference Citation Analysis]
|
| 501 |
Rehman S, Haynes J, Lima-fernandes E, Puri A, Haller A, Leung C, Agro L, Wang Y, O’brien C. Colorectal Cancer Stem Cells. Cancer Stem Cells 2016. [DOI: 10.1016/b978-0-12-803892-5.00007-3] [Reference Citation Analysis]
|
| 502 |
Khrenova MG, Kots ED, Kulakova AM, Polyakov IV. Modeling GTP hydrolysis in RasGAP protein complex. Moscow Univ Chem Bull 2016;71:21-24. [DOI: 10.3103/s0027131416010065] [Reference Citation Analysis]
|
| 503 |
Rotte A, Bhandaru M. Melanoma—Introduction, History and Epidemiology. Immunotherapy of Melanoma 2016. [DOI: 10.1007/978-3-319-48066-4_1] [Reference Citation Analysis]
|
| 504 |
Murugan AK, Munirajan AK, Alzahrani AS. MicroRNAs: Modulators of the Ras Oncogenes in Oral Cancer: miRNAs AND RAS ONCOGENES IN ORAL CANCER. J Cell Physiol 2016;231:1424-31. [DOI: 10.1002/jcp.25269] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 505 |
Dai X, Fan W, Wang Y, Huang L, Jiang Y, Shi L, Mckinley D, Tan W, Tan C. Combined Delivery of Let-7b MicroRNA and Paclitaxel via Biodegradable Nanoassemblies for the Treatment of KRAS Mutant Cancer. Mol Pharmaceutics 2016;13:520-33. [DOI: 10.1021/acs.molpharmaceut.5b00756] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 506 |
Barnoud T, Donninger H, Clark GJ. Ras Regulates Rb via NORE1A. J Biol Chem 2016;291:3114-23. [PMID: 26677227 DOI: 10.1074/jbc.M115.697557] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 507 |
Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Res 2016;76:675-85. [PMID: 26676756 DOI: 10.1158/0008-5472.CAN-15-1141] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 508 |
Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol 2016;37:6823-30. [PMID: 26662311 DOI: 10.1007/s13277-015-4523-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 509 |
Podbevšek P, Plavec J. KRAS promoter oligonucleotide with decoy activity dimerizes into a unique topology consisting of two G-quadruplex units. Nucleic Acids Res 2016;44:917-25. [PMID: 26656490 DOI: 10.1093/nar/gkv1359] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 510 |
Lu S, Jang H, Zhang J, Nussinov R. Inhibitors of Ras-SOS Interactions. ChemMedChem 2016;11:814-21. [PMID: 26630662 DOI: 10.1002/cmdc.201500481] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 511 |
Hernandez-Valladares M, Prior IA. Comparative proteomic analysis of compartmentalised Ras signalling. Sci Rep 2015;5:17307. [PMID: 26620772 DOI: 10.1038/srep17307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 512 |
Lih CJ, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V, Harper KN, Bouk CH, Rubinstein LV, Simon RM, Conley BA, Chen AP, Kummar S, Doroshow JH, Williams PM. Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. J Mol Diagn 2016;18:51-67. [PMID: 26602013 DOI: 10.1016/j.jmoldx.2015.07.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 513 |
Wang E, Karedan T, Perez CA. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Anticancer Drugs 2015;26:689-97. [PMID: 25974026 DOI: 10.1097/CAD.0000000000000247] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 514 |
Javier M, Filip J. RAS-RAF-MEK Pathway: Aberrations and Therapeutic Possibilities. Targeted Therapy in Translational Cancer Research 2015. [DOI: 10.1002/9781118468678.ch31] [Reference Citation Analysis]
|
| 515 |
Fabris L, Berton S, Pellizzari I, Segatto I, D'Andrea S, Armenia J, Bomben R, Schiappacassi M, Gattei V, Philips MR, Vecchione A, Belletti B, Baldassarre G. p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability. Proc Natl Acad Sci U S A 2015;112:13916-21. [PMID: 26512117 DOI: 10.1073/pnas.1508514112] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 516 |
Serrano C, Romagosa C, Hernández-Losa J, Simonetti S, Valverde C, Moliné T, Somoza R, Pérez M, Vélez R, Vergés R, Domínguez R, Carles J, Ramón Y Cajal S. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. Cancer 2016;122:99-107. [PMID: 26479291 DOI: 10.1002/cncr.29733] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 517 |
Cromm PM, Spiegel J, Grossmann TN, Waldmann H. Direkte Modulation von Aktivität und Funktion kleiner GTPasen. Angew Chem 2015;127:13718-41. [DOI: 10.1002/ange.201504357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 518 |
Aydin D, Bilici A, Kayahan S, Yavuzer D, Basar M, Aliustaoglu M. Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy. Clin Transl Oncol 2016;18:608-16. [PMID: 26459248 DOI: 10.1007/s12094-015-1405-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 519 |
Cromm PM, Spiegel J, Grossmann TN, Waldmann H. Direct Modulation of Small GTPase Activity and Function. Angew Chem Int Ed 2015;54:13516-37. [DOI: 10.1002/anie.201504357] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 520 |
Moriya M, Inoue S, Miyagawa-Tomita S, Nakashima Y, Oba D, Niihori T, Hashi M, Ohnishi H, Kure S, Matsubara Y, Aoki Y. Adult mice expressing a Braf Q241R mutation on an ICR/CD-1 background exhibit a cardio-facio-cutaneous syndrome phenotype. Hum Mol Genet 2015;24:7349-60. [PMID: 26472072 DOI: 10.1093/hmg/ddv435] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 521 |
Takai E, Yachida S. Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol 2015; 7(10): 250-258 [PMID: 26483879 DOI: 10.4251/wjgo.v7.i10.250] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 522 |
Bruntz RC, Lindsley CW, Brown HA. Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer. Pharmacol Rev 2014;66:1033-79. [PMID: 25244928 DOI: 10.1124/pr.114.009217] [Cited by in Crossref: 155] [Cited by in F6Publishing: 158] [Article Influence: 19.4] [Reference Citation Analysis]
|
| 523 |
Aoki Y, Niihori T, Inoue S, Matsubara Y. Recent advances in RASopathies. J Hum Genet 2016;61:33-9. [PMID: 26446362 DOI: 10.1038/jhg.2015.114] [Cited by in Crossref: 225] [Cited by in F6Publishing: 239] [Article Influence: 28.1] [Reference Citation Analysis]
|
| 524 |
Abdel-rahman O, Azim HA, Mikhail S, Salem ME. New hope on the horizon for patients with metastatic colorectal cancer. Colorectal Cancer 2015;4:229-39. [DOI: 10.2217/crc.15.28] [Reference Citation Analysis]
|
| 525 |
Khrenova MG, Grigorenko BL, Kolomeisky AB, Nemukhin AV. Hydrolysis of Guanosine Triphosphate (GTP) by the Ras·GAP Protein Complex: Reaction Mechanism and Kinetic Scheme. J Phys Chem B 2015;119:12838-45. [PMID: 26374425 DOI: 10.1021/acs.jpcb.5b07238] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 526 |
Tüfekçi Ö, Ören H, Demir Yenigürbüz F, Gözmen S, Karapınar TH, İrken G. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features. Turk J Haematol 2015;32:175-9. [PMID: 26316488 DOI: 10.4274/tjh.2014.0034] [Reference Citation Analysis]
|
| 527 |
Hartmann M, Gas-pascual E, Hemmerlin A, Rohmer M, Bach TJ. Development of an image-based screening system for inhibitors of the plastidial MEP pathway and of protein geranylgeranylation. F1000Res 2015;4:14. [DOI: 10.12688/f1000research.5923.2] [Reference Citation Analysis]
|
| 528 |
Nowotarski SL, Feith DJ, Shantz LM. Skin Carcinogenesis Studies Using Mouse Models with Altered Polyamines. Cancer Growth Metastasis 2015;8:17-27. [PMID: 26380554 DOI: 10.4137/CGM.S21219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 529 |
Hong L, Guo Y, BasuRay S, Agola JO, Romero E, Simpson DS, Schroeder CE, Simons P, Waller A, Garcia M, Carter M, Ursu O, Gouveia K, Golden JE, Aubé J, Wandinger-Ness A, Sklar LA. A Pan-GTPase Inhibitor as a Molecular Probe. PLoS One 2015;10:e0134317. [PMID: 26247207 DOI: 10.1371/journal.pone.0134317] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 530 |
Goel G. Evolving role of gene expression signatures as biomarkers in early-stage colon cancer. J Gastrointest Cancer. 2014;45:399-404. [PMID: 24989938 DOI: 10.1007/s12029-014-9634-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 531 |
Stintzing S, Stremitzer S, Sebio A, Lenz HJ. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. Hematol Oncol Clin North Am 2015;29:43-60. [PMID: 25475572 DOI: 10.1016/j.hoc.2014.09.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 532 |
Puerta-García E, Cañadas-Garre M, Calleja-Hernández MÁ. Molecular biomarkers in colorectal carcinoma. Pharmacogenomics 2015;16:1189-222. [PMID: 26237292 DOI: 10.2217/PGS.15.63] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 533 |
Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol 2015;16:15. [PMID: 25796376 DOI: 10.1007/s11864-015-0330-z] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 534 |
De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P, Delrio P. Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep. 2015;34:1087-1096. [PMID: 26151224 DOI: 10.3892/or.2015.4108] [Cited by in Crossref: 183] [Cited by in F6Publishing: 201] [Article Influence: 22.9] [Reference Citation Analysis]
|
| 535 |
Rimessi A, Patergnani S, Bonora M, Wieckowski MR, Pinton P. Mitochondrial Ca(2+) Remodeling is a Prime Factor in Oncogenic Behavior. Front Oncol 2015;5:143. [PMID: 26161362 DOI: 10.3389/fonc.2015.00143] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 536 |
Zhang RY, Du WQ, Zhang YC, Zheng JN, Pei DS. PLCε signaling in cancer. J Cancer Res Clin Oncol 2016;142:715-22. [PMID: 26109147 DOI: 10.1007/s00432-015-1999-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 537 |
Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16:281-298. [PMID: 25907612 DOI: 10.1038/nrm3979] [Cited by in Crossref: 382] [Cited by in F6Publishing: 392] [Article Influence: 47.8] [Reference Citation Analysis]
|
| 538 |
Nan X, Tamgüney TM, Collisson EA, Lin LJ, Pitt C, Galeas J, Lewis S, Gray JW, McCormick F, Chu S. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A 2015;112:7996-8001. [PMID: 26080442 DOI: 10.1073/pnas.1509123112] [Cited by in Crossref: 190] [Cited by in F6Publishing: 201] [Article Influence: 23.8] [Reference Citation Analysis]
|
| 539 |
Antic I, Biancucci M, Zhu Y, Gius DR, Satchell KJF. Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain. Nat Commun 2015;6:7396. [PMID: 26051945 DOI: 10.1038/ncomms8396] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 540 |
Ye HL, Li DD, Lin Q, Zhou Y, Zhou QB, Zeng B, Fu ZQ, Gao WC, Liu YM, Chen RW, Li ZH, Chen RF. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. World J Gastroenterol 2015; 21(21): 6621-6630 [PMID: 26074700 DOI: 10.3748/wjg.v21.i21.6621] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 541 |
Li W, Zhi W, Zou S, Qiu T, Ling Y, Shan L, Shi S, Ying J. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PLoS One 2015;10:e0128202. [PMID: 26042813 DOI: 10.1371/journal.pone.0128202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 542 |
Gibbs PE, Miralem T, Maines MD. Biliverdin reductase: a target for cancer therapy? Front Pharmacol 2015;6:119. [PMID: 26089799 DOI: 10.3389/fphar.2015.00119] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 543 |
Stewart AF, Hussain MA, García-Ocaña A, Vasavada RC, Bhushan A, Bernal-Mizrachi E, Kulkarni RN. Human β-cell proliferation and intracellular signaling: part 3. Diabetes 2015;64:1872-85. [PMID: 25999530 DOI: 10.2337/db14-1843] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 544 |
Epperla N, George B. An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. J Gastrointest Cancer 2016;47:206-9. [PMID: 26018827 DOI: 10.1007/s12029-015-9735-y] [Reference Citation Analysis]
|
| 545 |
Donninger H, Calvisi DF, Barnoud T, Clark J, Schmidt ML, Vos MD, Clark GJ. NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2. J Cell Biol 2015;208:777-89. [PMID: 25778922 DOI: 10.1083/jcb.201408087] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 546 |
Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol 2015;17:804-15. [PMID: 26005835 DOI: 10.1038/ncb3175] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 547 |
Lee WS, Lee JN, Baek JH, Park YH. RAS status in Korean patients with stage III and IV colorectal cancer. Clin Transl Oncol 2015;17:751-6. [PMID: 25997687 DOI: 10.1007/s12094-015-1301-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 548 |
Newlaczyl AU, Hood FE, Coulson JM, Prior IA. Decoding RAS isoform and codon-specific signalling. Biochem Soc Trans 2014;42:742-6. [PMID: 25109951 DOI: 10.1042/BST20140057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 549 |
Dai X, Jiang Y, Tan C. Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. PLoS One 2015;10:e0126653. [PMID: 25946136 DOI: 10.1371/journal.pone.0126653] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 550 |
Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 2015;15:340. [PMID: 25929517 DOI: 10.1186/s12885-015-1345-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 551 |
Qi X, Xie C, Hou S, Li G, Yin N, Dong L, Lepp A, Chesnik MA, Mirza SP, Szabo A, Tsai S, Basir Z, Wu S, Chen G. Identification of a ternary protein-complex as a therapeutic target for K-Ras-dependent colon cancer. Oncotarget 2014;5:4269-82. [PMID: 24962213 DOI: 10.18632/oncotarget.2001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 552 |
Mir R, Ah I, Javid J, Zuberi M, Guru S, Mirza M, Farooq S, Yadav P, Ray PC, Gupta N, Saxena A. Polymorphism T81C in H-RAS Oncogene Is Associated With Disease Progression in Imatinib (TKI) Treated Chronic Myeloid Leukemia Patients. World J Oncol 2015;6:321-8. [PMID: 29147425 DOI: 10.14740/wjon912e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 553 |
Arvelo F, Sojo F, Cotte C. Biology of colorectal cancer. Ecancermedicalscience 2015;9:520. [PMID: 25932044 DOI: 10.3332/ecancer.2015.520] [Cited by in Crossref: 67] [Cited by in F6Publishing: 79] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 554 |
Mironov VA, Khrenova MG, Lychko LA, Nemukhin AV. Computational characterization of the chemical step in the GTP hydrolysis by Ras-GAP for the wild-type and G13V mutated Ras. Proteins 2015;83:1046-53. [PMID: 25820867 DOI: 10.1002/prot.24802] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 555 |
Ni Y, Stingo FC, Baladandayuthapani V. Bayesian nonlinear model selection for gene regulatory networks. Biometrics 2015;71:585-95. [PMID: 25854759 DOI: 10.1111/biom.12309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 556 |
Murad AM, Murad LS. First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery. Curr Colorectal Cancer Rep 2015;11:54-69. [DOI: 10.1007/s11888-015-0259-4] [Reference Citation Analysis]
|
| 557 |
Massi D, Simi L, Sensi E, Baroni G, Xue G, Scatena C, Caldarella A, Pinzani P, Fontanini G, Carobbio A, Urso C, Mandalà M. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. Mod Pathol 2015;28:487-97. [PMID: 25341653 DOI: 10.1038/modpathol.2014.137] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 558 |
Huang MM, Leong SM, Chua HW, Tucker S, Cheong WC, Chiu L, Li MH, Koay ES. Highly sensitive KRAS mutation detection from formalin-fixed paraffin-embedded biopsies and circulating tumour cells using wild-type blocking polymerase chain reaction and Sanger sequencing. Mol Diagn Ther 2014;18:459-68. [PMID: 24664550 DOI: 10.1007/s40291-014-0098-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 559 |
Yeh HH, Tseng YF, Hsu YC, Lan SH, Wu SY, Raghavaraju G, Cheng DE, Lee YR, Chang TY, Chow NH, Hung WC, Liu HS. Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity. BMC Cancer 2015;15:172. [PMID: 25885317 DOI: 10.1186/s12885-015-1155-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 560 |
Langeberg LK, Scott JD. Signalling scaffolds and local organization of cellular behaviour. Nat Rev Mol Cell Biol 2015;16:232-44. [PMID: 25785716 DOI: 10.1038/nrm3966] [Cited by in Crossref: 200] [Cited by in F6Publishing: 205] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 561 |
Agudo-Ibáñez L, Herrero A, Barbacid M, Crespo P. H-ras distribution and signaling in plasma membrane microdomains are regulated by acylation and deacylation events. Mol Cell Biol 2015;35:1898-914. [PMID: 25776558 DOI: 10.1128/MCB.01398-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 562 |
Moreira AL, Eng J. Personalized therapy for lung cancer. Chest 2014;146:1649-57. [PMID: 25451351 DOI: 10.1378/chest.14-0713] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 563 |
Wang L, Yang H, Abel EV, Ney GM, Palmbos PL, Bednar F, Zhang Y, Leflein J, Waghray M, Owens S, Wilkinson JE, Prasad J, Ljungman M, Rhim AD, Pasca di Magliano M, Simeone DM. ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis. Genes Dev 2015;29:171-83. [PMID: 25593307 DOI: 10.1101/gad.253591.114] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 564 |
Warsinggih W, Yusuf I, Manuaba IBTW, Pusponegoro A. Associations of positive epidermal growth factor receptor expression and K-RAS gene mutations with various clinicopathological parameters and survival of colorectal carcinoma patients. Biomarkers and Genomic Medicine 2015;7:1-7. [DOI: 10.1016/j.bgm.2014.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 565 |
Guin S, Theodorescu D. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer. Acta Pharmacol Sin 2015;36:291-7. [PMID: 25557115 DOI: 10.1038/aps.2014.129] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 566 |
Knickelbein K, Zhang L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis 2015;2:4-12. [PMID: 25815366 DOI: 10.1016/j.gendis.2014.10.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 567 |
Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep 2015;5:8535. [PMID: 25705018 DOI: 10.1038/srep08535] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 568 |
Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Bortlicek Z, Topolcan O. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumour Biol 2015;36:5801-5. [PMID: 25702091 DOI: 10.1007/s13277-015-3249-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 569 |
Calvo KR, Price S, Braylan RC, Oliveira JB, Lenardo M, Fleisher TA, Rao VK. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood 2015;125:2753-8. [PMID: 25691160 DOI: 10.1182/blood-2014-11-567917] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 570 |
Scholtens A, Geukes Foppen MH, Blank CU, van Thienen JV, van Tinteren H, Haanen JB. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. Eur J Cancer 2015;51:642-52. [PMID: 25690538 DOI: 10.1016/j.ejca.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 571 |
Gorantla VC, Kirkwood JM. State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am 2014;28:415-35. [PMID: 24880939 DOI: 10.1016/j.hoc.2014.02.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 572 |
Functional networks of events that modulate phenotypic manifestation of cancer. Systems Biology of Cancer 2015. [DOI: 10.1017/cbo9780511979811.012] [Reference Citation Analysis]
|
| 573 |
Faller DV, Rankin AM. RAS signaling networks. Systems Biology of Cancer 2015. [DOI: 10.1017/cbo9780511979811.013] [Reference Citation Analysis]
|
| 574 |
Kim RK, Suh Y, Yoo KC, Cui YH, Kim H, Kim MJ, Gyu Kim I, Lee SJ. Activation of KRAS promotes the mesenchymal features of basal-type breast cancer. Exp Mol Med 2015;47:e137. [PMID: 25633745 DOI: 10.1038/emm.2014.99] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 575 |
Hartmann M, Gas-Pascual E, Hemmerlin A, Rohmer M, Bach TJ. Development of an image-based screening system for inhibitors of the plastidial MEP pathway and of protein geranylgeranylation. F1000Res 2015;4:14. [PMID: 26309725 DOI: 10.12688/f1000research.5923.1] [Reference Citation Analysis]
|
| 576 |
Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. J Thorac Oncol 2013;8:1492-501. [PMID: 24389431 DOI: 10.1097/JTO.0000000000000007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 577 |
Khattak MA, Martin H, Davidson A, Phillips M. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer. 2015;14:81-90. [PMID: 25666296 DOI: 10.1016/j.clcc.2014.12.011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 578 |
Jun S, Lee S, Kim HC, Ng C, Schneider AM, Ji H, Ying H, Wang H, DePinho RA, Park JI. PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. Cell Rep 2013;5:314-22. [PMID: 24209743 DOI: 10.1016/j.celrep.2013.09.026] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 579 |
Tang H, Chen Y. Molecular insight and resolution for tumors harboring the H-ras(G12V) mutation. RSC Adv 2015;5:20623-20633. [DOI: 10.1039/c4ra16763e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 580 |
Schäfer R. RAS Transformation Targets. Encyclopedia of Cancer 2015. [DOI: 10.1007/978-3-642-27841-9_4956-2] [Reference Citation Analysis]
|
| 581 |
Wong YH, Pellicer A, Liu W. RAS Genes. Encyclopedia of Cancer 2015. [DOI: 10.1007/978-3-642-27841-9_4951-2] [Reference Citation Analysis]
|
| 582 |
Cote GJ, Grubbs EG, Hofmann MC. Thyroid C-Cell Biology and Oncogenic Transformation. Recent Results Cancer Res 2015;204:1-39. [PMID: 26494382 DOI: 10.1007/978-3-319-22542-5_1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 583 |
Fernandes J. Antitumor Monoterpenes. Bioactive Essential Oils and Cancer 2015. [DOI: 10.1007/978-3-319-19144-7_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 584 |
Maiti S. Arsenic-Induced Mutagenesis and Carcinogenesis. Handbook of Arsenic Toxicology. Elsevier; 2015. pp. 233-79. [DOI: 10.1016/b978-0-12-418688-0.00009-5] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 585 |
McQuade J, Davies MA. Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag 2015;2:241-54. [PMID: 26594316 DOI: 10.2217/mmt.15.18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 586 |
Chiorean EG, Coveler A, Grim J, Grady WM. Targeted Therapies For Intestinal Tumorigenesis. Intestinal Tumorigenesis 2015. [DOI: 10.1007/978-3-319-19986-3_13] [Reference Citation Analysis]
|
| 587 |
Nangia-makker P, Yu Y, Farhana L, Ahmed K, Majumdar APN. Colorectal Cancer Stem Cells. Cancer Stem Cells: Emerging Concepts and Future Perspectives in Translational Oncology 2015. [DOI: 10.1007/978-3-319-21030-8_9] [Reference Citation Analysis]
|
| 588 |
Mascaux C, Shepherd FA. Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer. New Therapeutic Strategies in Lung Cancers 2015. [DOI: 10.1007/978-3-319-06062-0_11] [Reference Citation Analysis]
|
| 589 |
Xiang Z, Kaur V, Aburiziq IK, Mehta P, Emanuel P, Schichman SA. Natural history of chronic myelomonocytic leukemia: gene sequencing identifies multiple clonal molecular abnormalities associated with rapid progression to acute myeloid leukemia. Clin Case Rep 2014;2:265-70. [PMID: 25548628 DOI: 10.1002/ccr3.110] [Reference Citation Analysis]
|
| 590 |
Yan ZH, Cui LH, Wang XH, Li C, He X. Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer. World J Gastroenterol 2014; 20(48): 18338-18345 [PMID: 25561800 DOI: 10.3748/wjg.v20.i48.18338] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 591 |
Oliva B, Fernandez-Fuentes N. Knowledge-based modeling of peptides at protein interfaces: PiPreD. Bioinformatics 2015;31:1405-10. [PMID: 25540186 DOI: 10.1093/bioinformatics/btu838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 592 |
Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics 2015;15:327-39. [PMID: 25339196 DOI: 10.1002/pmic.201400200] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 593 |
Shan J, Donelan W, Hayner JN, Zhang F, Dudenhausen EE, Kilberg MS. MAPK signaling triggers transcriptional induction of cFOS during amino acid limitation of HepG2 cells. Biochim Biophys Acta 2015;1853:539-48. [PMID: 25523140 DOI: 10.1016/j.bbamcr.2014.12.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 594 |
Lemieux E, Cagnol S, Beaudry K, Carrier J, Rivard N. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene 2015;34:4914-27. [PMID: 25500543 DOI: 10.1038/onc.2014.416] [Cited by in Crossref: 104] [Cited by in F6Publishing: 114] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 595 |
Fokas E, O’Neill E, Gordon-Weeks A, Mukherjee S, McKenna WG, Muschel RJ. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Biochim Biophys Acta. 2015;1855:61-82. [PMID: 25489989 DOI: 10.1016/j.bbcan.2014.12.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 43] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 596 |
Liu QH, Shi ML, Sun C, Bai J, Zheng JN. Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy. Bioorg Med Chem Lett 2015;25:192-7. [PMID: 25515559 DOI: 10.1016/j.bmcl.2014.11.076] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 597 |
Boeckx N, Op de Beeck K, Deschoolmeester V, Van Camp G, Pauwels P, Peeters M. Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. Curr Colorectal Cancer Rep 2014;10:380-394. [DOI: 10.1007/s11888-014-0242-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 598 |
Dhillon T. Mechanisms of resistance to EGFR inhibitors in colorectal cancers. Colorectal Cancer 2014;3:511-20. [DOI: 10.2217/crc.14.37] [Reference Citation Analysis]
|
| 599 |
Tseng PC, Chen CL, Shan YS, Chang WT, Liu HS, Hong TM, Hsieh CY, Lin SH, Lin CF. An increase in integrin-linked kinase non-canonically confers NF-κB-mediated growth advantages to gastric cancer cells by activating ERK1/2. Cell Commun Signal 2014;12:69. [PMID: 25398317 DOI: 10.1186/s12964-014-0069-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 600 |
Strack J, Heni H, Gilsbach R, Hein L, Aktories K, Orth JH. Noncanonical G-protein-dependent modulation of osteoclast differentiation and bone resorption mediated by Pasteurella multocida toxin. mBio 2014;5:e02190. [PMID: 25389180 DOI: 10.1128/mBio.02190-14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 601 |
Alvarez-Moya B, Barceló C, Tebar F, Jaumot M, Agell N. CaM interaction and Ser181 phosphorylation as new K-Ras signaling modulators. Small GTPases 2011;2:99-103. [PMID: 21776410 DOI: 10.4161/sgtp.2.2.15555] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 602 |
Reiner DJ. Ras effector switching as a developmental strategy. Small GTPases 2011;2:109-12. [PMID: 21776412 DOI: 10.4161/sgtp.2.2.15775] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 603 |
Cox AD, Der CJ. Ras history: The saga continues. Small GTPases 2010;1:2-27. [PMID: 21686117 DOI: 10.4161/sgtp.1.1.12178] [Cited by in Crossref: 474] [Cited by in F6Publishing: 506] [Article Influence: 52.7] [Reference Citation Analysis]
|
| 604 |
Paul JM, Templeton SD, Baharani A, Freywald A, Vizeacoumar FJ. Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell. Trends Mol Med 2014;20:704-15. [PMID: 25446836 DOI: 10.1016/j.molmed.2014.09.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 605 |
Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C, Ricevuto E. The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? Crit Rev Oncol Hematol 2015;93:190-202. [PMID: 25459669 DOI: 10.1016/j.critrevonc.2014.10.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 606 |
Drosten M, Sum EY, Lechuga CG, Simón-Carrasco L, Jacob HK, García-Medina R, Huang S, Beijersbergen RL, Bernards R, Barbacid M. Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proc Natl Acad Sci U S A 2014;111:15155-60. [PMID: 25288756 DOI: 10.1073/pnas.1417549111] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 607 |
Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther 2014;13:2876-85. [PMID: 25281617 DOI: 10.1158/1535-7163.MCT-14-0074] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 608 |
Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Gastroenterology 2014;147:882-892.e8. [PMID: 24998203 DOI: 10.1053/j.gastro.2014.06.041] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 609 |
Goitre L, Trapani E, Trabalzini L, Retta SF. The Ras superfamily of small GTPases: the unlocked secrets. Methods Mol Biol 2014;1120:1-18. [PMID: 24470015 DOI: 10.1007/978-1-62703-791-4_1] [Cited by in Crossref: 111] [Cited by in F6Publishing: 84] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 610 |
Campos M, Kool MM, Daminet S, Ducatelle R, Rutteman G, Kooistra HS, Galac S, Mol JA. Upregulation of the PI3K/Akt pathway in the tumorigenesis of canine thyroid carcinoma. J Vet Intern Med 2014;28:1814-23. [PMID: 25231196 DOI: 10.1111/jvim.12435] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 611 |
Link WT, De Felice A. An FDA overview of rodent carcinogenicity studies of angiotensin II AT-1 receptor blockers: pulmonary adenomas and carcinomas. Regul Toxicol Pharmacol 2014;70:555-63. [PMID: 25223563 DOI: 10.1016/j.yrtph.2014.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 612 |
Burkitt Wright EM, Kerr B. Molecular Genetics of Costello Syndrome. eLS 2014. [DOI: 10.1002/9780470015902.a0021471] [Reference Citation Analysis]
|
| 613 |
Schmidt ML, Donninger H, Clark GJ. Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A. J Biol Chem 2014;289:31102-10. [PMID: 25217643 DOI: 10.1074/jbc.M114.594283] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 614 |
Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy? Br J Cancer 2015;112:217-26. [PMID: 25180764 DOI: 10.1038/bjc.2014.476] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 615 |
Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di nicolantonio F, Bardelli A. RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells. Cell Reports 2014;8:1475-83. [DOI: 10.1016/j.celrep.2014.07.033] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 616 |
Wu BL, Lv GQ, Zou HY, Du ZP, Wu JY, Zhang PX, Xu LY, Li EM. Exploration of potential roles of a new LOXL2 splicing variant using network knowledge in esophageal squamous cell carcinoma. ScientificWorldJournal 2014;2014:431792. [PMID: 25254241 DOI: 10.1155/2014/431792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 617 |
Karnati HK, Yalagala RS, Undi R, Pasupuleti SR, Gutti RK. Therapeutic potential of siRNA and DNAzymes in cancer. Tumour Biol 2014;35:9505-21. [PMID: 25149153 DOI: 10.1007/s13277-014-2477-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 618 |
Chamberlain CE, Scheel DW, McGlynn K, Kim H, Miyatsuka T, Wang J, Nguyen V, Zhao S, Mavropoulos A, Abraham AG, O'Neill E, Ku GM, Cobb MH, Martin GR, German MS. Menin determines K-RAS proliferative outputs in endocrine cells. J Clin Invest 2014;124:4093-101. [PMID: 25133424 DOI: 10.1172/JCI69004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 619 |
Wynne GM, Russell AJ. Drug Discovery Approaches for Rare Neuromuscular Diseases. Orphan Drugs and Rare Diseases 2014. [DOI: 10.1039/9781782624202-00257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 620 |
Rebecca VW, Smalley KS. Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol 2014;91:417-25. [PMID: 25107706 DOI: 10.1016/j.bcp.2014.07.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 621 |
Carver J, Dexheimer TS, Hsu D, Weng MT, Smith JL, Guha R, Jadhav A, Simeonov A, Luo J. A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. PLoS One 2014;9:e103836. [PMID: 25093678 DOI: 10.1371/journal.pone.0103836] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 622 |
Paliogiannis P, Cossu A, Tanda F, Palmieri G, Palomba G. KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncol Lett 2014;8:1422-6. [PMID: 25202344 DOI: 10.3892/ol.2014.2411] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 623 |
Baderna D, Colombo A, Romeo M, Cambria F, Teoldi F, Lodi M, Diomede L, Benfenati E. Soil quality in the Lomellina area using in vitro models and ecotoxicological assays. Environmental Research 2014;133:220-31. [DOI: 10.1016/j.envres.2014.05.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 624 |
Baro M, de Llobet LI, Figueras A, Skvortsova I, Mesia R, Balart J. Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours. Br J Cancer 2014;111:1310-8. [PMID: 25077442 DOI: 10.1038/bjc.2014.432] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 625 |
Drosten M, Lechuga CG, Barbacid M. Ras in epidermal proliferation. Oncotarget 2014;5:5194-5. [PMID: 25114036 DOI: 10.18632/oncotarget.2275] [Reference Citation Analysis]
|
| 626 |
Ling Y, Wang Z, Wang X, Li X, Wang X, Zhang W, Dai H, Chen L, Zhang Y. Hybrid molecule from Farnesylthiosalicylic acid-diamine and phenylpropenoic acid as Ras-related signaling inhibitor with potent antitumor activities. Chem Biol Drug Des 2015;85:145-52. [PMID: 25043275 DOI: 10.1111/cbdd.12393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 627 |
Inoue S, Moriya M, Watanabe Y, Miyagawa-Tomita S, Niihori T, Oba D, Ono M, Kure S, Ogura T, Matsubara Y, Aoki Y. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome. Hum Mol Genet 2014;23:6553-66. [PMID: 25035421 DOI: 10.1093/hmg/ddu376] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 628 |
Lengyel P. Wanderings in biochemistry. J Biol Chem 2014;289:19254-68. [PMID: 24867946 DOI: 10.1074/jbc.X114.554121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 629 |
Charette N, Vandeputte C, Stärkel P. Ras in digestive oncology: from molecular biology to clinical implications. Current Opinion in Oncology 2014;26:454-61. [DOI: 10.1097/cco.0000000000000088] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 630 |
Boyango I, Barash U, Naroditsky I, Li JP, Hammond E, Ilan N, Vlodavsky I. Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res 2014;74:4504-14. [PMID: 24970482 DOI: 10.1158/0008-5472.CAN-13-2962] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 631 |
Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014;120:3446-56. [PMID: 24948110 DOI: 10.1002/cncr.28864] [Cited by in Crossref: 533] [Cited by in F6Publishing: 574] [Article Influence: 59.2] [Reference Citation Analysis]
|
| 632 |
Anderson T, Hu R, Yang C, Yoon HS, Yong K. Pancreatic cancer gene therapy using an siRNA-functionalized single walled carbon nanotubes (SWNTs) nanoplex. Biomater Sci 2014;2:1244. [DOI: 10.1039/c4bm00019f] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 633 |
Mandalà M, Merelli B, Massi D. Nras in melanoma: targeting the undruggable target. Crit Rev Oncol Hematol 2014;92:107-22. [PMID: 24985059 DOI: 10.1016/j.critrevonc.2014.05.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 634 |
Hendifar A, Tan CR, Annamalai A, Tuli R. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. Expert Rev Anticancer Ther. 2014;14:1051-1061. [PMID: 24898788 DOI: 10.1586/14737140.2014.922881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 635 |
Johnson DB, Smalley KS, Sosman JA. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 2014;20:4186-92. [PMID: 24895460 DOI: 10.1158/1078-0432.CCR-13-3270] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 636 |
Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med 2014;174:964-70. [PMID: 24710960 DOI: 10.1001/jamainternmed.2014.594] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 637 |
Troiani T, Venturini F, Napolitano S, Martini G, Gambardella V, Ciardiello F, Martinelli E. Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. Colorectal Cancer 2014;3:299-308. [DOI: 10.2217/crc.14.17] [Reference Citation Analysis]
|
| 638 |
Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136:83-90. [PMID: 24806288 DOI: 10.1002/ijc.28955] [Cited by in Crossref: 96] [Cited by in F6Publishing: 104] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 639 |
Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S, Raab H, Sauer R, Wittekind C, Rödel C. Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial. JCO 2014;32:1554-62. [DOI: 10.1200/jco.2013.54.3769] [Cited by in Crossref: 256] [Cited by in F6Publishing: 284] [Article Influence: 28.4] [Reference Citation Analysis]
|
| 640 |
Guégan JP, Ezan F, Gailhouste L, Langouët S, Baffet G. MEK1/2 overactivation can promote growth arrest by mediating ERK1/2-dependent phosphorylation of p70S6K. J Cell Physiol 2014;229:903-15. [PMID: 24501087 DOI: 10.1002/jcp.24521] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 641 |
Aguilar BJ, Nkembo AT, Duverna R, Poku RA, Amissah F, Ablordeppey SY, Lamango NS. Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer. Eur J Med Chem 2014;81:323-33. [PMID: 24852279 DOI: 10.1016/j.ejmech.2014.05.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 642 |
Tinti M, Dissanayake K, Synowsky S, Albergante L, MacKintosh C. Identification of 2R-ohnologue gene families displaying the same mutation-load skew in multiple cancers. Open Biol 2014;4:140029. [PMID: 24806839 DOI: 10.1098/rsob.140029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 643 |
Zeng T, Wang Q, Fu J, Lin Q, Bi J, Ding W, Qiao Y, Zhang S, Zhao W, Lin H, Wang M, Lu B, Deng X, Zhou D, Yin Z, Wang H. Impeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven Tumorigenesis. Cell Reports 2014;7:871-82. [DOI: 10.1016/j.celrep.2014.03.045] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 644 |
Takashima A, English B, Chen Z, Cao J, Cui R, Williams RM, Faller DV. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol 2014;9:1003-14. [PMID: 24506253 DOI: 10.1021/cb400837t] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 645 |
Kumar SS, Price TJ, Townsend AR, Hocking C, Hardingham JE. Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. Colorectal Cancer 2014;3:223-32. [DOI: 10.2217/crc.14.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 646 |
Khan S, Cameron S, Blaschke M, Moriconi F, Naz N, Amanzada A, Ramadori G, Malik IA. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: Role of cytokines. World J Gastroenterol 2014; 20(11): 2979-2994 [PMID: 24659889 DOI: 10.3748/wjg.v20.i11.2979] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 647 |
Li Y, Han C, Wang J, Yang Y, Zhang J, Zhang S, Yang L. Insight into the structural features of pyrazolopyrimidine- and pyrazolopyridine-based B-Raf(V600E) kinase inhibitors by computational explorations. Chem Biol Drug Des 2014;83:643-55. [PMID: 24373283 DOI: 10.1111/cbdd.12276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 648 |
Lin MW, Wu CT, Kuo SW, Chang YL, Yang PC. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy. Ann Surg Oncol 2014;21:2555-62. [PMID: 24643899 DOI: 10.1245/s10434-014-3642-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 649 |
Prakash P, Gorfe AA. Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras. Mol Simul 2014;40:839-47. [PMID: 26491216 DOI: 10.1080/08927022.2014.895000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 650 |
Ashton-Beaucage D, Udell CM, Gendron P, Sahmi M, Lefrançois M, Baril C, Guenier AS, Duchaine J, Lamarre D, Lemieux S, Therrien M. A functional screen reveals an extensive layer of transcriptional and splicing control underlying RAS/MAPK signaling in Drosophila. PLoS Biol 2014;12:e1001809. [PMID: 24643257 DOI: 10.1371/journal.pbio.1001809] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 651 |
Zhang X, Ma Y, Wu Y, Lin L, Ma X, Zhang Y. Aberrant promoter methylation and silencing of RASSF2A gene in cervical cancer. J Obstet Gynaecol Res 2014;40:1375-81. [PMID: 24605823 DOI: 10.1111/jog.12322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 652 |
Eastmond DA, Vulimiri SV, French JE, Sonawane B. The use of genetically modified mice in cancer risk assessment: challenges and limitations. Crit Rev Toxicol 2013;43:611-31. [PMID: 23985072 DOI: 10.3109/10408444.2013.822844] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 653 |
Kang CM, Babicky ML, Lowy AM. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas 2014;43:183-9. [PMID: 24518495 DOI: 10.1097/MPA.0000000000000088] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 654 |
Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE 3rd, Marcucci G, Bloomfield CD, de la Chapelle A. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A 2014;111:4179-84. [PMID: 24586049 DOI: 10.1073/pnas.1401727111] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 655 |
Rasool S, Rasool V, Naqvi T, Ganai BA, Shah BA. Genetic unraveling of colorectal cancer. Tumour Biol. 2014;35:5067-5082. [PMID: 24573608 DOI: 10.1007/s13277-014-1713-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 656 |
Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, Steinberg SM, Khleif SN. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014;12:55. [PMID: 24565030 DOI: 10.1186/1479-5876-12-55] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 657 |
Herreros-Villanueva M, Chen CC, Yuan SS, Liu TC, Er TK. KRAS mutations: analytical considerations. Clin Chim Acta 2014;431:211-20. [PMID: 24534449 DOI: 10.1016/j.cca.2014.01.049] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 658 |
Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res 2011;24:902-21. [PMID: 21914141 DOI: 10.1111/j.1755-148X.2011.00908.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 659 |
Er T, Chen C, Bujanda L, Herreros-villanueva M. Clinical relevance of KRAS mutations in codon 13: Where are we? Cancer Letters 2014;343:1-5. [DOI: 10.1016/j.canlet.2013.09.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 660 |
Wu Z, Yan M, Hu S, Yu Z, Zhu Y, Cheng Y, Liu H, Zhang Y, Yao S, Tang W, Lu T. Design, synthesis and biological evaluation of indole derivatives as novel inhibitors targeting B-Raf kinase. Chinese Chemical Letters 2014;25:351-4. [DOI: 10.1016/j.cclet.2013.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 661 |
Sanz-garcía E, Elez E, Macarulla T, Dienstmann R, Salazar R, Tabernero J. Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. Curr Colorectal Cancer Rep 2014;10:55-61. [DOI: 10.1007/s11888-013-0205-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 662 |
Rishikaysh P, Dev K, Diaz D, Qureshi WM, Filip S, Mokry J. Signaling involved in hair follicle morphogenesis and development. Int J Mol Sci 2014;15:1647-70. [PMID: 24451143 DOI: 10.3390/ijms15011647] [Cited by in Crossref: 181] [Cited by in F6Publishing: 192] [Article Influence: 20.1] [Reference Citation Analysis]
|
| 663 |
Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. Cell Death Differ 2014;21:720-34. [PMID: 24440911 DOI: 10.1038/cdd.2013.196] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 664 |
Terragni R, Casadei Gardini A, Sabattini S, Bettini G, Amadori D, Talamonti C, Vignoli M, Capelli L, Saunders JH, Ricci M, Ulivi P. EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model? PLoS One 2014;9:e85388. [PMID: 24454858 DOI: 10.1371/journal.pone.0085388] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 665 |
Schuld NJ, Vervacke JS, Lorimer EL, Simon NC, Hauser AD, Barbieri JT, Distefano MD, Williams CL. The chaperone protein SmgGDS interacts with small GTPases entering the prenylation pathway by recognizing the last amino acid in the CAAX motif. J Biol Chem 2014;289:6862-76. [PMID: 24415755 DOI: 10.1074/jbc.M113.527192] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 666 |
Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW. Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss. Genes Cancer 2013;4:476-85. [PMID: 24386508 DOI: 10.1177/1947601913513268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 667 |
Sudhir PR, Chen JY. Functional phosphoproteomics of oncogenic KRAS signaling. Methods Mol Biol 2014;1120:157-66. [PMID: 24470024 DOI: 10.1007/978-1-62703-791-4_10] [Reference Citation Analysis]
|
| 668 |
Stout MC, Asiimwe E, Birkenstamm JR, Kim SY, Campbell PM. Analyzing Ras-associated cell proliferation signaling. Methods Mol Biol 2014;1170:393-409. [PMID: 24906326 DOI: 10.1007/978-1-4939-0888-2_21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 669 |
Walker DM, Wang R, Webb LJ. Conserved electrostatic fields at the Ras–effector interface measured through vibrational Stark effect spectroscopy explain the difference in tilt angle in the Ras binding domains of Raf and RalGDS. Phys Chem Chem Phys 2014;16:20047-60. [DOI: 10.1039/c4cp00743c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 670 |
Erickson JW, Antonyak MA, Fuji R, Cerione RA. Rho GTPases in Cancer. Ras Superfamily Small G Proteins: Biology and Mechanisms 1 2014. [DOI: 10.1007/978-3-7091-1806-1_18] [Reference Citation Analysis]
|
| 671 |
Ornellas AA, Alves G, Schwindt ABDS. Pathology and Genetics. Management of Penile Cancer 2014. [DOI: 10.1007/978-1-4939-0461-7_4] [Reference Citation Analysis]
|
| 672 |
Greco A, Miranda C, Borrello MG, Pierotti MA. Thyroid Cancer. Cancer Genomics. Elsevier; 2014. pp. 265-80. [DOI: 10.1016/b978-0-12-396967-5.00016-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 673 |
Shackelford RE, Ghayouri M, Coppola D, Hakam A. Molecular Pathology and Diagnostics of Gynecologic Malignancies. Molecular Pathology and Diagnostics of Cancer 2014. [DOI: 10.1007/978-94-007-7192-5_12] [Reference Citation Analysis]
|
| 674 |
Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, Bar-Eli M. Why is melanoma so metastatic? Pigment Cell Melanoma Res 2014;27:19-36. [PMID: 24106873 DOI: 10.1111/pcmr.12172] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 675 |
Nakada M, Kita D, Furuta T, Watanabe T, Hayashi Y, Hamada J. Signaling Cascades Driving the Malignant Phenotype of Glioma Cells. Glioma Cell Biology 2014. [DOI: 10.1007/978-3-7091-1431-5_3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 676 |
d’Isa R, Brambilla R, Fasano S. Behavioral Methods for the Study of the Ras–ERK Pathway in Memory Formation and Consolidation: Passive Avoidance and Novel Object Recognition Tests. Methods in Molecular Biology 2014. [DOI: 10.1007/978-1-62703-791-4_9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 677 |
Aguda BD. The Significance of the Feedback Loops between Kras and Ink4a in Pancreatic Cancer. Molecular Diagnostics and Treatment of Pancreatic Cancer. Elsevier; 2014. pp. 281-96. [DOI: 10.1016/b978-0-12-408103-1.00012-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 678 |
Burzynski SR, Patil SS. The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme. JCT 2014;05:929-945. [DOI: 10.4236/jct.2014.510099] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 679 |
Hanrahan AJ, Iyer G, Solit DB. Intracellular Signaling. Abeloff's Clinical Oncology 2014. [DOI: 10.1016/b978-1-4557-2865-7.00002-3] [Reference Citation Analysis]
|
| 680 |
Wulff-barreiro E. The Fate of Ochoa’s School in the Origins of Oncogenetics in US (I). OJGen 2014;04:392-406. [DOI: 10.4236/ojgen.2014.45037] [Reference Citation Analysis]
|
| 681 |
Li M, Li Y, Zhao X, Gao X. Roles of the three Ras proteins in the regulation of dimorphic transition in the yeast Yarrowia lipolytica. FEMS Yeast Res 2014;14:451-63. [DOI: 10.1111/1567-1364.12129] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 682 |
Martin P, Leighl NB, Tsao MS, Shepherd FA. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 2013;8:530-42. [PMID: 23524403 DOI: 10.1097/JTO.0b013e318283d958] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 683 |
Luo F, Poulogiannis G, Ye H, Hamoudi R, Dong G, Zhang W, Ibrahim AE, Arends MJ. Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation. Int J Exp Pathol 2014;95:8-15. [PMID: 24354449 DOI: 10.1111/iep.12064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 684 |
Liau S, Tuveson DA. Pancreatic cancer. Molecular Oncology 2013. [DOI: 10.1017/cbo9781139046947.049] [Reference Citation Analysis]
|
| 685 |
Gee F, Fisher K, Klemstein U, Poulin GB. An RNAi-based dimorphic genetic screen identified the double bromodomain protein BET-1 as a sumo-dependent attenuator of RAS-mediated signalling. PLoS One 2013;8:e83659. [PMID: 24349540 DOI: 10.1371/journal.pone.0083659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 686 |
Cox AD, Decristo MJ. Ras. Molecular Oncology 2013. [DOI: 10.1017/cbo9781139046947.022] [Reference Citation Analysis]
|
| 687 |
Sumita K, Yoshino H, Sasaki M, Majd N, Kahoud ER, Takahashi H, Takeuchi K, Kuroda T, Lee S, Charest PG, Takeda K, Asara JM, Firtel RA, Anastasiou D, Sasaki AT. Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis. J Biol Chem 2014;289:3950-9. [PMID: 24338482 DOI: 10.1074/jbc.M113.531178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 688 |
Gonzalez-Perez A, Mustonen V, Reva B, Ritchie GR, Creixell P, Karchin R, Vazquez M, Fink JL, Kassahn KS, Pearson JV. Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods. 2013;10:723-729. [PMID: 23900255 DOI: 10.1038/nmeth.2562] [Cited by in Crossref: 120] [Cited by in F6Publishing: 138] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 689 |
Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One. 2013;8:e81628. [PMID: 24339949 DOI: 10.1371/journal.pone.0081628] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 690 |
Cao Z, Li X, Li J, Kang B, Chen J, Luo W, Huang C. SUMOylation of RhoGDIα is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cells. Mol Oncol 2014;8:285-96. [PMID: 24342356 DOI: 10.1016/j.molonc.2013.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 691 |
Beamer LC, Linder L, Wu B, Eggert J. The Impact of Genomics on Oncology Nursing. Nursing Clinics of North America 2013;48:585-626. [DOI: 10.1016/j.cnur.2013.09.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 692 |
Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P. Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. Onco Targets Ther. 2013;6:1761-1769. [PMID: 24348051 DOI: 10.2147/ott.s43828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 693 |
Mallucci L, Wells V. The end of KRAS, and other, cancers? A new way forward. Drug Discov Today 2014;19:383-7. [PMID: 24291216 DOI: 10.1016/j.drudis.2013.11.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 694 |
Hashida N, Ping X, Nishida K. MAPK activation in mature cataract associated with Noonan syndrome. BMC Ophthalmol 2013;13:70. [PMID: 24219368 DOI: 10.1186/1471-2415-13-70] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 695 |
Young LC, Hartig N, Muñoz-Alegre M, Oses-Prieto JA, Durdu S, Bender S, Vijayakumar V, Vietri Rudan M, Gewinner C, Henderson S, Jathoul AP, Ghatrora R, Lythgoe MF, Burlingame AL, Rodriguez-Viciana P. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth. Mol Cell 2013;52:679-92. [PMID: 24211266 DOI: 10.1016/j.molcel.2013.10.004] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 696 |
Yu B, Luo J. Synthetic lethal genetic screens in Ras mutant cancers. Enzymes 2013;34 Pt. B:201-19. [PMID: 25034106 DOI: 10.1016/B978-0-12-420146-0.00009-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 697 |
Chen Y, Xin X, Li J, Xu J, Yu X, Li T, Mo Z, Hu Y. RTK/ERK pathway under natural selection associated with prostate cancer. PLoS One 2013;8:e78254. [PMID: 24223781 DOI: 10.1371/journal.pone.0078254] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 698 |
Azrak SS, Ginel-Picardo A, Drosten M, Barbacid M, Santos E. Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications. BMC Genomics 2013;14:731. [PMID: 24156637 DOI: 10.1186/1471-2164-14-731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 699 |
Drosten M, Lechuga CG, Barbacid M. Genetic analysis of Ras genes in epidermal development and tumorigenesis. Small GTPases 2013;4:236-41. [PMID: 24150175 DOI: 10.4161/sgtp.26905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 700 |
Lu A, Pfeffer SR. Golgi-associated RhoBTB3 targets cyclin E for ubiquitylation and promotes cell cycle progression. J Cell Biol 2013;203:233-50. [PMID: 24145166 DOI: 10.1083/jcb.201305158] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 701 |
Barault L, Lamba S, Di Nicolantonio F. Ras Mutations in Cancer. In: John Wiley & Sons, Ltd, editor. eLS. Wiley; 2001. [DOI: 10.1002/9780470015902.a0025010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 702 |
Weston C, Bond M, Croft W, Ladds G. The coordination of cell growth during fission yeast mating requires Ras1-GTP hydrolysis. PLoS One 2013;8:e77487. [PMID: 24147005 DOI: 10.1371/journal.pone.0077487] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 703 |
Levinsohn JL, Teng J, Craiglow BG, Loring EC, Burrow TA, Mane SS, Overton JD, Lifton RP, McNiff JM, Lucky AW, Choate KA. Somatic HRAS p.G12S mutation causes woolly hair and epidermal nevi. J Invest Dermatol 2014;134:1149-52. [PMID: 24129065 DOI: 10.1038/jid.2013.430] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 704 |
Zhao YC, Chen H, Sun L, Qiu M, Chen XD. Clinical significance of expression of Ras protein activator like 1 and extracellular regulated protein kinase in gastric cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(28): 2929-2936 [DOI: 10.11569/wcjd.v21.i28.2929] [Reference Citation Analysis]
|
| 705 |
Alan JK, Lundquist EA. Mutationally activated Rho GTPases in cancer. Small GTPases 2013;4:159-63. [PMID: 24088985 DOI: 10.4161/sgtp.26530] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 706 |
Bello DM, Ariyan CE, Carvajal RD. Melanoma Mutagenesis and Aberrant Cell Signaling. Cancer Control 2013;20:261-81. [DOI: 10.1177/107327481302000404] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 707 |
Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 2013;26:1307-19. [PMID: 23619604 DOI: 10.1038/modpathol.2013.74] [Cited by in Crossref: 80] [Cited by in F6Publishing: 88] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 708 |
Baderna D, Colombo A, Amodei G, Cantù S, Teoldi F, Cambria F, Rotella G, Natolino F, Lodi M, Benfenati E. Chemical-based risk assessment and in vitro models of human health effects induced by organic pollutants in soils from the Olona valley. Science of The Total Environment 2013;463-464:790-801. [DOI: 10.1016/j.scitotenv.2013.06.088] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 709 |
Zhang N, Su Y, Xu L. Targeting PKCε by miR-143 regulates cell apoptosis in lung cancer. FEBS Lett 2013;587:3661-7. [PMID: 24070896 DOI: 10.1016/j.febslet.2013.09.018] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 710 |
Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 2013;19:6183-92. [PMID: 24045185 DOI: 10.1158/1078-0432.CCR-12-3904] [Cited by in Crossref: 144] [Cited by in F6Publishing: 155] [Article Influence: 14.4] [Reference Citation Analysis]
|
| 711 |
Vetterkind S, Poythress RH, Lin QQ, Morgan KG. Hierarchical scaffolding of an ERK1/2 activation pathway. Cell Commun Signal 2013;11:65. [PMID: 23987506 DOI: 10.1186/1478-811X-11-65] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 712 |
Khazak V, Eyrisch S, Kato J, Tamanoi F, Golemis EA. A two-hybrid approach to identify inhibitors of the RAS-RAF interaction. Enzymes 2013;33 Pt A:213-48. [PMID: 25033807 DOI: 10.1016/B978-0-12-416749-0.00010-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 713 |
Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14:16365-16385. [PMID: 23965959 DOI: 10.3390/ijms140816365] [Cited by in Crossref: 279] [Cited by in F6Publishing: 305] [Article Influence: 27.9] [Reference Citation Analysis]
|
| 714 |
Prakash P, Gorfe AA. Lessons from computer simulations of Ras proteins in solution and in membrane. Biochim Biophys Acta 2013;1830:5211-8. [PMID: 23906604 DOI: 10.1016/j.bbagen.2013.07.024] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 715 |
Aslan JE, McCarty OJ. Rho GTPases in platelet function. J Thromb Haemost 2013;11:35-46. [PMID: 23121917 DOI: 10.1111/jth.12051] [Cited by in Crossref: 122] [Cited by in F6Publishing: 125] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 716 |
Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 2013;29:2238-44. [PMID: 23884480 DOI: 10.1093/bioinformatics/btt395] [Cited by in Crossref: 311] [Cited by in F6Publishing: 321] [Article Influence: 31.1] [Reference Citation Analysis]
|
| 717 |
Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, Nawrocki ST. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death Dis. 2013;4:e728. [PMID: 23868061 DOI: 10.1038/cddis.2013.259] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 718 |
Marsh V, Davies EJ, Williams GT, Clarke AR. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. J Pathol. 2013;230:165-173. [PMID: 23483557 DOI: 10.1002/path.4189] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 719 |
Sundaram MV. Canonical RTK-Ras-ERK signaling and related alternative pathways. WormBook 2013;:1-38. [PMID: 23908058 DOI: 10.1895/wormbook.1.80.2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 720 |
Drosten M, Lechuga CG, Barbacid M. Ras signaling is essential for skin development. Oncogene 2014;33:2857-65. [PMID: 23831572 DOI: 10.1038/onc.2013.254] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 721 |
London CA. Kinase dysfunction and kinase inhibitors. Vet Dermatol 2013;24:181-7.e39-40. [PMID: 23331696 DOI: 10.1111/j.1365-3164.2012.01081.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 722 |
Orr B, Compton DA. A double-edged sword: how oncogenes and tumor suppressor genes can contribute to chromosomal instability. Front Oncol 2013;3:164. [PMID: 23825799 DOI: 10.3389/fonc.2013.00164] [Cited by in Crossref: 36] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 723 |
Yim JH, Baek JH, Lee CW, Kim MJ, Yun HS, Hong EH, Lee SJ, Park JK, Um HD, Hwang SG. Identification of HDAC4 as a target of γ-catenin that regulates the oncogenic K-Ras-mediated malignant phenotype of Rat2 cells. Biochem Biophys Res Commun 2013;436:436-42. [PMID: 23747726 DOI: 10.1016/j.bbrc.2013.05.122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 724 |
Kessler T, Hache H, Wierling C. Integrative analysis of cancer-related signaling pathways. Front Physiol 2013;4:124. [PMID: 23760067 DOI: 10.3389/fphys.2013.00124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 725 |
Rimessi A, Marchi S, Patergnani S, Pinton P. H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling. Oncogene 2014;33:2329-40. [DOI: 10.1038/onc.2013.192] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 726 |
Greco A, Miranda C, Borrello MG, Pierotti MA. Molecular genetics of thyroid cancer. Clinical Management of Thyroid Cancer 2013. [DOI: 10.2217/ebo.12.402] [Reference Citation Analysis]
|
| 727 |
Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013;10:390-9. [PMID: 23712190 DOI: 10.1038/nrclinonc.2013.83] [Cited by in Crossref: 139] [Cited by in F6Publishing: 144] [Article Influence: 13.9] [Reference Citation Analysis]
|
| 728 |
Kim RK, Suh Y, Lim EJ, Yoo KC, Lee GH, Cui YH, Son A, Hwang E, Uddin N, Yi JM, Kang SG, Lee SJ. A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer. Cancer Lett 2013;337:49-57. [PMID: 23707634 DOI: 10.1016/j.canlet.2013.05.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 729 |
Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013;497:638-642. [PMID: 23698361 DOI: 10.1038/nature12205] [Cited by in Crossref: 460] [Cited by in F6Publishing: 486] [Article Influence: 46.0] [Reference Citation Analysis]
|
| 730 |
Aran V, Prior IA. Compartmentalized Ras signaling differentially contributes to phenotypic outputs. Cell Signal 2013;25:1748-53. [PMID: 23707528 DOI: 10.1016/j.cellsig.2013.05.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 731 |
Ren CG, Wang L, Jia XE, Liu YJ, Dong ZW, Jin Y, Chen Y, Deng M, Zhou Y, Zhou Y, Ren RB, Pan WJ, Liu TX. Activated N-Ras signaling regulates arterial-venous specification in zebrafish. J Hematol Oncol 2013;6:34. [PMID: 23663822 DOI: 10.1186/1756-8722-6-34] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 732 |
Nagano H, Ishii H, Marubashi S, Haraguchi N, Eguchi H, Doki Y, Mori M. Novel therapeutic target for cancer stem cells in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19:600-605. [PMID: 22892595 DOI: 10.1007/s00534-012-0543-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 733 |
Ouerhani S, Bougatef K, Soltani I, Elgaaied AB, Abbes S, Menif S. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer. Mol Biol Rep 2013;40:4109-14. [PMID: 23640097 DOI: 10.1007/s11033-013-2512-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 734 |
Le X, Pugach EK, Hettmer S, Storer NY, Liu J, Wills AA, DiBiase A, Chen EY, Ignatius MS, Poss KD, Wagers AJ, Langenau DM, Zon LI. A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development 2013;140:2354-64. [PMID: 23615277 DOI: 10.1242/dev.088427] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 735 |
Knabe N, Jung EM, Freihorst D, Hennicke F, Horton JS, Kothe E. A central role for Ras1 in morphogenesis of the basidiomycete Schizophyllum commune. Eukaryot Cell 2013;12:941-52. [PMID: 23606288 DOI: 10.1128/EC.00355-12] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 736 |
Na KY, Kim YW, Park YK. Mitogen-activated protein kinase pathway in osteosarcoma. Pathology 2012;44:540-6. [PMID: 22935974 DOI: 10.1097/PAT.0b013e32835803bc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 737 |
Jeong JH, Park SH, Park MJ, Kim MJ, Kim KH, Park PW, Seo YH, Lee JH, Park J, Hong J, Ahn JY. N-ras mutation detection by pyrosequencing in adult patients with acute myeloid leukemia at a single institution. Ann Lab Med 2013;33:159-66. [PMID: 23667841 DOI: 10.3343/alm.2013.33.3.159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 738 |
London CA. Kinase Dysfunction and Kinase Inhibitors. Advances in Veterinary Dermatology 2013. [DOI: 10.1002/9781118644317.ch25] [Reference Citation Analysis]
|
| 739 |
Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013;19:2688-98. [PMID: 23549875 DOI: 10.1158/1078-0432.CCR-12-2556] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 740 |
Boffetta P, Islami F. The contribution of molecular epidemiology to the identification of human carcinogens: current status and future perspectives. Annals of Oncology 2013;24:901-8. [DOI: 10.1093/annonc/mds543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 741 |
Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak VK, Koomen JM, Smalley KS. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther 2013;12:901-12. [PMID: 23538902 DOI: 10.1158/1535-7163.MCT-12-1003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 742 |
Chang-Yew Leow C, Gerondakis S, Spencer A. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J 2013;3:e105. [PMID: 23524590 DOI: 10.1038/bcj.2013.1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 743 |
Bond M, Croft W, Tyson R, Bretschneider T, Davey J, Ladds G. Quantitative analysis of human ras localization and function in the fission yeast Schizosaccharomyces pombe. Yeast 2013;30:145-56. [PMID: 23447405 DOI: 10.1002/yea.2949] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 744 |
Vaid S, Ariz M, Chaturbedi A, Kumar GA, Subramaniam K. PUF-8 negatively regulates RAS/MAPK signalling to promote differentiation of C. elegans germ cells. Development 2013;140:1645-54. [PMID: 23487310 DOI: 10.1242/dev.088013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 745 |
Pfeiffer V, Götz R, Xiang C, Camarero G, Braun A, Zhang Y, Blum R, Heinsen H, Nieswandt B, Rapp UR. Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum. PLoS One 2013;8:e58259. [PMID: 23505473 DOI: 10.1371/journal.pone.0058259] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 746 |
Cogoi S, Zorzet S, Rapozzi V, Géci I, Pedersen EB, Xodo LE. MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice. Nucleic Acids Res 2013;41:4049-64. [PMID: 23471001 DOI: 10.1093/nar/gkt127] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 747 |
Shin SH, Kim SC, Hong SM, Kim YH, Song KB, Park KM, Lee YJ. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas 2013;42:216-22. [PMID: 23344532 DOI: 10.1097/MPA.0b013e31825b6ab0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 748 |
Arango BA, Akunyili I. Newer Agents in Colon Cancer: What’s Next? Curr Colorectal Cancer Rep 2013;9:74-84. [DOI: 10.1007/s11888-012-0157-y] [Reference Citation Analysis]
|
| 749 |
Nagalingam RS, Sundaresan NR, Gupta MP, Geenen DL, Solaro RJ, Gupta M. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J Biol Chem 2013;288:11216-32. [PMID: 23447532 DOI: 10.1074/jbc.M112.442384] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 750 |
Lin G, Hu R, Law W, Chen C, Wang Y, Li Chin H, Nguyen QT, Lai CK, Yoon HS, Wang X, Xu G, Ye L, Cheng C, Yong K. Biodegradable Nanocapsules as siRNA Carriers for Mutant K-Ras Gene Silencing of Human Pancreatic Carcinoma Cells. Small 2013;9:2757-63. [DOI: 10.1002/smll.201201716] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 751 |
Chen CC, Er TK, Liu YY, Hwang JK, Barrio MJ, Rodrigo M, Garcia-Toro E, Herreros-Villanueva M. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 2013;8:e55793. [PMID: 23437064 DOI: 10.1371/journal.pone.0055793] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 752 |
Elsabah MT, Adel I. Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. J Egypt Natl Canc Inst 2013;25:51-6. [PMID: 23499207 DOI: 10.1016/j.jnci.2013.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 753 |
Tso PH, Wang Y, Yung LY, Tong Y, Lee MM, Wong YH. RGS19 inhibits Ras signaling through Nm23H1/2-mediated phosphorylation of the kinase suppressor of Ras. Cell Signal 2013;25:1064-74. [PMID: 23416464 DOI: 10.1016/j.cellsig.2013.02.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 754 |
Grunwald A, Gottfried I, Cox AD, Haklai R, Kloog Y, Ashery U. Rasosomes originate from the Golgi to dispense Ras signals. Cell Death Dis 2013;4:e496. [PMID: 23412389 DOI: 10.1038/cddis.2013.16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 755 |
Afonso FJ, Anido U, Fernández-Calvo O, Vázquez-Estévez S, León L, Lázaro M, Ramos M, Antón-Aparicio L. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor. Clin Transl Oncol 2013;15:425-33. [PMID: 23401018 DOI: 10.1007/s12094-012-0985-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 756 |
Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol 2013;8:183-8. [PMID: 23400451 DOI: 10.1007/s11523-013-0266-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 757 |
Zamkova M, Khromova N, Kopnin BP, Kopnin P. Ras-induced ROS upregulation affecting cell proliferation is connected with cell type-specific alterations of HSF1/SESN3/p21Cip1/WAF1 pathways. Cell Cycle 2013;12:826-36. [PMID: 23388456 DOI: 10.4161/cc.23723] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 758 |
Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets. 2013;17:507-531. [PMID: 23360111 DOI: 10.1517/14728222.2013.764990] [Cited by in Crossref: 85] [Cited by in F6Publishing: 96] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 759 |
Huang TL, Pian JP, Pan BT. Oncogenic Ras suppresses Cdk1 in a complex manner during the incubation of activated Xenopus egg extracts. Arch Biochem Biophys 2013;532:61-72. [PMID: 23376039 DOI: 10.1016/j.abb.2013.01.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] |
